Sulfur-containing fused ring compound, pharmaceutical composition containing same, and preparation method therefor and use thereof

By using sulfur-containing fused ring compounds as PET-CT tracers, early diagnosis of Parkinson's disease has been solved, and the problem of difficulty in early identification of diseases in the prior art is achieved, and the diagnosis and treatment opportunities before neurons have been lost are achieved .

WO2024240186A1PCT designated stage expired Publication Date: 2024-11-28SHANGHAI BRAEGEN PHARM CO LTD
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/094698
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The existing technology is difficult to diagnose Parkinson's disease early, especially before neurons are lost, and it is unable to effectively curb the progress of the disease, and there is a lack of early identification methods for central nervous system diseases.

Method used

A sulfur-containing fused ring compound is provided as a PET-CT tracer for imaging α-synuclein aggregates in Lewy bodies and Lewy neurites to achieve the possibility of early diagnosis of Parkinson's disease.

Benefits of technology

Through imaging, Parkinson's disease can be diagnosed before neurons have been lost, providing opportunities for early treatment and increasing the possibility of curbing disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024094698_28112024_PF_FP_ABST
    Figure CN2024094698_28112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are a sulfur-containing fused ring compound, a pharmaceutical composition containing same, and a preparation method therefor and the use thereof. Specifically disclosed is a sulfur-containing fused ring compound as shown in formula A, I-A, II-A, III-A, IV-A, V-A, VI-A or VII, or a pharmaceutically acceptable salt, a tautomer or a radioisotope labeled derivative thereof. The sulfur-containing fused ring compound of the present disclosure can be used as a PET-CT tracer and is used for developing and imaging α-synuclein aggregates in Lewy bodies and Lewy neurites, so as to diagnose diseases of the central nervous system.
Need to check novelty before this filing date? Find Prior Art

Description

Sulfur-containing fused ring compound, pharmaceutical composition containing the same, preparation method and application thereof

[0001] This application claims priority to Chinese patent application CN2023105816049, filed on May 22, 2023. This application incorporates the entire text of the aforementioned Chinese patent application. Technical Field

[0002] The present invention relates to a sulfur-containing fused ring compound, a pharmaceutical composition containing the same, a preparation method thereof and applications thereof. Background Art

[0003] Parkinson's disease (PD) can be characterized by the progressive development of Lewy bodies (LBs) and Lewy neurites (LNs). These LBs and LNs are primarily composed of aggregates of the protein α-synuclein (Spillantini et al. 1997 Nature; 388: 839-40), which is found in healthy neurons as an unfolded membrane-bound protein. α-synuclein detaches from the membrane and assumes a β-sheet conformation, allowing aggregation and subsequent formation of LBs and LNs.

[0004] Kotzbauer et al. report the use of PET tracers for imaging α-synuclein aggregates in Lewy bodies and Lewy neurites. Clinical and Translational Imaging, 2016, 5, 3-14. 18 F]-fluoro-L-dopa is used as a PET tracer to assess the function of dopaminergic neurons. SPECT tracers [ 123 I]-2-[β]-methoxycarbonyl-3-[β]-(4-iodophenyl)-tropane is used to assess the function of monoamine vesicular transporters. WO2004 / 075882 discloses an in vivo imaging method to diagnose the presence of abnormally folded or aggregated proteins and / or amyloid fibrils or amyloid proteins in a subject, wherein the method comprises administering a radiolabeled inositol derivative. WO2004 / 075882 reports that in vivo imaging methods can be used for the diagnosis of PD. See also WO2010 / 063701, WO2004 / 100998 and WO2005 / 013889.

[0005] The above-mentioned in vivo imaging technology targets the disease process at the stage when LB and LN are present in the central nervous system. At this stage, clinical symptoms are obvious, and approximately 80% of striatal dopamine neurons and 50% of substantia nigra neurons are lost. Since neurons in the CNS cannot regenerate on their own after cell death, neuroprotective treatment will only benefit neurons if they are still alive at the time of diagnosis. For patients, it is advantageous to treat them as early as possible to curb the progression of the disease. Therefore, a method for identifying PD before significant neuronal loss is needed.

[0006] CN2019800317559 reports a class of styrylbenzothiazole derivatives that can be used as in vivo imaging agents for diagnosing Parkinson's disease (PD) or other degenerative disorders or central nervous system disorders. Specifically disclosed is compound F0502B that specifically binds to α-synuclein.

[0007] Summary of the Invention

[0008] The present invention provides a sulfur-containing fused ring compound, a pharmaceutical composition containing the same, a preparation method, and applications thereof. The sulfur-containing fused ring compound of the present invention can be used as a PET-CT tracer for imaging α-synuclein aggregates in Lewy bodies and Lewy neurites to diagnose central nervous system diseases.

[0009] The present invention solves the above technical problems through the following technical solutions.

[0010] The present invention provides a sulfur-containing fused ring compound as shown in Formula A, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof;

[0011] Wherein, the sulfur-containing fused ring compound represented by formula A is as follows:

[0012] In formula A,

[0013] R 1 F, Cl, Br, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0014] R 1-1 H, C 1-6Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0015] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0016] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0017] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0018] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0019] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0020] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0021] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0022] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0R 2-2-1 ;

[0023] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0024] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0025] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0026] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0027] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0028] R3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0029] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0030] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0031] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0032] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0033] R 5 -OH or -NR 5-1 R 5-2 ;

[0034] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0035] And when R 5 When it is -OH, R 1 F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0036] R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced -OC 1-6 alkyl;

[0037] R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0038] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0039] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0040] The compound must meet one or more of the following conditions:

[0041] Condition (1)R 1 F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0042] Condition (2)R 2 -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1, 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0043] Condition (3)R 3 H, -OH, C 2-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 Substituted 5-10 membered heteroaryl.

[0044] In a certain embodiment, in the sulfur-containing fused ring compound represented by Formula A, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative, the definitions of certain groups may be as described below, and the definitions of other groups may be as described in any embodiment of the present invention (hereinafter referred to as "in a certain embodiment"): The sulfur-containing fused ring compound represented by Formula A is shown in Formula A-1:

[0045] In one embodiment, in Formula A, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 ; preferably -OR 1-1 or -NR1-2 R 1-3 ; More preferably -OH, -OCH3, -NH2 or -NHCH3.

[0046] In one embodiment, in Formula A, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; preferably -OH, -OC 1-6 Alkyl or -NR 2- 0 R 2-1 ; More preferably -OH, -OCH3, -NH2 or -NHCH3.

[0047] In one embodiment, in Formula A, R 3 H, -OH or C 1-6 Alkyl; preferably H, -OH or C 2-6 Alkyl; more preferably H, -OH or isopropyl, or, more preferably OH, ethyl or isopropyl.

[0048] In one embodiment, in Formula A, R 4 C 1-6 alkyl.

[0049] In one embodiment, in Formula A, R 1-1 H or C 1-6 alkyl.

[0050] In one embodiment, in Formula A, R 1-2 and R 1-3 are independently H or C 1-6 alkyl.

[0051] In one embodiment, in Formula A, R 2-1 For H.

[0052] In one embodiment, in Formula A, R 2-0 H or C 1-6 alkyl.

[0053] In one embodiment, in Formula A, R 5 is -OH, -NH2 or -NHCH3; preferably R 5 It is -OH.

[0054] The present invention also provides a sulfur-containing fused ring compound as shown in Formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof; characterized in that:

[0055] The sulfur-containing fused ring compound shown in Formula IA is as follows:

[0056] In Formula IA,

[0057] R 1 F, Cl, Br, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0058] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0059] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0060] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0061] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0062] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0063] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0064] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0065] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0066] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0067] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0068] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0069] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0070] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0071] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0072] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0073] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0074] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0075] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0076] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0077] R 5 -OH or -NR 5-1 R 5-2 ;

[0078] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0079] R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced -OC 1-6 alkyl;

[0080] R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0081] And when R 5 When it is -OH, R 1 F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; in the 5-10 membered heteroaryl, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0082] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0083] The sulfur-containing fused ring compound represented by formula II-A is as follows:

[0084] In formula II-A,

[0085] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0086] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0087] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0088] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0089] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0090] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0091] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0092] R 2 -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0093] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0094] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0095] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0096] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0097] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R3-9 substituted 5-10 membered heteroaryl;

[0098] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0099] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0100] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0101] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0102] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0103] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0104] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0105] R 5 -OH or -NR 5-1 R 5-2 ;

[0106] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0107] R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced -OC 1-6 alkyl;

[0108] R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0109] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0110] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0111] The sulfur-containing fused ring compound represented by formula VA is as follows:

[0112] In formula VA,

[0113] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6Substituted C 3-6 Cycloalkyl;

[0114] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0115] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0116] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0117] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0118] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0119] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0120] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0121] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0122] R2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0123] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0124] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0125] R 3 H, -OH, C 2-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0126] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0127] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0128] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0129] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0130] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0131] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0132] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0133] R 5 -OH or -NR 5-1 R 5-2 ;

[0134] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0135] R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced -OC 1-6 alkyl;

[0136] R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0137] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0138] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0139] The sulfur-containing fused ring compound represented by formula III-A is shown below:

[0140] In formula III-A,

[0141] X is N or CR a ;

[0142] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0143] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0144] R 1-2 and R 1-3 Independently H, C1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0145] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0146] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0147] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0148] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0149] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0150] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0151] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0152] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0153] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0154] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0155] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0156] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0157] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0158] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0159] R a H or C 1-6 alkyl;

[0160] or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time;

[0161] R 5 -OH or -NR 5-1 R 5-2 ;

[0162] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0163] R 6 H, -OC1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced -OC 1-6 alkyl;

[0164] R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0165] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0166] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0167] The sulfur-containing fused ring compound represented by formula IV-A is shown below:

[0168] In formula IV-A,

[0169] X is N or CR a ;

[0170] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0171] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0172] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0173] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0174] R2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0175] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0176] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0177] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0178] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0179] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0180] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0181] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0182] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0183] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0184] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0185] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0186] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0187] R a H or C 1-6 alkyl;

[0188] or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time;

[0189] R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced -OC 1-6 alkyl;

[0190] R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0191] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0192] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0193] The sulfur-containing fused ring compound represented by formula VI-A is as follows:

[0194] In Formula VI-A,

[0195] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0196] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0197] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0198] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0199] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0200] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0201] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0202] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0203] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0204] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0205] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0206] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0207] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0208] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0209] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0210] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0211] R 4 H, C 2-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0212] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0213] R 4-2 、R4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0214] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0215] R 5 -OH or -NR 5-1 R 5-2 ;

[0216] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0217] R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced -OC 1-6 alkyl;

[0218] R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0219] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0220] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0221] The sulfur-containing fused ring compound represented by Formula VII is shown below:

[0222] R 1 F, Cl, Br, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0223] R 1-1H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0224] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0225] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0226] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0227] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0228] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0229] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0230] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0231] R 2-2 、R 2-3 、R 2-4 and R 2-5are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0232] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0233] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0234] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0235] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0236] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0237] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0238] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0239] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0240] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0241] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0242] R 5 -OH or -NR 5-1 R5-2 ;

[0243] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0244] R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced -OC 1-6 alkyl;

[0245] R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0246] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3.

[0247] The present invention provides a sulfur-containing fused ring compound as represented by Formula I, II, III, IV, V or VI, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof;

[0248] Wherein, the sulfur-containing fused ring compound represented by formula I is as follows:

[0249] In Formula I,

[0250] R 1 F, Cl, Br, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0251] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0252] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0253] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0254] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0255] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0256] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0257] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0258] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0259] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0260] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0261] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0262] R3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0263] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0264] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0265] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0266] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0267] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0268] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0269] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0270] R 5 -OH or -NR 5-1 R 5-2 ;

[0271] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0272] And when R 5 When it is -OH, R 1 F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0273] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0274] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0275] The sulfur-containing fused ring compound shown in Formula II is as follows:

[0276] In Formula II,

[0277] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0278] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0279] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0280] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0281] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0282] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0283] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0284] R 2 -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0285] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0286] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0287] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0288] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0289] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0290] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0291] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0292] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0293] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0294] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0295] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0296] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0297] R 5 -OH or -NR 5-1 R 5-2 ;

[0298] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0299] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0300] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0301] The sulfur-containing fused ring compound represented by formula III is as follows:

[0302] In formula III,

[0303] X is N or CR a ;

[0304] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0305] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0306] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0307] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0308] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0309] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0310] R 2-2 、R 2-3 、R2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0311] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0312] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0313] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0314] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0315] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0316] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0317] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0318] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0319] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0320] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0321] R aH or C 1-6 alkyl;

[0322] or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time;

[0323] R 5 -OH or -NR 5-1 R 5-2 ;

[0324] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0325] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0326] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0327] The sulfur-containing fused ring compound shown in Formula IV is as follows:

[0328] In Formula IV,

[0329] X is N or CR a ;

[0330] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0331] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0332] R 1-2 and R 1-3 Independently H, C1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0333] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0334] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0335] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0336] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0337] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0338] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0339] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0340] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0341] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0342] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0343] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0344] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0345] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0346] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0347] R a H or C 1-6 alkyl;

[0348] or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time;

[0349] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0350] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0351] The sulfur-containing fused ring compound represented by formula V is as follows:

[0352] In Formula V,

[0353] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0354] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0355] R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0356] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0357] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0358] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0359] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0360] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0361] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0362] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0363] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0364] R 2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0365] R 3 H, -OH, C 2-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0366] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0367] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0368] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0369] R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0370] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0371] R 4-2、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0372] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0373] R 5 -OH or -NR 5-1 R 5-2 ;

[0374] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0375] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0376] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0377] The sulfur-containing fused ring compound shown in Formula VI is as follows:

[0378] In Formula VI,

[0379] R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl;

[0380] R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl;

[0381] R 1-2 and R 1-3 Independently H, C 1-6Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl;

[0382] R 1-4 、R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ;

[0383] R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0384] R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0385] R 1-4-1 and R 1-4-2 are independently H or C 1-6 alkyl;

[0386] R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced -OC 1-6 alkyl;

[0387] R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl;

[0388] R 2-2 、R 2-3 、R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ;

[0389] R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0390] R2-2-0 and R 2-2-1 are independently H or C 1-6 alkyl;

[0391] R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced -OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl;

[0392] R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl;

[0393] R 3-2 、R 3-3 、R 3-4 、R 3-5 、R 3-6 、R 3-7 、R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0394] R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0395] R 4 H, C 2-6 Alkyl, C 2-6Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, By 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced -OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl;

[0396] R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl;

[0397] R 4-2 、R 4-3 、R 4-4 、R 4-5 、R 4-6 、R 4-7 、R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0398] R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2;

[0399] R 5 -OH or -NR 5-1 R 5-2 ;

[0400] R 5-1 and R 5-2 are independently H or C 1-6 alkyl;

[0401] In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0402] In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3.

[0403] In a certain embodiment, in the sulfur-containing fused ring compound represented by Formula IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI (e.g., I, II, III, IV, V or VI), its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative, the definitions of certain groups may be as described below, and the definitions of other groups may be as described in any embodiment of the present invention (hereinafter referred to as "in a certain embodiment"): In Formula I, R 1 Br, -OR 1-1 or -NR 1-2 R 1-3 ; preferably -OR 1-1 or -NR 1-2 R 1-3 ; More preferably -OH, -OCH3, -NH2 or -NHCH3.

[0404] In one embodiment, in Formula IA or Formula I, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 .

[0405] In one embodiment, in Formula IA or Formula I, R 3 H, -OH or C 1-6 alkyl.

[0406] In one embodiment, in Formula IA or Formula I, R 4 C 1-6 alkyl.

[0407] In one embodiment, in Formula IA or Formula I, R 1-1 H or C 1-6 alkyl.

[0408] In one embodiment, in Formula IA or Formula I, R 1-2 and R 1-3 are independently H or C 1-6 alkyl.

[0409] In one embodiment, in Formula IA or Formula I, R 2-1 For H.

[0410] In one embodiment, in Formula IA or Formula I, R 2-0H or C 1-6 alkyl.

[0411] In one embodiment, in Formula IA or Formula I, R 5 is -OH, -NH2 or -NHCH3; preferably R 5 It is -OH.

[0412] In one embodiment, in Formula IA or Formula I, R 1 is Br, -OH, -OCH3, -NH2 or -NHCH3;

[0413] R 2 is H, -OH, -OCH3, -NH2 or -NHCH3;

[0414] R 3 H, -OH or C 1-6 alkyl;

[0415] R 4 C 1-6 alkyl;

[0416] R 5 It is -OH, -NH2 or -NHCH3.

[0417] In one embodiment, in Formula IA or Formula I, R 1 is Br, -OH, -OCH3, -NH2 or -NHCH3;

[0418] R 2 is H;

[0419] R 3 C 1-6 alkyl;

[0420] R 4 C 1-6 alkyl;

[0421] R 5 It is -OH, -NH2 or -NHCH3.

[0422] In a certain embodiment, in Formula II-A or Formula II, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 .

[0423] In a certain embodiment, in Formula II-A or Formula II, R 2 -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; preferably -OH, -OCH3, -NH2 or -NHCH3.

[0424] In a certain embodiment, in Formula II-A or Formula II, R 3 H, -OH or C 1-6 alkyl.

[0425] In a certain embodiment, in Formula II-A or Formula II, R 4 C 1-6 alkyl.

[0426] In a certain embodiment, in Formula II-A or Formula II, R 1-1 H or C 1-6 alkyl.

[0427] In a certain embodiment, in Formula II-A or Formula II, R 1-2 and R 1-3 are independently H or C 1-6 alkyl.

[0428] In a certain embodiment, in Formula II-A or Formula II, R 2-1 For H.

[0429] In a certain embodiment, in Formula II-A or Formula II, R 2-0 H or C 1-6 alkyl.

[0430] In a certain embodiment, in Formula II-A or Formula II, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

[0431] In a certain embodiment, in Formula II-A or Formula II, R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3;

[0432] R 2 is -OH, -OCH3, -NH2 or -NHCH3;

[0433] R 3 H, -OH or C 1-6 alkyl;

[0434] R 4 C 1-6 alkyl;

[0435] R 5 It is -OH, -NH2 or -NHCH3.

[0436] In a certain embodiment, in Formula II-A or Formula II, R 1 For Br;

[0437] R 2is -OH, -OCH3, -NH2 or -NHCH3;

[0438] R 3 C 1-6 alkyl;

[0439] R 4 C 1-6 alkyl;

[0440] R 5 It is -OH.

[0441] In a certain embodiment, in Formula III-A or Formula III, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 .

[0442] In a certain embodiment, in Formula III-A or Formula III, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time; preferably R 2 H, or R a With R 2 Together they form -(NH)- or -(CH=CH)-.

[0443] In a certain embodiment, in Formula III-A or Formula III, R 3 H, -OH or C 1-6 alkyl.

[0444] In a certain embodiment, in Formula III-A or Formula III, R 4 C 1-6 alkyl.

[0445] In a certain embodiment, in Formula III-A or Formula III, R 1-1 H or C 1-6 alkyl.

[0446] In a certain embodiment, in Formula III-A or Formula III, R 1-2 and R 1-3 are independently H or C 1-6 alkyl.

[0447] In a certain embodiment, in Formula III-A or Formula III, R 2-1 For H.

[0448] In a certain embodiment, in Formula III-A or Formula III, R 2-0 H or C 1-6 alkyl.

[0449] In a certain embodiment, in Formula III-A or Formula III, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

[0450] In one embodiment, in Formula III-A or Formula III, X is N or CR a ;

[0451] R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3;

[0452] R 2 H; or, R a With R 2 Together they form -NH- or -CH=CH-;

[0453] R 3 H, -OH or C 1-6 alkyl;

[0454] R 4 C 1-6 alkyl;

[0455] R 5 It is -OH, -NH2 or -NHCH3.

[0456] In one embodiment, in Formula III-A or Formula III, X is N or CR a ;

[0457] R 1 For Br;

[0458] R 2 H; or, R a With R 2 Together they form -NH- or -CH=CH-;

[0459] R 3 C 1-6 alkyl;

[0460] R 4 C 1-6 alkyl;

[0461] R 5 It is -OH.

[0462] In a certain embodiment, in Formula IV-A or Formula IV, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 .

[0463] In one embodiment, in Formula IV, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time; preferably R 2 H, or R a With R 2 Together they form -(NH)- or -(CH=CH)-.

[0464] In a certain embodiment, in Formula IV-A or Formula IV, R 3 H, -OH or C 1-6 alkyl.

[0465] In a certain embodiment, in Formula IV-A or Formula IV, R 4 C 1-6 alkyl.

[0466] In a certain embodiment, in Formula IV-A or Formula IV, R 1-1 H or C 1-6 alkyl.

[0467] In a certain embodiment, in Formula IV-A or Formula IV, R 1-2 and R 1-3 are independently H or C 1-6 alkyl.

[0468] In a certain embodiment, in Formula IV-A or Formula IV, R 2-1 For H.

[0469] In a certain embodiment, in Formula IV-A or Formula IV, R 2-0 C 1-6 alkyl.

[0470] In one embodiment, in Formula IV-A or Formula IV, in Formula IV, X is N or CR a ;

[0471] R 1is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3;

[0472] R 2 H; or, R a With R 2 Together they form -NH- or -(CH=CH)-;

[0473] R 3 H, -OH or C 1-6 alkyl;

[0474] R 4 C 1-6 alkyl.

[0475] In one embodiment, in Formula IV-A or Formula IV, X is N or CR a ;

[0476] R 1 For Br;

[0477] R 2 H; or, R a With R 2 Together they form -NH- or -(CH=CH)-;

[0478] R 3 C 1-6 alkyl;

[0479] R 4 C 1-6 alkyl.

[0480] In one embodiment, in Formula VA or Formula V, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 .

[0481] In one embodiment, in Formula VA or Formula V, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 .

[0482] In one embodiment, in Formula VA or Formula V, R 3 H, -OH or C 2-6 Alkyl; preferably H, -OH or isopropyl; or preferably -OH, ethyl or isopropyl; most preferably ethyl.

[0483] In one embodiment, in Formula VA or Formula V, R 4 C 1-6 alkyl.

[0484] In one embodiment, in Formula VA or Formula V, R 1-1 H or C 1-6 alkyl.

[0485] In one embodiment, in Formula VA or Formula V, R 1-2 and R 1-3 are independently H or C 1-6 alkyl.

[0486] In one embodiment, in Formula VA or Formula V, R 2-1 For H.

[0487] In one embodiment, in Formula VA or Formula V, R 2-0 H or C 1-6 alkyl.

[0488] In one embodiment, in Formula VA or Formula V, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

[0489] In one embodiment, in Formula VA or Formula V, R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3;

[0490] R 2 is H, -OH, -OCH3, -NH2 or -NHCH3;

[0491] R 3 is H, -OH or isopropyl; or R 3 is -OH, ethyl or isopropyl;

[0492] R 4 C 1-6 alkyl;

[0493] R 5 It is -OH, -NH2 or -NHCH3.

[0494] In one embodiment, in Formula VA or Formula V, R 1 For Br;

[0495] R 2 is H;

[0496] R 3 is H, -OH or isopropyl; or R 3 is -OH, ethyl or isopropyl;

[0497] R 4 C 1-6 alkyl;

[0498] R 5 It is -OH.

[0499] In a certain embodiment, in Formula VI-A or Formula VI, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 .

[0500] In a certain embodiment, in Formula VI-A or Formula VI, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 .

[0501] In a certain embodiment, in Formula VI-A or Formula VI, R 3 H, -OH or C 1-6 alkyl.

[0502] In a certain embodiment, in Formula VI-A or Formula VI, R 4 C 2-6 Alkyl; preferably ethyl or isopropyl.

[0503] In a certain embodiment, in Formula VI-A or Formula VI, R 1-1 H or C 1-6 alkyl.

[0504] In a certain embodiment, in Formula VI-A or Formula VI, R 1-2 and R 1-3 are independently H or C 1-6 alkyl.

[0505] In a certain embodiment, in Formula VI-A or Formula VI, R 2-1 For H.

[0506] In a certain embodiment, in Formula VI-A or Formula VI, R 2-0 H or C 1-6 alkyl.

[0507] In a certain embodiment, in Formula VI-A or Formula VI, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

[0508] In a certain embodiment, in Formula VI-A or Formula VI, R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3;

[0509] R 2 is H, -OH, -OCH3, -NH2 or -NHCH3;

[0510] R 3 H, -OH or C1-6 alkyl;

[0511] R 4 C 2-6 alkyl;

[0512] R 5 It is -OH, -NH2 or -NHCH3.

[0513] In a certain embodiment, in Formula VI-A or Formula VI, R 1 For Br;

[0514] R 2 is H;

[0515] R 3 H, -OH or C 1-6 alkyl;

[0516] R 4 is ethyl or isopropyl;

[0517] R 5 It is -OH.

[0518] In one embodiment, in Formula VII, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 .

[0519] In one embodiment, in Formula VII, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 .

[0520] In one embodiment, in Formula VII, R 3 H, -OH or C 1-6 alkyl.

[0521] In one embodiment, in Formula VII, R 4 C 2-6 alkyl.

[0522] In one embodiment, in Formula VII, R 1-1 H or C 1-6 alkyl.

[0523] In one embodiment, in Formula VII, R 1-2 and R 1-3 are independently H or C 1-6 alkyl.

[0524] In one embodiment, in Formula VII, R 2-1 For H.

[0525] In one embodiment, in Formula VII, R 2-0 H or C 1-6 alkyl.

[0526] In one embodiment, in Formula VII, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

[0527] In one embodiment, in Formula IA, II-A, III-A, IV-A, VA, VI-A or VII, R 6 H, or -OC 1-6 Alkyl; preferably H or methoxy.

[0528] In one embodiment, in Formula VII, R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3;

[0529] R 2 is H, -OH, -OCH3, -NH2 or -NHCH3;

[0530] R 3 H, -OH or C 1-6 alkyl;

[0531] R 4 C 1-6 alkyl;

[0532] R 5 is -OH, -NH2 or -NHCH3;

[0533] R 6 It is a methoxy group.

[0534] In one embodiment, in Formula VII, R 1 is Br, -OH, -OCH3, -NH2 or -NHCH3;

[0535] R 2 is H;

[0536] R 3 C 1-6 alkyl;

[0537] R 4 C 1-6 alkyl;

[0538] R 5 is -OH, -NH2 or -NHCH3;

[0539] R 6 It is a methoxy group.

[0540] In a certain embodiment, in Formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, the C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; for example, methyl, ethyl or isopropyl; for another example, methyl.

[0541] In a certain embodiment, in Formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, the C 2-6 Alkenyl is independently ethenyl, propenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl or t-butenyl.

[0542] In a certain embodiment, in Formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, the C 2-6 Alkynyl is independently ethynyl, n-propynyl, isopropynyl, n-butynyl, isobutynyl, sec-butynyl or tert-butynyl.

[0543] In a certain embodiment, in A, IA, II-A, III-A, IV-A, VA, VI-A, VII, Formula I, II, III, IV, V or VI, the C 3-6 Cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopropyl, cyclopentyl or cyclohexyl.

[0544] In one embodiment, in Formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, the -OC 1-6 Alkyl is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy; for example, methoxy.

[0545] In one embodiment, in Formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, the halogen is independently F, Cl, Br or I.

[0546] In a certain embodiment, in Formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, the C 6-10 Aryl is independently phenyl or naphthyl, for example phenyl.

[0547] In a certain embodiment, in Formula A, VA, VI-A, V or VI, the C 2-6Alkyl is independently ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; for example, ethyl or isopropyl.

[0548] In one embodiment, the sulfur-containing fused ring compound as shown in Formula IA is selected from any one of the following compounds:

[0549] In one embodiment, the sulfur-containing fused ring compound as shown in Formula II-A is selected from any one of the following compounds:

[0550] In one embodiment, the sulfur-containing fused ring compound represented by formula III-A is selected from any one of the following compounds:

[0551] In one embodiment, the sulfur-containing fused ring compound represented by formula IV-A is selected from any one of the following compounds:

[0552] In one embodiment, the sulfur-containing fused ring compound represented by formula VA is selected from any one of the following compounds:

[0553] In one embodiment, the sulfur-containing fused ring compound represented by Formula VI-A is selected from any one of the following compounds:

[0554] In one embodiment, the sulfur-containing fused ring compound represented by Formula VII is selected from the following compounds:

[0555] In one embodiment, the radioisotope-labeled derivative is 18 F. 11 C. 124 I. 123 I or 13 Compounds obtained by replacing F, C, I or N atoms in the sulfur-containing fused ring compounds shown in Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, their pharmaceutically acceptable salts, or their tautomers; preferably 18 F.

[0556] The present invention also provides a pharmaceutical composition comprising the sulfur-containing fused ring compound represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof, and a pharmaceutical excipient.

[0557] The present invention also provides a kit comprising the sulfur-containing fused ring compound represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof, and instructions for use.

[0558] The present invention provides the use of the sulfur-containing fused ring compound represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative in the preparation of a PET-CT tracer.

[0559] The PET-CT tracer can be used to perform imaging of α-synuclein aggregates in Lewy bodies and Lewy neurites; for example, the PET-CT tracer is used to perform imaging of Parkinson's disease, Lewy body dementia, and multiple system atrophy.

[0560] The PET-CT tracer can be used to diagnose and exclude progressive supranuclear palsy or corticobasal degeneration.

[0561] The present invention also provides a sulfur-containing fused ring compound as shown in Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a radioisotope-labeled derivative thereof for use as an in vivo imaging agent for diagnosing central nervous system diseases; the central nervous system diseases may be diseases related to α-synuclein expression; for example, diseases related to α-synuclein precursor fibril expression; for another example, the diseases related to α-synuclein expression are Parkinson's disease, Lewy body dementia or multiple system atrophy.

[0562] The present invention also provides a sulfur-containing fused ring compound as shown in Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a radioisotope-labeled derivative thereof as an in vivo imaging agent for diagnosing and excluding progressive supranuclear palsy or corticobasal degeneration.

[0563] The five diseases mentioned above all fall under the umbrella of Parkinson's disease and share common clinical manifestations, such as tremors and unsteady gait, making diagnosis difficult. However, Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) are α-synucleinopathies, characterized by misfolded and abnormally aggregated α-synuclein in the brain. Injecting a tracer can reveal this abnormality, thus diagnosing the disease. Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) do not exhibit abnormal α-synuclein aggregation in the brain, so imaging is not performed, thus ruling out these two conditions.

[0564] The present invention also provides a method for brain imaging, comprising the following steps:

[0565] (1) administering to a subject the sulfur-containing fused ring compound represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a radioisotope-labeled derivative thereof;

[0566] (2) Scanning the subject's brain.

[0567] The present invention also provides a method for detecting α-synuclein precursor fibrils in the brain, comprising the following steps:

[0568] (1) administering to a subject the sulfur-containing fused ring compound represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a radioisotope-labeled derivative thereof;

[0569] (2) Detecting the sulfur-containing fused ring compound represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, its pharmaceutically acceptable salt, its tautomer, or its radioactive isotope-labeled derivative.

[0570] The present invention also provides a method for diagnosing whether a subject suffers from Parkinson's disease or has a potential risk of suffering from Parkinson's disease, comprising the following steps:

[0571] (1) administering to a subject the sulfur-containing fused ring compound represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a radioisotope-labeled derivative thereof;

[0572] (2) detecting the sulfur-containing fused ring compound represented by A, IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a radioactive isotope-labeled derivative thereof;

[0573] (3) Based on the test results of step (2), diagnose whether the subject suffers from Parkinson's disease or has a potential risk of suffering from Parkinson's disease.

[0574] The sulfur-containing fused ring compound of the present application has good affinity and selectivity for α-Syn aggregates. The structure-activity relationship study found that the sulfur-containing fused ring compound R shown in formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII 1 The position can form a hydrogen bond with the hydroxyl group on T44 of α-Syn, R 2 The position can form a hydrogen bond with the carboxylic acid group of E46 on α-Syn, R 5 The position can form hydrogen bonds with the amide group backbone structure of G41 on α-Syn, R 3 、R 4 The position can enhance the van der Waals force through hydrophobic interaction; and IA, II-A, VA or VI-A can span three α-Syn protein layers, and the compounds of formula III-A and IV-A can span two α-Syn protein layers, and can have better α-Syn affinity.

[0575] Unless otherwise specified, the terms used in this invention have the following meanings:

[0576] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0577] The term "alkyl" refers to a group having a specified number of carbon atoms (e.g., C 1-6 ). Alkyl includes, but is not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl and n-hexyl.

[0578] The term "alkenyl" refers to a straight or branched hydrocarbon chain radical having at least one double bond, consisting solely of carbon and hydrogen atoms, with a designated carbon atom (e.g., C 2-6 ), and is connected to the rest of the molecule by a single bond, for example, alkenyl includes but is not limited to vinyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, n-pentenyl, 2-methylbutenyl, 2,2-dimethylpropenyl and n-hexenyl, etc.

[0579] The term "alkynyl" refers to a straight or branched hydrocarbon chain radical having at least one triple bond, consisting solely of carbon and hydrogen atoms, with a designated carbon atom (e.g., C 2-6) and is connected to the rest of the molecule by a single bond, for example, alkynyl includes but is not limited to ethynyl, n-propynyl, isopropynyl, n-butynyl, isobutynyl, sec-butynyl, tert-butynyl, n-pentynyl, 2-methylbutynyl, 2,2-dimethylpropynyl or n-hexynyl, etc.

[0580] The term "cycloalkyl" refers to a cycloalkyl group having the specified number of carbon atoms (e.g., C 3-6 ) and is composed only of carbon atoms. Cycloalkyl includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0581] The term "aryl" refers to a radical having the specified number of carbon atoms (e.g., C 6-10 ) is a cyclic hydrocarbon group consisting only of carbon atoms, which is monocyclic or polycyclic, and at least one of the groups is aromatic (in accordance with Huckel's rule). Aryl groups include but are not limited to phenyl and naphthyl.

[0582] The term "heteroaryl" refers to a cyclic hydrocarbon group having a specified number of carbon atoms (e.g., 5-10 members), a specified number of heteroatoms (e.g., 1, 2, or 3), a specified heteroatom species (one or more of N, O, and S), which is monocyclic or polycyclic, and at least one radical is aromatic (in accordance with Huckel's rule). When the heteroaryl is polycyclic and has one aromatic ring and one non-aromatic ring, the heteroaryl is connected to the other fragments in the molecule via the aromatic ring or the non-aromatic ring. Heteroaryl includes, but is not limited to, furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, and indolyl.

[0583] The term "heterocycloalkyl" refers to a stable saturated (e.g., 3-6 membered) heterocyclic hydrocarbon group composed of carbon atoms and heteroatoms (N, O, or S), such as aziridine, oxiranyl, oxetane, thietanyl, tetrahydrothienyl, or thiazolidinyl.

[0584] A "-" at the end of a group means that the group is attached to another fragment in the molecule through that site. For example, -OCH3 refers to a methoxy group, in which the oxygen atom is attached to the rest of the molecule.

[0585] the term Represents a mixture of cis and trans forms.

[0586] When any variable (such as the group R 1-3 ) appears multiple times in the definition of a compound, their definitions are independent of each other and do not affect each other. For example, 1-3 Substituted C 1-6 Alkyl refers to C 1-6 The alkyl group will be replaced by 3 R 1-3 Replacement, 3 R 1-3The definitions of are independent of each other and do not affect each other. They can be the same or different.

[0587] The term "pharmaceutically acceptable salt" refers to a salt obtained by reacting a compound with a pharmaceutically acceptable (safe and suitable for patient use) acid or base. When the compound contains a relatively acidic functional group, a base addition salt can be obtained by contacting the free form of the compound with a sufficient amount of a pharmaceutically acceptable base in a suitable inert solvent. Pharmaceutically acceptable base addition salts include, but are not limited to, sodium salts, potassium salts, calcium salts, aluminum salts, magnesium salts, bismuth salts, ammonium salts, and the like. When the compound contains a relatively basic functional group, an acid addition salt can be obtained by contacting the free form of the compound with a sufficient amount of a pharmaceutically acceptable acid in a suitable inert solvent. Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochlorides, sulfates, methanesulfonates, and the like. For details, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use (P. Heinrich Stahl, 2002).

[0588] The term "positron emission tomography (PET)" refers to an imaging technique that produces images (e.g., three-dimensional images) by detecting pairs of gamma rays emitted indirectly by a positron-emitting radionuclide tracer. Computer analysis then constructs an image of the tracer concentration within the area. The radiotracer is administered to a subject, for example into the bloodstream. Typically, there is a waiting period while the tracer becomes concentrated in the target area; the subject is then placed in an imaging scanner. When the radionuclide undergoes positron-emitting decay, it emits a positron (the antiparticle of the electron, with the opposite charge) until it slows to a point where it can interact with the electron, producing a pair of (gamma) photons traveling in generally opposite directions. These are detected in a scanning device. The technique typically utilizes the simultaneous or coincident detection of a pair of photons traveling in generally opposite directions (scanners typically have a built-in tolerance for slight directional errors). Photons that fail to arrive as a pair (i.e., within a timing window) are typically ignored. The photon source is typically positioned along a coincident line (also called a line of response, or LOR). This data is used to generate the image.

[0589] The term "radioisotope-labeled derivative" refers to a compound that has one or more atoms in the compound molecule replaced by a radioisotope, making it identifiable and useful as a tracer. It has the same chemical and biological properties as the corresponding unlabeled compound, except that it is radioactive and can be traced using radioactive detection techniques, such as 18 F. 11 C or 13C replaces an atom in the compound. In the present invention, the radioisotope-labeled derivative refers to a sulfur-containing fused ring compound as represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt of a sulfur-containing fused ring compound as represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, or a radioisotope-labeled compound of a tautomer of a sulfur-containing fused ring compound as represented by Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII.

[0590] After administering the in vivo imaging moiety-labeled sulfur-containing fused ring compound disclosed herein to a subject, the subject is then imaged. Methods for detecting the sulfur-containing fused ring compound, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a radiolabeled derivative thereof as shown in Formula A, IA, II-A, III-A, IV-A, VA, VI-A, or VII are conventional in the art, and the sulfur-containing fused ring compound can be administered at any suitable dose. Any suitable imaging device (e.g., a device capable of collecting magnetic resonance images (MRI), positron emission tomography (PET scan), or computed tomography (CT scan)) can be used to image the subject.

[0591] The term "α-synuclein deposits" refers to insoluble protein inclusions containing the protein α-synuclein. Lewy bodies (LBs) and Lewy neurites (LNs) are well-known insoluble protein inclusions, of which α-synuclein is the main component, and are reported to be present in the central nervous system (CNS) as well as the ANS in PD. However, PD is generally considered a disease of the CNS, and in vivo imaging methods for detecting deposits of α-synuclein, a PD target, in the CNS are known.

[0592] " Central nervous system " (CNS) is a part of the nervous system of vertebrates, and is made up of brain and spinal cord.In CNS, endothelial cells are more closely packed together than the rest of the body by means of " tight junction proteins ", and tight junction proteins are multifunctional complexes, form a seal between adjacent epithelial cells, thereby preventing most dissolved molecules from passing from one side of the epithelial layer to the other side. This forms the blood-brain barrier (BBB), which prevents the movement of all molecules except those molecules (such as oxygen, carbon dioxide, ethanol and steroid hormones) that pass through the cell membrane by means of fat solubility and those molecules allowed by specific transport systems (such as sugar and some amino acids). Generally, substances (such as antibodies) with a molecular weight greater than 500Da cannot pass through BBB by passive diffusion, while smaller molecules can usually. In order to contact the target in vivo with the CNS, its chemical structure must be adjusted so that it passes through BBB, or alternatively, a relatively invasive procedure must be used by which the in vivo imaging agent is directly administered into the CNS.

[0593] The term "pharmaceutical excipients" refers to excipients and additives used in the production of drugs and the preparation of prescriptions. They are all substances contained in pharmaceutical preparations other than active ingredients. For details, please refer to the Pharmacopoeia of the People's Republic of China (2020 edition) or the Handbook of Pharmaceutical Excipients (Raymond C Rowe, 2009). Excipients are mainly used to provide a safe, stable and functional pharmaceutical composition. They can also provide methods to enable the active ingredient to be dissolved at a desired rate after the subject receives the administration, or to promote the effective absorption of the active ingredient after the subject receives the composition. The pharmaceutical excipients may be an inert filler, or provide a certain function, such as stabilizing the overall pH value of the composition or preventing the degradation of the active ingredient of the composition. The pharmaceutical excipients may include one or more of the following excipients: binders, suspending agents, emulsifiers, diluents, fillers, granulating agents, adhesives, disintegrants, lubricants, anti-adhesive agents, glidants, wetting agents, gelling agents, absorption delaying agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents and sweeteners.

[0594] The "detecting" step of the disclosed methods involves detecting the signal outside the human body, or by using a detector designed for use in the body (e.g., intravascular radiation) or an optical detector (e.g., an endoscope) (e.g., suitable for detecting signals in the intestine) or a radiation detector designed for intraoperative use. The detecting step can also be understood as acquiring signal data.

[0595] The in vivo imaging method selected for detecting the signal emitted by the in vivo imaging moiety depends on the nature of the signal. Thus, when the signal is from paramagnetic metal ions, magnetic resonance imaging (MRI) is used, when the signal is gamma rays, single photon emission tomography (SPECT) is used, when the signal is positrons, positron emission tomography (PET) is used, and when the signal is optically active, optical imaging is used. All of these are suitable for use in the methods of the present disclosure, with PET and SPECT being preferred because they are least likely to be affected by background and are therefore diagnostically useful.

[0596] The pharmaceutical compositions of the present invention can be prepared according to the disclosed content using any method known to those skilled in the art, such as conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, embedding or lyophilizing processes.

[0597] When used as a drug, the sulfur-containing fused ring compound shown in Formula A, IA, II-A, III-A, IV-A, VA, VI-A or VII, its pharmaceutically acceptable salt, its tautomer, or its radiolabeled derivative can be administered in any form of a pharmaceutical composition. These compositions can be prepared according to methods well known in the pharmaceutical field and can be administered in various ways, depending on whether local or systemic treatment is required and the area to be treated. Administration can be topical (including epidermal and transdermal, ocular and mucosal, including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of a powder or aerosol, including by nebulizer; intratracheal or intranasal), oral (solid and liquid preparations) or parenteral administration. Examples of solid oral preparations include, but are not limited to, powders, capsules, caplets, soft capsules and tablets. Examples of liquid preparations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs and solutions. Examples of topical formulations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops, or serum formulations. Examples of formulations for parenteral administration include, but are not limited to, solutions for injection, dry formulations that can be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, emulsions, creams, gels, drops, suppositories, sprays, liquids, and powders. Examples of other suitable formulations of the pharmaceutical compositions include, but are not limited to, eye drops and other ophthalmic preparations; aerosols, such as nasal sprays or inhalers. Oral administration may include dosage forms formulated for once-daily or twice-daily (BID) administration. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular, or injection or infusion; or intracranial, such as intrathecal or intraventricular administration. Parenteral administration may be in the form of a single bolus dose, or may be by continuous infusion pump. Conventional pharmaceutical carriers, water, powder or oily bases, thickeners, etc. may be necessary or desirable. The pharmaceutical compositions comprising the present invention may also be in the form of controlled-release or delayed-release dosage forms (eg, liposomes or microspheres).

[0598] The term "treat" refers to any of the following: (1) alleviating one or more biological manifestations of a disease; (2) interfering with one or more points in the biological cascade that leads to a disease; or (3) slowing the progression of one or more biological manifestations of a disease.

[0599] The term "prevent" refers to reducing the risk of developing a disease.

[0600] The term "subject" refers to any animal that has been or is about to be treated, preferably a mammal, most preferably a human. Mammals include but are not limited to cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc.

[0601] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.

[0602] The reagents and raw materials used in the present invention are commercially available.

[0603] The positive progress of the present invention is that the sulfur-containing fused ring compound of the present invention can be used as a PET-CT tracer to image α-synuclein aggregates in Lewy bodies and Lewy neurites to diagnose central nervous system diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0604] Figure 1 shows the binding of the compounds to the cell α-syn aggregation model. The scale of the graph is 40 μm.

[0605] FIG2 shows the binding of compounds to SNCATg mouse brain slices treated with rotenone. The scale of the graph is 40 μm.

[0606] FIG3 shows the binding of the compound to brain slices of human DLB patients. The scale of the graph is 40 μm. DETAILED DESCRIPTION

[0607] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.

[0608] Example 1: Synthesis of Compound 1

[0609] Synthesis of 2-(4-amino-3-bromoyl)-N-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzothiazol-6-amine

[0610] Step 1: Synthesis of 2,5-dimethyl-6-nitrobenzothiazole

[0611] 2,5-Dimethylbenzothiazole (16 g, 98.15 mmol) was added to concentrated sulfuric acid (200 mL) under an ice bath. Potassium nitrate (10.9 g, 107.96 mmol) was added portionwise, followed by stirring at room temperature for 3 hours. After the reaction, the reaction solution was poured into ice water (2.0 L). A yellow solid precipitated and was filtered. The filter cake was washed with saturated sodium carbonate and water to obtain a crude product. The crude product was purified by silica gel column chromatography (PE:EA = 0-15%) to obtain 7.4 g of a yellow solid, with a yield of 36%. LC-MS (ESI): [M+H] + =209.0; 1HNMR (400MHz, CDCl3) δ8.43(s,1H),7.76(s,1H),2.81(s,3H),2.64(s,3H).

[0612] Step 2: Synthesis of methyl 3-bromo-4-((di-tert-butyloxycarbonyl)amino)benzoate

[0613] Methyl 4-amino-3-bromobenzoate (25 g, 108.7 mmol) was added to a mixture of tetrahydrofuran and acetonitrile (800 mL, v / v = 1 / 1). 4-Dimethylaminopyridine (13.27 g, 108.7 mmol) was then added dropwise under ice-cooling. Di-tert-butyl dicarbonate (75 mL, 326.1 mmol) was added. The reaction mixture was allowed to react at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and citric acid (10% by mass) was added. The mixture was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to yield 46 g of a yellow solid in a 98.6% yield. LC-MS (ESI): [M+Na] + =454.0.

[0614] Step 3: Synthesis of methyl 3-bromo-4-(tert-butoxycarbonylamino)benzoate

[0615] Methyl 3-bromo-4-((di-tert-butyloxycarbonyl)amino)benzoate (46 g, 107.2 mmol) was added to methanol (700 mL), followed by potassium carbonate (22.5 g, 163.0 mmol). The mixture was heated to 50°C and reacted for 12 hours. The mixture was filtered and the filtrate was concentrated under reduced pressure. The filter cake was washed with DCM / MeOH (20:1). The combined organic phases were purified by silica gel column chromatography (PE:EA = 20:1) to obtain 22 g of a solid, with a yield of 62.3%. LC-MS (ESI): [M-56+H] + =273.9.

[0616] Step 4: Synthesis of tert-butyl (2-bromo-4-hydroxymethyl)phenylcarbamate

[0617] Lithium aluminum hydride (5 g, 33.7 mmol) was added to anhydrous tetrahydrofuran (200 mL). A solution of methyl 3-bromo-4-(tert-butoxycarbonylamino)benzoate (22 g, 66.8 mmol) in tetrahydrofuran (60 mL) was added dropwise under ice-cooling. The mixture was heated to 50°C and reacted for 12 hours. Water (5 mL), 15% NaOH (5 mL), and H₂O (15 mL) were added to quench the reaction. The mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 2:1) to obtain 14 g of a colorless oil in a 69.6% yield. LC-MS (ESI): [M-56-17+H] + =229.9.

[0618] Step 5: Synthesis of 3-bromo-4-(tert-butoxycarbonylamino)benzaldehyde

[0619] tert-Butyl (2-bromo-4-hydroxymethyl)phenylcarbamate (14 g, 46.5 mmol) was added to dichloromethane (150 mL). Dessmartin (29.58 g, 69.77 mmol) was added portionwise under an ice bath. The mixture was allowed to react at room temperature for 2 hours. Ethyl acetate was added for extraction, filtered, and the combined organic phases were purified by silica gel column chromatography (PE:EA = 0-70%) to afford 13 g of a yellow solid in a 93.4% yield. LC-MS (ESI): [M+H-56] + =245.9.

[0620] Step 6: Synthesis of (E)-tert-butyl-(2-bromo-4-(2-(5-methyl-6-nitrobenzothiazol-2-vinyl)phenyl)carbamate

[0621] 2,5-Dimethyl-6-nitrobenzothiazole (2.78 g, 13.4 mmol) was added to tetrahydrofuran (60 mL). Sodium hydride (1.6 g, 40.13 mmol, wt: 60%) was added under ice-cooling and stirred at room temperature for 30 minutes. 3-Bromo-4-(tert-butoxycarbonylamino)benzaldehyde (4 g, 13.38 mmol) was then added and allowed to react at room temperature for 14 hours. Water was added to quench the mixture, and the mixture was extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and chromatographed on a silica gel column (DCM:EA = 100:1) to afford 2.8 g of a black solid in a 42.8% yield. LC-MS (ESI): [M+H] + =492.0; 1 H NMR (400MHz, CDCl3) δ8.47(s,1H),8.18(d,J=12Hz,1H),7.80(s,1H),7.68(d,J=2.0Hz,1H),7 .46-7.43(m,1H),7.41(s,1H),7.21(d,J=8.0Hz,1H),7.07(s,1H),2.66(s,3H),1.48(s,9H).

[0622] Step 7: Synthesis of tert-butyl (E)-(4-(2-(6-amino-5-methylbenzothiazol-2-yl)vinyl)-2-bromophenylcarbamate

[0623] (E)-tert-Butyl-(2-bromo-4-(2-(5-methyl-6-nitrobenzothiazol-2-vinyl)phenyl)carbamate (2.80 g, 5.77 mmol) was added to a mixture of tetrahydrofuran and ethanol (80 mL, v / v = 1:1). An aqueous solution of ammonium chloride (3.1 g, 57.3 mmol) (15 mL) was added. Iron powder (3.2 g, 57.3 mmol) was added at room temperature and the mixture was reacted at 80°C for 2 hours. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated to obtain 2.6 g of a red solid with a yield of 99.0%. LC-MS (ESI): [M+H] + =462.1.

[0624] Step 8: Synthesis of tert-butyl (E)-(2-bromo-4-(2-(2-hydroxyethoxy)ethyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate

[0625] Tert-butyl (E)-(4-(2-(6-amino-5-methylbenzothiazol-2-yl)vinyl)-2-bromophenylcarbamate (2.6 g, 5.66 mmol) was added to DMF (30 mL), followed by 2-chloroethoxyethanol (3.54 g, 28.32 mmol), potassium carbonate (2.34 g, 16.99 mmol), and potassium iodide (940 mg, 5.66 mmol). The mixture was reacted at 100°C for 48 hours. The reaction solution was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (DCM:EA=3:1) to afford 1.4 g of a red oil with a yield of 36.7%. LC-MS (ESI): [M+H] + =550.1.

[0626] Step 9: Synthesis of tert-butyl (E)-tert-butyl (2-bromo-4-(2-(2-hydroxyethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate

[0627] Tert-butyl (E)-(2-bromo-4-(2-(2-hydroxyethoxy)ethyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate (1.4 g, 2.56 mmol) was added to methanol (15 mL), followed by 30% aqueous formaldehyde solution (0.3 mL). The mixture was stirred on ice for 30 minutes. Sodium cyanoborohydride (242 mg, 3.84 mmol) was added. The reaction was allowed to react at room temperature for 1 hour. The reaction solution was concentrated and purified by silica gel column chromatography (DCM:EA = 3:1) to afford 1.4 g of a red oil in a 97.2% yield. LC-MS (ESI): [M+H] + =564.1.

[0628] Step 10: Synthesis of (E)-2-(2-(3-bromo-4-((tert-butoxycarbonylamino)phenylvinyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate

[0629] tert-Butyl (E)-tert-butyl (2-bromo-4-(2-(2-hydroxyethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate (1.4 g, 2.49 mmol) was added to dichloromethane (15 mL), followed by triethylamine (1.4 mL) and p-toluenesulfonyl chloride (948 mg, 4.99 mmol) under ice-cooling. The mixture was allowed to react at room temperature for 16 hours. Water was added to quench the mixture, and the mixture was extracted with ethyl acetate. The organic phase was concentrated and purified by silica gel column chromatography (PE:EA = 5:1) to afford 1.7 g of a light green solid in a 95.5% yield. LC-MS (ESI): [M+H] + =718.1.

[0630] Step 11: Synthesis of tert-butyl (E)-(2-bromo-4-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate

[0631] (E)-2-(2-(3-bromo-4-((tert-butoxycarbonylamino)phenylvinyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (1.7 g, 2.38 mmol), Kryptofix 222 (2.24 g, 5.94 mmol), and potassium fluoride (1.38 g, 23.77 mmol) were added to acetonitrile (15 mL) and reacted at 60°C for 2 hours. The reaction solution was cooled to room temperature, concentrated, and purified by silica gel column chromatography (PE:EA = 4:1) to afford 450 mg of a light green oil in a 33.6% yield. LC-MS (ESI): [M+H] + =566.1; 1 H NMR (400MHz, CDCl3) δ8.14(d,J=8.0Hz,1H),7.70–7.65(m,2H),7.45–7.41(m,2H),7.21–7.17(m,2H),7.03(s,1H),4. 53–4.51(m,1H),4.41–4.39(m,1H),3.66–3.56(m,4H),3.14(t,J=8.0Hz,2H),2.76(s,3H),2.56(s,3H),1.48(s,9H).

[0632] Step 12: Synthesis of 2-(4-amino-3-bromoyl)-N-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzothiazol-6-amine

[0633] Tert-butyl (E)-(2-bromo-4-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate (200 mg, 0.35 mmol) was added to dichloromethane (2.5 mL), followed by trifluoroacetic acid (1 mL), and the mixture was allowed to react at room temperature for 2 hours. The reaction solution was concentrated, saturated sodium carbonate solution was added, and the pH was adjusted to approximately 8. The mixture was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was dissolved in methanol and analyzed by Prep-HPLC (10 mM ammonium bicarbonate) to yield 93 mg of a yellow oil in a 57.3% yield. LC-MS (ESI): [M+H] + =464.1,466.1; 1 H NMR (400MHz, DMSO-d6) δ7.77(d,J=2.0Hz,1H),7.71(d,J=12.3,2H),7.48(dd,J=8.4,2.0Hz,1H),7.38–7.25(m,2H),6.81(d,J=8.4Hz,1H),5.80( s,2H),4.57–4.55(m,1H),4.45–4.43(m,1H),3.68–3.66(m,1H),3.62–3 .58(m,3H),3.10(t,J=6.0Hz,2H),2.77–2.75(m,3H),2.38–2.36(m,3H).

[0634] Example 2: Synthesis of 2-(3-bromo-4-methylamino)phenylvinyl-N-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzothiazol-6-amine

[0635] Tert-butyl (E)-(2-bromo-4-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate was synthesized according to the method of Example 1.

[0636] Step 1: Synthesis of (E)-(2-bromo-4-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)(tert-butyl methylcarbamate)

[0637] Tert-butyl (E)-(2-bromo-4-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate (250 mg, 0.44 mmol) was added to DMF (3 mL), and sodium hydride (26 mg, 0.66 mmol, wt: 60%) was added under ice-cooling. The mixture was stirred at this temperature for 20 minutes, followed by the addition of iodomethane (75 mg, 0.53 mmol). The mixture was stirred at room temperature for 1 hour. After completion of the reaction, water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give 210 mg of a yellow oil with a yield of 85.6%. LC-MS (ESI): [M+H] + =580.2.

[0638] Step 2: Synthesis of 2-(3-bromo-4-methylamino)phenylvinyl-N-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzothiazol-6-amine

[0639] (E)-(2-Bromo-4-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenyl)(methylcarbamic acid tert-butyl ester) (210 mg, 0.36 mmol) was added to dichloromethane (2.5 mL), followed by trifluoroacetic acid (1 mL), and the mixture was allowed to react at room temperature for 2 hours. The reaction solution was concentrated, saturated sodium carbonate solution was added, and the pH was adjusted to approximately 8. The mixture was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was dissolved in methanol and analyzed by Prep-HPLC (10 mM ammonium bicarbonate) to give 57 mg of a yellow oil in a 33.1% yield. LC-MS (ESI): [M+H] + =478.1,480.1; 1 H NMR(400MHz,DMSO-d6)δ7.86(d,J=2.0Hz,1H),7.74–7.69(m,2H),7.62-7.5 9(m,1H),7.41–7.28(m,2H),6.66-6.63(m,1H),5.84–5.77(m,1H),4.57–4. 55(m,1H),4.45–4.43(m,1H),3.68–3.66(m,1H),3.62-3.58(m,3H),3.10(t ,J=6.0Hz,2H),2.81(d,J=4.8Hz,3H),2.76–2.74(m,3H),2.39–2.37(m,3H).

[0640] Example 3: Synthesis of Compounds A and B

[0641] Compounds A and B were synthesized according to Examples 1 and 2.

[0642] Compound A: LC-MS (ESI): [M+H] + =417.2.

[0643] Compound B: LC-MS (ESI): [M+H] + =403.2.

[0644] Another synthesis method of compound A

[0645] Synthesis of (E)-4-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzothiazol-2-yl)vinyl)-2-methoxyphenol

[0646] Step 1: Synthesis of 3-methoxy-4-(methoxymethoxy)benzaldehyde

[0647] 4-Hydroxy-3-methoxybenzaldehyde (3 g, 19.73 mmol) and N,N-diisopropylethylamine (5.09 g, 39.47 mmol) were added to dichloromethane (30 mL), and bromomethyl methyl ether (1.9 mL, 23.68 mmol, density 1.54 g / cm 3 ), then stirred at room temperature for 12 hours under nitrogen. After the reaction, the crude product was concentrated and chromatographed on a silica gel column (PE:EA=3:1) to give 3.3 g of a colorless oil (85% yield). LC-MS (ESI): [M+H] + =197.2; 1 H NMR (400MHz, CDCl3) δ9.87(s,1H),7.49-7.40(m,2H),7.28-7.26(m,1H),5.33(s,2H),3.95(s,3H),3.52(s,3H).

[0648] Step 2: Synthesis of (E)-2-(3-methoxy-4-(methoxymethoxy)phenyl)-5-methyl-6-nitrobenzo[d]thiazole

[0649] 2,5-Dimethyl-6-nitrobenzothiazole (1.9 g, 9.27 mmol) was added to tetrahydrofuran (40 mL). Sodium hydride (742 mg, 18.55 mmol, 60% by mass) was added under ice-cooling and stirred for 40 minutes under nitrogen. 3-Methoxy-4-(methoxymethoxy)benzaldehyde (2 g, 10.20 mmol) was dissolved in tetrahydrofuran (5 mL) under ice-cooling and added to the reaction flask. The reaction was allowed to proceed at room temperature for 4 hours under nitrogen. Saturated aqueous ammonium chloride (10 mL) was added to quench the mixture, filtered, and the filter cake washed with ethyl acetate (20 mL) to afford 2.9 g of an orange solid in an 81% yield. LC-MS (ESI): [M+H] + =387.3; 1 H NMR (400MHz, DMSO-d6) δ8.90(s,1H),8.01(s,1H),7.73(d,J=16.0Hz,1H),7.63(d,J=16.0Hz,1H),7.51(d,J=2.0 Hz,1H),7.32(dd,J=8.4,2.0Hz,1H),7.12(d,J=8.4Hz,1H),5.23(s,2H),3.87(s,3H),3.40(s,3H),2.65(s,3H).

[0650] Step 3: Synthesis of (E)-2-(3-methoxy-4-(methoxymethoxy)phenylvinyl)-5-methylbenzo[d]thiazol-6-amine

[0651] (E)-2-(3-methoxy-4-(methoxymethoxy)phenyl)-5-methyl-6-nitrobenz[d]thiazole (2.90 g, 7.51 mmol) was added to ethanol (50 mL), followed by a 5 mL solution of ammonium chloride (3.98 g, 75.12 mmol). Iron powder (2.10 g, 37.56 mmol) was then added at room temperature. The reaction mixture was allowed to react at 80°C for 2 hours. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated. Water (20 mL) was added, and the mixture was extracted with dichloromethane / methanol (20 / 1) (20 mL x 3). The organic phases were combined and concentrated to yield 2.1 g of an orange solid in a 78% yield. LC-MS (ESI): [M+H] + =357.3; 1 H NMR (400MHz, CDCl3) δ7.78(s,1H),7.55-7.30(m,2H),7.18-7.10(m,4H),5.28(s,2H),3.95(s,3H),3.54(s,3H),2.33(s,3H).

[0652] Step 4: Synthesis of (E)-2-(2-(2-(3-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)amino)ethoxy)ethanol

[0653] (E)-2-(3-methoxy-4-(methoxymethoxy)phenylvinyl)-5-methylbenzo[d]thiazol-6-amine (1.6 g, 4.49 mmol) was added to DMF (20 mL), along with 2-chloroethoxyethanol (2.80 g, 22.47 mmol), potassium carbonate (1.86 g, 13.48 mmol), and potassium iodide (746 mg, 4.49 mmol). The mixture was reacted at 100°C for 48 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, concentrated, and purified by silica gel column chromatography (DCM:EA = 1:1) to afford 1.0 g of a red oil in a 38% yield. LC-MS (ESI): [M+H] + =445.3; 1 H NMR (400MHz, CDCl3) δ7.70(s,1H),7.31(d,J=4.8Hz,2H),7.15(d,J=8.4Hz,1H),7.12(d,J=1.6Hz,1H),7.09-7.08(m,1H),7. 03(s,1H),5.27(s,2H),3.93(s,3H),3.86-3.76(m,4H),3.68-3.63(m,2H),3.53(s,3H),3.43(t,J=5.2Hz,2H),2.31(s,3H).

[0654] Step 5: Synthesis of (E)-2-(2-(2-(3-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)amino)ethoxy)ethanol

[0655] (E)-2-(2-(2-(3-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)amino)ethoxy)ethanol (900 mg, 2.03 mmol), 40% aqueous formaldehyde solution (304 mg, 2.03 mmol), and glacial acetic acid (0.2 mL) were added to methanol (10 mL) and stirred in an ice bath for 30 minutes. Sodium cyanoborohydride (255 mg, 4.05 mmol) was added and the mixture was allowed to react at room temperature for 12 hours. The reaction solution was concentrated and purified by silica gel column chromatography (DCM:EA = 1:1) to give 600 mg of a yellow solid in a 60% yield. LC-MS (ESI): [M+H] + =459.4; 1H NMR(400MHz, CDCl3)δ7.85(s,1H),7.52-7.46(m,1H),7.31-7.28(m,2H),7.20-7.18(m,1H),7.14-7.12(m,2 H),5.28(s,2H),3.95(s,3H),3.73-3.68(m,4H),3.54(s,3H),3.53(s,3H),3.35-2.95(m,4H),2.64(s,3H).

[0656] Step 6: Synthesis of (E)-2-(2-(2-(3-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)amino)ethoxy-4-methylbenzenesulfonic acid ethyl ester

[0657] (E)-2-(2-(2-(3-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)amino)ethoxy)ethanol (550 mg, 1.20 mmol) and triethylamine (485 mg, 4.80 mmol) were added to dichloromethane (6 mL). p-Toluenesulfonyl chloride (456 mg, 2.40 mmol) was then added under an ice bath. The mixture was reacted at room temperature for 16 hours under a nitrogen atmosphere. The organic phase was concentrated and purified by silica gel column chromatography (PE:EA = 3:1) to afford 650 mg of a yellow solid in 88% yield. LC-MS (ESI): [M+H] + =613.3; 1 H NMR (400MHz, DMSO-d6) δ7.77(d,J=8.4Hz,2H),7.71(d,J=6.4Hz,2H),7.50(d,J=4.0Hz,2 H),7.45(dd,J=5.2,2.8Hz,3H),7.25(dd,J=8.4,1.6Hz,1H),7.09(d,J=8.4Hz,1H),5.20 (s,2H),4.14-4.07(m,2H),3.86(s,3H),3.58-3.52(m,2H),3.49(t,J=6.0Hz,2H),3.40( s,3H),3.00(t,J=6.0Hz,2H),2.70(s,3H),2.53-2.47(m,2H),2.38(s,3H),2.33(s,3H).

[0658] Step 7: Synthesis of (E)-N-(2-(2-fluoroethoxy)ethyl)-2-(3-methoxy-4-(methoxymethoxy)phenyl)-N,5-dimethylbenzo[d]thiazol-6-amine

[0659] Ethyl (E)-2-(2-(2-(3-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)amino)ethoxy-4-methylbenzenesulfonate (300 mg, 0.49 mmol), Kryptofix 222 (462 mg, 1.22 mmol), and potassium fluoride (284 mg, 4.90 mmol) were added to acetonitrile (3 mL) and reacted at 60°C for 2 hours under nitrogen. The reaction solution was cooled to room temperature, concentrated, and purified by silica gel column chromatography (PE:EA = 5:1) to afford 112 mg of a yellow oil in a 50% yield. LC-MS (ESI): [M+H] + =461.3; 1 H NMR (400MHz, CDCl3) δ7.76 (s, 1H), 7.53 (s, 1H), 7.38 (d, J = 16.Hz, 1H), 7.2 9-7.25(m,1H),7.17(d,J=8.0Hz,1H),7.13(d,J=1.8Hz,1H),7.12-7.08(m, 1H),5.27(s,2H),4.64-4.53(m,1H),4.53-4.40(m,1H),3.94(s,3H),3.72- 3.62(m,4H),3.52(s,3H),3.22(t,J=6.0Hz,2H),2.84(s,3H),2.44(s,3H).

[0660] Step 8: Synthesis of (E)-4-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzothiazol-2-yl)vinyl)-2-methoxyphenol

[0661] (E)-N-(2-(2-fluoroethoxy)ethyl)-2-(3-methoxy-4-(methoxymethoxy)phenyl)-N,5-dimethylbenzo[d]thiazol-6-amine (112 mg, 0.24 mmol) was added to dichloromethane (2.5 mL), followed by trifluoroacetic acid (0.5 mL), and the mixture was allowed to react at room temperature for 2 hours. The reaction mixture was concentrated to obtain a crude product, which was dissolved in methanol. MPLC (ACN / Water) analysis yielded 48 mg of a yellow oil with a yield of 47.5%. LC-MS (ESI): [M+H] + =417.3; 1H NMR (400MHz, DMSO-d6) δ9.45 (s, 1H), 7.72 (d, J = 11.2Hz, 2H), 7.41 (m, 2H), 7.37 (d, J = 1.6Hz, 1H), 7.14 (dd, J = 8.0, 2.0Hz, 1H), 6.80 (d, J = 8.0Hz, 1H),4.61-4.53(m,1H),4.48-4.41(m,1H),3.85(s,3H),3.69-3.65(m,1 H),3.63-3.56(m,3H),3.10(t,J=6.0Hz,2H),2.75(s,3H),2.37(s,3H); 19 F NMR(376MHz,DMSO-d6)δ-221.35.

[0662] Another synthetic method of compound B

[0663] Synthesis of (E)-4-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazolyl)vinyl)catechol

[0664] Step 1: Synthesis of 3,4-bis(methoxymethoxy)benzaldehyde

[0665] 3,4-Dihydroxybenzaldehyde (3 g, 27.74 mmol) and N,N-diisopropylethylamine (11.2 g, 86.95 mmol) were added to dichloromethane (40 mL), and bromomethyl methyl ether (4.2 mL, 52.17 mmol, density 1.54 g / cm 3 ), followed by stirring at room temperature for 16 hours under nitrogen protection. After the reaction, the crude product was concentrated and chromatographed on a silica gel column (PE:EA=3:1) to obtain 4.4 g of a yellow oil with a yield of 89%. LC-MS (ESI): [M+H] + =227.2; 1 H NMR (400MHz, CDCl3) δ9.87 (s, 1H), 7.68 (d, J = 2.0Hz, 1H), 7.51 (dd, J = 8.4, 2.0Hz ,1H),7.29(d,J=8.4Hz,1H),5.33(s,2H),5.30(s,2H),3.53(s,3H),3.52(s,3H).

[0666] Step 2: Synthesis of (E)-2-(3,4-bis(methoxymethoxy)phenylvinyl)-5-methyl-6-nitrobenzo[d]thiazole

[0667] 2,5-Dimethyl-6-nitrobenzothiazole (1.67 g, 8.04 mmol) was added to tetrahydrofuran (40 mL). Sodium hydride (643 mg, 16.09 mmol, 60% by mass) was added under ice-cooling and stirred for 40 minutes under nitrogen. 3,4-Bis(methoxymethoxy)benzaldehyde (2 g, 8.84 mmol) was dissolved in tetrahydrofuran (5 mL) under ice-cooling and added to the reaction flask. The reaction was allowed to proceed at room temperature for 4 hours under nitrogen. The mixture was quenched with saturated ammonium chloride solution, filtered, and the filter cake was washed with ethyl acetate (20 mL) to yield 2.7 g of an orange solid (80% yield). LC-MS (ESI): [M+H] + =417.3; 1 H NMR (400MHz, DMSO-d6) δ8.89(s,1H),8.01(s,1H),7.71(d,J=16Hz,1H),7.56(d,J=16Hz,2H),7.42 -7.41(m,1H),7.17(d,J=7.6Hz,1H),5.27(d,J=6.4Hz,4H),3.44(s,3H),3.41(s,3H),2.64(s,3H).

[0668] Step 3: Synthesis of (E)-2-(3,4-bis(methoxymethoxy)phenylvinyl)-5-methylbenzo[d]thiazol-6-amine

[0669] (E)-2-(3,4-Bis(methoxymethoxy)phenylvinyl)-5-methyl-6-nitrobenzo[d]thiazole (2.70 g, 6.49 mmol) was added to ethanol (50 mL), followed by a 5 mL solution of ammonium chloride (3.44 g, 64.90 mmol). Iron powder (1.8 g, 32.45 mmol) was then added at room temperature. The mixture was allowed to react at 80°C for 2 hours. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated. Water (20 mL) was added, and the mixture was extracted with dichloromethane / methanol (20 / 1) (20 mL x 3). The organic phases were combined and concentrated to yield 2.0 g of an orange solid (80.0% yield). LC-MS (ESI): [M+H] + =387.3; 1 H NMR (400MHz, CDCl3) δ7.75 (s, 1H), 7.40-7.30 (m, 2H), 7.26-7.18 (m, 4H), 5.28 (d, J = 2.4Hz, 4H), 3.53 (s, 6H), 2.34 (s, 3H).

[0670] Step 4: Synthesis of (E)-2-(2-(2-(3,4-bis(methoxymethoxy)phenylvinyl)-5-methylbenzo[d]thiazol-6-yl)amino)ethoxy)ethanol

[0671] (E)-2-(3,4-Bis(methoxymethoxy)phenylvinyl)-5-methylbenzo[d]thiazol-6-amine (1.8 g, 4.66 mmol) was added to DMF (20 mL), along with 2-chloroethoxyethanol (2.91 g, 23.31 mmol), potassium carbonate (1.93 g, 13.98 mmol), and potassium iodide (774 mg, 4.66 mmol). The mixture was reacted at 100°C for 48 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, concentrated, and purified by silica gel column chromatography (DCM:EA = 1:1) to afford 1.1 g of a red oil in a 45% yield. LC-MS (ESI): [M+H] + =475.3; 1 H NMR (400MHz, CDCl3) δ7.66(s,1H),7.40(s,1H),7.27(S,2H),7.16(s,2H),6.99(s,1H),5.28(d,J=2.4Hz, 4H), 3.85-3.76 (m, 4H), 3.66-3.63 (m, 2H), 3.54 (s, 3H), 3.53 (s, 3H), 3.42 (t, J = 5.2Hz, 2H), 2.28 (s, 3H).

[0672] Step 5: Synthesis of (E)-2-(2-(2-(3,4-bis(methoxymethoxy)phenylvinyl)-5-methylbenzothiazol-6-yl)(methyl)aminoethoxy)ethanol

[0673] (E)-2-(2-(2-(3,4-bis(methoxymethoxy)phenylvinyl)-5-methylbenzo[d]thiazol-6-yl)amino)ethoxy)ethanol (1 g, 2.10 mmol), 40% aqueous formaldehyde solution (316 mg, 2.10 mmol), and glacial acetic acid (0.2 mL) were added to methanol (10 mL) and stirred in an ice bath for 30 minutes. Sodium cyanoborohydride (265 mg, 4.21 mmol) was added. The reaction was allowed to react at room temperature for 12 hours. The reaction solution was concentrated and purified by silica gel column chromatography (DCM:EA = 1:1) to give 700 mg of a yellow solid in a 63% yield. LC-MS (ESI): [M+H] + =489.4; 1 H NMR(400MHz, CDCl3)δ7.81(s,1H),7.45-7.38(m,2H),7.30-7.26(m,2H),7.19(s,2H), 5.28(d,J=2.4Hz,4H),3.78-3.63(m,4H),3.54(m,9H),3.38-2.75(m,4H),2.52(s,3H).

[0674] Step 6: Synthesis of (E)-2-(2-(2-(3,4-bis(methoxymethoxy)phenylvinyl)-5-methylbenzothiazol-6-yl)(methyl)aminoethoxy)4-methylbenzenesulfonic acid ethyl ester

[0675] (E)-2-(2-(2-(3,4-bis(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)aminoethoxy)ethanol (566 mg, 1.14 mmol) was added to dichloromethane (6 mL), followed by triethylamine (463 mg, 4.59 mmol). p-Toluenesulfonyl chloride (436 mg, 2.29 mmol) was added under ice-cooling. The mixture was allowed to react at room temperature for 16 hours under nitrogen protection. The reaction solution was concentrated and purified by silica gel column chromatography (PE:EA = 3:1) to afford 650 mg of a yellow solid in 88% yield. LC-MS (ESI): [M+H] + =643.3; 1 H NMR (400MHz, DMSO-d6) δ7.77(d,J=8.0Hz,2H),7.71(d,J=6.4Hz,2H),7.52(d,J=1.6Hz,1H),7.50-7.41(m,4H),7.35(dd,J=8.4,1.6 Hz,1H),7.14(d,J=8.4Hz,1H),5.26(d,J=13.2Hz,4H),4.15-4.05(m,2H),3.59-3.53(m,2H),3.49(t, J=6.0Hz,2H),3.44(s,3H),3.41(s,3H),3.00(t,J=6.0Hz,2H),2.70(s,3H),2.38(s,3H),2.33(s,3H).

[0676] Step 7: Synthesis of (E)-2-(3,4-bis(methoxymethoxy)phenylvinyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine

[0677] Ethyl (E)-2-(2-(2-(3,4-bis(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)aminoethoxy)-4-methylbenzenesulfonate (300 mg, 0.46 mmol), Kryptofix 222 (440 mg, 1.17 mmol), and potassium fluoride (271 mg, 4.67 mmol) were added to acetonitrile (3 mL) and reacted at 60°C for 2 hours under nitrogen. The reaction solution was cooled to room temperature, concentrated, and purified by silica gel column chromatography (PE:EA = 5:1) to afford 450 mg of a yellow oil in a 52% yield. LC-MS (ESI): [M+H] + =491.4; 1 H NMR (400MHz, CDCl3) δ7.72(s,1H),7.50(s,1H),7.38(s,1H),7.33(d,J=16.0Hz,1H),7.26-7.22(m,1H),7.14(s,2H),5.24(d,J=3.6Hz ,4H),4.60-4.50(m,1H),4.47-4.39(m,1H),3.69-3.58(m,4H),3.51(s,3H),3.49(s,3H),3.20-3.14(m,2H),2.81(s,3H),2.41(s,3H).

[0678] Step 8: Synthesis of (E)-4-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazolyl)vinyl)catechol

[0679] (E)-2-(3,4-bis(methoxymethoxy)phenylvinyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine (120 mg, 0.24 mmol) was added to dichloromethane (2.5 mL), followed by trifluoroacetic acid (0.5 mL), and the mixture was allowed to react at room temperature for 2 hours. The reaction mixture was concentrated to obtain a crude product, which was dissolved in methanol. MPLC (ACN / Water) analysis yielded 47 mg of a yellow oil with a yield of 47.9%. LC-MS (ESI): [M+H] + =403.3; 1H NMR (400MHz, DMSO-d6) δ9.42 (s, 1H), 9.11 (s, 1H), 7.71 (d, J = 8.8Hz, 2H), 7.35 (d ,J=16.0Hz,1H),7.18(d,J=16.0Hz,1H),7.09(d,J=2.0Hz,1H),7.02(dd,J=8.0, 2.0Hz,1H),6.77(d,J=8.0Hz,1H),4.61-4.51(m,1H),4.47-4.41(m,1H),3.71-3 .64(m,1H),3.63-3.56(m,3H),3.10(t,J=6.0Hz,2H),2.75(s,3H),2.36(s,3H); 19 F NMR(376MHz,DMSO-d6)δ-221.35.

[0680] Example 4: Synthesis of Compound C

[0681] Compound C was synthesized according to Examples 1 and 2.

[0682] Compound C: LC-MS (ESI): [M+H] + =402.2.

[0683] Another synthetic route of compound C

[0684] Synthesis of (E)-2-amino-4-(2-(6-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzothiazol-2-yl)vinyl)phenol

[0685] Step 1: Synthesis of methyl 3-(tert-butyloxycarbonyl)amino)-4-hydroxybenzoate

[0686] Methyl 4-hydroxy-3-nitrobenzoate (10 g, 50.76 mmol) was added to methanol (60 mL), followed by palladium on carbon (1 g) and di-tert-butyl dicarbonate (16.6 g, 76.14 mmol). The mixture was reacted at room temperature under hydrogen for 16 h. After completion of the reaction, the mixture was filtered and the filtrate was concentrated under reduced pressure to obtain 13.1 g of a light yellow oil with a yield of 97%. LC-MS (ESI): [M+H-56] + =212.1.

[0687] Step 2: Synthesis of methyl 3-(tert-butyloxycarbonyl)amino)-4-(methoxymethoxy)benzoate

[0688] Methyl 3-(tert-butoxycarbonyl)amino)-4-hydroxybenzoate (13.1 g, 49.06 mmol) was added to dichloromethane (100 mL), followed by N,N-diisopropylethylamine (12.8 mL, 73.59 mmol). Bromo(methoxy)methane (4.81 mL, 58.88 mmol) was added dropwise under an ice bath and allowed to react at room temperature for 2 hours. After completion of the reaction, the mixture was diluted with water (30 mL) and extracted with dichloromethane (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and chromatographed on a silica gel column (PE:EA = 5:1) to yield 13.5 g of a white solid in an 88.2% yield. LC-MS (ESI): [M+H-56] + =256.1; 1 H NMR (400MHz, DMSO-d6) δ8.39(d,J=2.0Hz,1H),8.25(s,1H),7.65(dd,J=8.8,2.4H z, 1H), 7.19 (d, J = 8.4Hz, 1H), 5.30 (s, 2H), 3.83 (s, 3H), 3.42 (s, 3H), 1.49 (s, 9H).

[0689] Step 3: Synthesis of tert-butyl (5-(hydroxymethyl)-2-(methoxymethoxy)phenyl)carbamate

[0690] Under an ice bath, lithium aluminum hydride (3.3 g, 86.82 mmol) was added portionwise to a solution of methyl 3-(tert-butoxycarbonyl)amino)-4-(methoxymethoxy)benzoate (13.5 g, 43.41 mmol) in tetrahydrofuran (140 mL). The mixture was allowed to react at room temperature for 3 hours. Water (50 mL) was added sequentially to quench the reaction. The mixture was extracted with dichloromethane (30 mL x 3), filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 5:1) to afford 8.87 g of a yellow oil in a 72.2% yield. LC-MS (ESI): [M+H-56] + =228.1; 1 H NMR (400MHz, DMSO-d6) δ7.97(s,1H),7.69(s,1H),7.04(d,J=8.4Hz,1H),6.93(dd,J=8.4,2.4 Hz, 1H), 5.17 (s, 2H), 5.09 (t, J = 5.6Hz, 1H), 4.40 (d, J = 5.6Hz, 2H), 3.40 (s, 3H), 1.47 (s, 9H).

[0691] Step 4: Synthesis of tert-butyl (5-formyl-2-(methoxymethoxy)phenyl)carbamate

[0692] tert-Butyl (5-(hydroxymethyl)-2-(methoxymethoxy)phenyl)carbamate (8.87 g, 35.06 mmol) was added to dichloromethane (100 mL). Dess-Martin reagent (29.73 g, 70.12 mmol) was added portionwise under an ice bath and allowed to react at room temperature for 20 hours. Saturated aqueous sodium bicarbonate (50 mL) was added, and the mixture was extracted with dichloromethane (100 mL x 3). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA = 5:1) to afford 5.8 g of a light yellow solid in a 65.9% yield. LC-MS (ESI): [M+H-56] + =226.1; 1 H NMR (400MHz, DMSO-d6) δ9.86 (s, 1H), 8.34 (s, 1H), 8.29 (d, J = 2.4Hz, 1H), 7.61 (dd ,J=8.4,2.0Hz,1H),7.28(d,J=8.4Hz,1H),5.34(s,2H),3.43(s,3H),1.49(s,9H).

[0693] Step 5: Synthesis of tert-butyl (E)-(2-(methoxymethoxy)-5-(2-(5-methyl-6-nitrobenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate

[0694] 2,5-Dimethyl-6-nitrobenzothiazole (5.46 g, 26.20 mmol) was added to tetrahydrofuran (100 mL). Sodium hydride (2.38 g, 59.61 mmol) was added under ice-cooling and stirred at room temperature for 30 minutes. Tert-butyl (5-formyl-2-(methoxymethoxy)phenyl)carbamate (6.7 g, 23.82 mmol) was then added and allowed to react at room temperature for 4 hours. The mixture was quenched by the addition of water (50 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and chromatographed on a silica gel column (PE:EA = 1:1) to afford 6.8 g of a black solid in a 60.5% yield. LC-MS (ESI): [M+H-56] + =472.3; 1 H NMR (400MHz, DMSO-d6) δ8.89(s,1H),8.20(s,1H),8.09(s,1H),7.73(d,J=16.0Hz,1H),7.51(dd,J=8.4,2.0 Hz,1H),7.46(d,J=16.0Hz,1H),7.17(d,J=8.8Hz,1H),5.28(s,2H),3.43(s,3H),2.65(s,3H),1.50(s,9H).

[0695] Step 6: Synthesis of tert-butyl (E)-(5-(2-(6-amino-5-methylbenzo[d]thiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)carbamate

[0696] Tert-butyl (E)-(2-(methoxymethoxy)-5-(2-(5-methyl-6-nitrobenzo[d]thiazol-2-yl)vinyl)phenyl)carbamate (3 g, 6.37 mmol) was added to a mixture of ethanol and water (40 mL, v / v = 1 / 1), followed by ammonium chloride (3.44 g, 63.69 mmol) and iron powder (3.57 g, 63.69 mmol). The mixture was reacted at 80°C for 20 hours. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated to give 1.39 g of a brown solid in a 49.5% yield. LC-MS (ESI): [M+H-56] + =442.4; 1 H NMR (400MHz, DMSO-d6) δ8.15(s,1H),7.99(s,1H),7.53(s,1H),7.39(dd,J=8.8,2.4Hz,1H),7.28(d,J =7.6Hz,2H),7.13(d,J=8.4Hz,1H),7.10(s,1H),5.25(s,2H),3.42(s,3H),2.19(s,3H),1.50(s,9H).

[0697] Step 7: Synthesis of tert-butyl (E)-(5-(2-(6-(2-(2-(2-hydroxyethoxy)ethyl)amino)-5-methylbenzothiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)carbamate

[0698] Tert-butyl (E)-(5-(2-(6-amino-5-methylbenzo[d]thiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)carbamate (1.18 g, 2.67 mmol) was added to N,N-dimethylformamide (16 mL), followed by 2-chloroethoxyethanol (3.32 g, 26.76 mmol), potassium carbonate (1.11 g, 8.03 mmol), and potassium iodide (0.44 g, 2.67 mmol). The mixture was reacted at 100°C for 48 hours. The reaction mixture was cooled to room temperature, and water (50 mL) was added. The mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and chromatographed on a silica gel column (PE:EA = 1:2) to afford 0.65 g of a yellow oil in a 45.9% yield. LC-MS (ESI): [M+H] + =530.4; 1H NMR (400MHz, DMSO-d6) δ8.15(s,1H),8.00(s,1H),7.96(s,1H),7.58(s,1H),7.40(dd,J=8.8,2.4Hz,1H),7.30(d,J=9.6Hz,1H),7.13(t,J=5.2H z,2H),5.25(s,2H),5.14(t,J=5.6Hz,1H),4.65(t,J=5.2Hz,1H),3.73– 3.58(m,4H),3.54–3.48(m,4H),3.43(s,3H),2.21(s,3H),1.50(s,9H).

[0699] Step 8: Synthesis of tert-butyl (E)-(5-(2-(6-(2-(2-(2-hydroxyethoxy)ethyl)(methyl)amino)-5-methylbenzothiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)carbamate

[0700] Tert-butyl (E)-(5-(2-(6-(2-(2-(2-hydroxyethoxy)ethyl)amino)-5-methylbenzothiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)carbamate (0.65 g, 1.23 mmol) was added to methanol (15 mL), followed by 30% aqueous formaldehyde solution (73.7 mg, 2.46 mmol). The mixture was stirred in an ice bath for 30 minutes. Sodium cyanoborohydride (2.08 g, 9.83 mmol) was added, and the mixture was allowed to react at room temperature for 20 hours. The reaction solution was concentrated and purified by silica gel column chromatography (PE:EA = 1:2) to afford 0.48 g of a yellow solid in a 71.9% yield. LC-MS (ESI): [M+H] + =544.4; 1 H NMR (400MHz, DMSO-d6) δ8.16 (s, 1H), 8.05 (s, 1H), 7.73 (d, J = 3.2Hz, 2H), 7. 51–7.40(m,2H),7.33(d,J=16.4Hz,1H),7.14(d,J=8.8Hz,1H),5.26(s,2H) ,4.57(t,J=5.6Hz,1H),3.58(t,J=6.0Hz,2H),3.48(q,J=5.2Hz,2H),3.45– 3.38(m,5H),3.09(t,J=6.0Hz,2H),2.76(s,3H),2.37(s,3H),1.50(s,9H).

[0701] Step 9: Synthesis of (E)-ethyl 2-(2-(2-(3-(tert-butoxycarbonyl)amino)-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)4-methylbenzenesulfonate

[0702] Tert-butyl (E)-(5-(2-(6-(2-(2-(2-hydroxyethoxy)ethyl)(methyl)amino)-5-methylbenzothiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)carbamate (0.48 g, 0.88 mmol) was added to dichloromethane (10 mL), followed by the addition of triethylamine (356.5 mg, 3.53 mmol) and p-toluenesulfonyl chloride (335.3 mg, 1.76 mmol) under ice-cooling. The reaction was allowed to react at room temperature for 20 hours. The mixture was quenched by the addition of water (50 mL) and extracted with ethyl acetate (100 mL x 3). The organic phase was concentrated and purified by silica gel column chromatography (PE:EA = 1:2) to afford 0.43 g of a yellow solid in a 58.6% yield. LC-MS (ESI): [M+H] + =698.3; 1 H NMR (400MHz, DMSO-d6) δ8.18(s,1H),8.04(s,1H),7.81–7.67(m,4H),7.52–7.41(m,4H),7.34(d,J=16.0Hz,1H),7.15(d,J=8.4Hz,1H),5. 27(s,2H),4.14–4.07(m,2H),3.61–3.45(m,4H),3.43(s,3H),3.01(t,J=6.0Hz,2H),2.71(s,3H),2.40(s,3H),2.33(s,3H),1.50(s,9H).

[0703] Step 10: Synthesis of tert-butyl (E)-(5-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)carbamate

[0704] (E)-ethyl 2-(2-(2-(3-(tert-butoxycarbonyl)amino)-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)4-methylbenzenesulfonate (0.33 g, 0.47 mmol), [bmim][BF4] (6 mL), and potassium fluoride (359.8 mg, 2.37 mmol) were added to acetonitrile (6 mL) and reacted at 100°C for 5 hours. The reaction solution was cooled to room temperature, concentrated, and purified by silica gel column chromatography (PE:EA = 1:1) to afford 160 mg of a yellow oil in a 62.0% yield. LC-MS (ESI): [M+H] + =546.4; 1 H NMR(400MHz,DMSO-d6)δ8.17(s, 1H),8.03(s,1H),7.74(d,J=8.8Hz,2H),7.51–7.41(m,2H),7.33(d,J=16.0Hz,1H),7.15(d,J=8.4Hz,1H),5.26(s,2H),4.60– 4.52(m,1H),4.48–4.40(m,1H),3.71–3.58(m,4H),3.43(s,3H),3.11(t,J=6.0Hz,2H),2.76(s,3H),2.38(s,3H),1.50(s,9H).

[0705] Step 11: Synthesis of (E)-2-amino-4-(2-(6-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzothiazol-2-yl)vinyl)phenol

[0706] Tert-butyl (E)-(5-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)carbamate (100 mg, 0.18 mmol) was added to 1,4-dioxane (1 mL), followed by a 4 M solution of hydrochloric acid in 1,4-dioxane (4 mL). The mixture was allowed to react at room temperature for 4 hours. The reaction mixture was filtered, and the filter cake was washed with ethyl acetate (20 mL) and then diethyl ether (10 mL) to afford 34.1 mg of an orange solid in a 46.3% yield. LC-MS (ESI): [M+H] + =402.2; 1H NMR (400MHz, CD3OD) δ8.45(s,1H),7.96(s,1H),7.73–7.65(m,3H),7.40(d,J=16.0Hz,1H),7.09(d,J=8.0Hz,1 H),4.57–4.48(m,1H),4.45–4.38(m,1H),4.01(t,J=4.8Hz,2H),3.65–3.44(m,4H),3.40(s,3H),2.68(s,3H); 19 FNMR(376MHz,CD3OD)δ-221.33.

[0707] Example 5: Synthesis of Compound D

[0708] Compound D was synthesized according to Examples 1 and 2.

[0709] Compound D: LC-MS (ESI): [M+H] + =416.2.

[0710] Another synthetic route of compound D

[0711] Synthesis of (E)-4-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-2-(methylamino)phenol

[0712] Step 1: Synthesis of tert-butyl (E)-(5-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)(methyl)carbamate

[0713] Tert-butyl (E)-(5-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)carbamate (120 mg, 0.22 mmol) was added to N,N-dimethylformamide (3 mL). Sodium hydride (17.6 mg, 0.44 mmol, w%: 60%) was added under ice-cooling. The mixture was allowed to react under ice-cooling for 0.5 h. Methyl iodide (62.6 mg, 0.44 mmol) was then added and the reaction was allowed to proceed at room temperature overnight. After completion of the reaction, the mixture was diluted with water (30 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and purified by silica gel column chromatography (PE:EA = 5:1) to afford 89 mg of a white solid in a 72.3% yield. LC-MS (ESI): [M+H] +=560.4; 1 H NMR (400MHz, DMSO-d6) δ7.75(s,1H),7.74(s,1H),7.70–7.58(m,2H),7.48(d,J=2.4Hz,2H),7.19(d,J=8.8Hz,1H),5.2 8(s,2H),4.61–4.38(m,2H),3.74–3.56(m,4H),3.41(s,3H),3.19–2.95(m,5H),2.76(s,3H),2.38(s,3H),1.49(s,9H).

[0714] Step 2: Synthesis of (E)-4-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-2-(methylamino)phenol

[0715] Tert-butyl (E)-(5-(2-(6-(2-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-2-(methoxymethoxy)phenyl)(methyl)carbamate (89 mg, 0.16 mmol) was added to 1,4-dioxane (0.5 mL), followed by a 4 M solution of hydrochloric acid in 1,4-dioxane (2 mL). The mixture was allowed to react at room temperature for 5 hours. The reaction mixture was filtered, and the filter cake was washed with ethyl acetate (20 mL) and then diethyl ether (10 mL) to give 34.4 mg of an orange solid with a yield of 52.1%. LC-MS (ESI): [M+H] + =416.2; 19 F NMR (376MHz, DMSO) δ-221.32; 1 H NMR (400MHz, CD3OD) δ8.44(s,1H),7.96(s,1H),7.78–7.66(m,3H),7.44(d,J=16.4Hz,1H),7.12(d,J=8.8H z,1H),4.57–4.37(m,2H),4.01(t,J=5.0Hz,2H),3.65–3.47(m,4H),3.40(s,3H),3.10(s,3H),2.68(s,3H).

[0716] Example 6: Synthesis of Compounds E and F

[0717] Compounds E and F were synthesized according to Examples 1 and 2.

[0718] Compound E: LC-MS (ESI): [M+H] +=495.1,497.1.

[0719] Compound F: LC-MS (ESI): [M+H] + =481.0,483.0.

[0720] Another synthetic route of compound E

[0721] Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-3-methoxyphenol

[0722] Step 1: Synthesis of 3-bromo-2,4-dihydroxybenzoic acid

[0723] To a solution of 2-bromo-1,3-benzenediol (10.0 g, 52.91 mmol) in dry acetonitrile (200 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (24.2 g, 158.73 mmol). Carbon dioxide gas was bubbled through the reaction mixture at room temperature for 24 hours. After completion of the reaction, the carbon dioxide gas was vented and the pH of the reaction mixture was adjusted to approximately 5-6 with 2N hydrochloric acid. The mixture was diluted with water and extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a silica gel column (EA:AcOH = 100:1) to afford 11.2 g of a pink solid in a 91% yield. 1 H NMR (400MHz, DMSO-d6) δ 13.81 (s, 1H), 12.28 (s, 1H), 11.21 (s, 1H), 7.64 (d, J = 8.8Hz, 1H), 6.55 (d, J = 8.8Hz, 1H).

[0724] Step 2: 8-Bromo-7-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one

[0725] 3-Bromo-2,4-dihydroxybenzoic acid (5.0 g, 21.46 mmol) was dissolved in TFA (39.1 g, 343.4 mmol). Trifluoroacetic anhydride (23.0 g, 107.3 mmol) was slowly added dropwise at 0°C for approximately 20 minutes. Acetone (6.2 g, 0.73 mmol) was then slowly added dropwise at room temperature for approximately 30 minutes. The reaction was stirred at 90°C under nitrogen for 36 hours. The solvent was removed by concentration under reduced pressure at 55°C. Toluene (20 mL) was added to the crude product, and the solvent was removed by vacuum evaporation. This process was repeated three times to obtain the crude product. The crude product was purified on a silica gel column (PE:EA = 22:78) to obtain 2.3 g of a white solid in a 39% yield. LC-MS (ESI): [MH] - =271.0,273.0; 1 H NMR (400MHz, DMSO-d6) δ11.69(s,1H),7.71(d,J=8.8Hz,1H),6.79(d,J=8.4Hz,1H),1.69(s,6H).

[0726] Step 3: Synthesis of 8-bromo-7-(methoxymethoxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one

[0727] 8-Bromo-7-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (2.3 g, 8.42 mmol) was dissolved in DCM (20 mL), triethylamine (2.6 g, 25.26 mmol) was added, and then MOMBr (2.1 g, 16.84 mmol) was added dropwise at 0°C. The mixture was reacted at room temperature for 16 hours. The reaction solution was extracted with ethyl acetate (50 mL×3), and the organic phases were combined and washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a silica gel column (PE:MTBE=87:13) to obtain 2.1 g of a white solid product with a yield of 78.6%. 1 H NMR (400MHz, DMSO-d6) δ7.86 (d, J = 8.8 Hz, 1H), 7.05 (d, J = 8.8 Hz, 1H), 5.42 (s, 2H), 3.43 (s, 3H), 1.72 (s, 6H).

[0728] Step 4: Synthesis of 2-bromo-6-hydroxymethyl-3-(methoxymethoxy)phenol

[0729] To a solution of 8-bromo-7-(methoxymethoxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (2.1 g, 6.62 mmol) in tetrahydrofuran (20 mL) was added lithium aluminum hydride (503 mg, 13.24 mmol) at 0°C. The mixture was stirred at 0°C for 15 minutes and then at room temperature for 2 hours. After completion of the reaction, 20 mL of tetrahydrofuran was added to the reaction mixture under an ice bath. 0.5 mL of water was slowly added dropwise and stirred for 5 minutes. 0.5 mL of 15% sodium hydroxide solution was then added dropwise and stirred for 15 minutes. Then, 1.5 mL of water was added dropwise and stirred for 10 minutes. The pH was adjusted to approximately 6 with 2N HCl and filtered. The filtrate was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to afford 1.4 g of crude product as a light yellow oil, which was used directly in the next step without purification. LC-MS(ESI):[MH] - =261.1,263.0.

[0730] Step 5: (3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)methanol

[0731] To a solution of 2-bromo-6-hydroxymethyl-3-(methoxymethoxy)phenol (1.6 g, 6.08 mmol) and potassium carbonate (2.5 g, 18.24 mmol) in DMF (20 mL) was added iodomethane (1.7 g, 12.16 mmol). The reaction was allowed to react at room temperature for 16 hours. The reaction solution was extracted with ethyl acetate (50 mL × 3), and the organic phases were combined and washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a silica gel column (PE:MTBE = 82:18) to obtain 1.8 g of the product as a colorless oil with a yield of 95%. 1 H NMR (400 MHz, DMSO-d6) δ7.34 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 5.26 (s, 2H), 5.12 (t, J = 5.6, 1H), 4.50–4.49 (m, 2H), 3.75 (s, 3H), 3.40 (s, 3H). Step 6: Synthesis of 3-bromo-2-methoxy-4-(methoxymethoxy)benzaldehyde

[0732] To a solution of (3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)methanol (1.6 g, 5.77 mmol) in dichloromethane was added Dess-Martin reagent (4.9 g, 11.55 mmol) over five minutes at 0°C. The reaction was allowed to react at room temperature for two hours. The reaction solution was concentrated and purified by silica gel column chromatography (PE:MTBE = 89:11) to afford 1.5 g of a colorless oil in a 94% yield.1 H NMR (400MHz, DMSO-d6) δ10.12(s,1H),7.77(d,J=8.8Hz,1H),7.16(d,J=8.8Hz,1H),5.41(s,2H),3.92(s,3H),3.42(s,3H).

[0733] Step 7: Synthesis of (E)-2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methyl-6-nitrobenzothiazole

[0734] 2,5-Dimethyl-6-nitrobenzothiazole (1.48 g, 6.97 mmol) was added to tetrahydrofuran (20 mL). Sodium hydride (429 mg, 10.72 mmol, 60%) was added at 0°C and stirred at 0°C for 30 minutes. 3-Bromo-2-methoxy-4-(methoxymethoxy)benzaldehyde (1.50 g, 5.36 mmol) was then added and allowed to react at room temperature for 16 hours. The mixture was quenched by the addition of aqueous ammonium chloride and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:DCM = 0-100%) to afford 1.47 g of a yellow solid in a 58.9% yield. LC-MS (ESI): [M+H] + =465.2,467.1; 1 H NMR (400MHz, CDCl3) δ8.55(s,1H),7.92(s,1H),7.84(d,J=16.4Hz,1H),7.58(d,J=8.8Hz,1H),7. 43(d,J=16.8Hz,1H),7.03(d,J=8.8Hz,1H),5.31(s,2H),3.93(s,3H),3.54(s,3H),2.75(s,3H).

[0735] Step 8: Synthesis of (E)-2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-amine

[0736] (E)-2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methyl-6-nitrobenzothiazole (1.42 g, 3.05 mmol) was added to methanol (20 mL), followed by ammonium chloride (1.63 g, 30.50 mmol) and iron powder (854 mg, 15.25 mmol). The reaction was allowed to proceed at 70°C under nitrogen for 16 hours. The filtrate was filtered, concentrated, and purified by silica gel column chromatography (DCM:MeOH = 96:4) to afford 1.27 g of a yellow solid in a 95.6% yield. LC-MS (ESI): [M+H] + =435.1,437.1; 1 H NMR(400MHz, DMSO-d6)δ7.84(d,J=8.8Hz,1H),7.56(s,1H),7.49–7.39(m,2H),7. 10–7.06(m,2H),5.34(s,2H),5.30(s,2H),3.81(s,3H),3.42(s,3H),2.18(s,3H).

[0737] Step 9: Synthesis of (E)-2-(2-((2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)amino)ethoxy)ethan-1-ol

[0738] (E)-2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-amine (1.25 g, 2.87 mmol) was added to DMF (10 mL), along with 2-chloroethoxyethanol (1.07 g, 8.61 mmol), potassium carbonate (1.19 g, 8.61 mmol), and potassium iodide (94 mg, 0.57 mmol). The reaction was allowed to proceed at 100°C under nitrogen for 24 hours. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (DCM:MeOH = 95:5) to afford 580 mg of a yellow oil in a 39% yield. LC-MS (ESI): [M+H] + =523.2,525.2; 1H NMR (400MHz, DMSO-d6) δ7.85(d,J=9.2Hz,1H),7.61(s,1H),7.50–7.41(m,2H),7.13(s,1H),7.08(d,J=8.8Hz,1H),5.34(s,2H),5.17(t,J=6.4Hz, 1H),4.64(t,J=5.2Hz,1H),3.81(s,3H),3.67(t,J=6.0Hz,2H),3.55–3.5 1(m,2H),3.50–3.47(m,2H),3.43(s,3H),3.36–3.35(m,2H),2.21(s,3H).

[0739] Step 10: Synthesis of (E)-2-(2-((2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethan-1-ol

[0740] (E)-2-(2-((2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)amino)ethoxy)ethan-1-ol (580 mg, 1.11 mmol) was added to methanol (4 mL), followed by formaldehyde (333 mg, 11.10 mmol), and stirred at 0°C for 15 minutes. Sodium cyanoborohydride (140 mg, 2.22 mmol) was added. The reaction was allowed to react at room temperature for 16 hours. Water was added, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined and washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (DCM:MeOH = 95:5) to give 460 mg of a yellow solid in a yield of 77.5%. LC-MS (ESI): [M+H] + =537.2,539.2; 1 H NMR (400MHz, DMSO-d6) δ7.89(d,J=8.8Hz,1H),7.75(d,J=8.4Hz,2H),7.61–7.51(m,2H),7.09(d,J=8.8Hz,1H),5.36(s,2H),4.56(t,J=5.6Hz ,1H),3.83(s,3H),3.58(t,J=6.0Hz,2H),3.48–3.45(m,2H),3.43(s,3 H), 3.42–3.39 (m, 2H), 3.09 (t, J = 6.0Hz, 2H), 2.76 (s, 3H), 2.37 (s, 3H).

[0741] Step 11: Synthesis of (E)-2-(2-((2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethyl-4-methylbenzenesulfonate

[0742] A solution of (E)-2-(2-((2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethan-1-ol (410 mg, 0.76 mmol), triethylamine (307 mg, 3.04 mmol), and p-toluenesulfonyl chloride (291 mg, 1.53 mmol) in dichloromethane (3 mL) was reacted at room temperature under nitrogen for 16 hours. The mixture was extracted with ethyl acetate (30 mL × 3), and the combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA = 70:30) to afford 460 mg of a yellow solid in a 78.8% yield. LC-MS (ESI): [M+H] + =691.2,693.2; 1 H NMR(400MHz,DMSO-d6)δ7.89(d,J=8.8Hz,1H),7.77(d,J=8.4Hz,3H),7.70(s,1 H),7.61–7.51(m,2H),7.45(d,J=8.4Hz,2H),7.09(d,J=8.8Hz,1H),5.36(s,2H ),4.10(t,J=4.4Hz,2H),3.83(s,3H),3.55(t,J=4.4Hz,2H),3.49(t,J=6.0Hz, 2H), 3.43 (s, 3H), 3.01 (t, J = 5.6Hz, 2H), 2.71 (s, 3H), 2.39 (s, 3H), 2.33 (s, 3H).

[0743] Step 12: Synthesis of (E)-2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzothiazol-6-amine

[0744] (E)-2-(2-((2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethyl-4-methylbenzenesulfonate (300 mg, 0.43 mmol) was added to anhydrous acetonitrile (6 mL, 20 v), followed by cesium fluoride (327 mg, 2.15 mmol) and 1-butyl-3-methylimidazolium tetrafluoroborate (6 mL, 20 v). The reaction was incubated at 100°C under nitrogen for 2 hours. The mixture was quenched with water and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA=82:18) to afford 180 mg of a yellow solid in a yield of 77.6%. LC-MS (ESI): [M+H] + =539.2,541.2. 1 HNMR(400MHz, DMSO-d6)δ7.89(d,J=9.2Hz,1H),7.76(d,J=8.0Hz,2H),7.61–7.51(m,2H),7.09(d,J=8.8Hz,1H),5.36(s,2H),4.56(t,J=4Hz, 1H),4.44(t,J=4Hz,1H),3.83(s,3H),3.67(t,J=4.4Hz,1H),3.63–3.5 8(m,3H),3.43(s,3H),3.11(t,J=6.4Hz,2H),2.76(s,3H),2.38(s,3H).

[0745] Step 13: (E)-2-Bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-3-methoxyphenol

[0746] To a solution of (E)-2-(3-bromo-2-methoxy-4-(methoxymethoxy)phenylvinyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzothiazol-6-amine (80 mg, 0.15 mmol) in 1,4-dioxane (1.5 mL) was added dropwise a 4 M hydrochloric acid solution in 1,4-dioxane (1.5 mL) at room temperature. The mixture was allowed to react at room temperature for 2 hours. Ethyl acetate (6 mL) was added to the reaction solution, which was filtered, rinsed with ethyl acetate and then with diethyl ether, and the filter cake was dried to afford 65.3 mg of an orange solid (88% yield). LC-MS (ESI): [M+H] + =495.1,497.1; 19 F NMR (376MHz, DMSO) δ-221.33; 1H NMR (400MHz, DMSO-d6) δ11.06(s,1H),8.31(s,1H),7.90(s,1H),7.75(d,J=8.8Hz,1H),7.69–7.65(d,J=16.0Hz,1H),7.51–7.47(d,J=1 6.0Hz,1H),6.91(d,J=8.8Hz,1H),4.52(t,J=8.0Hz,1H),4.41–4.39(m,1H),3.81(s,3H),3.62–3.52(m,6H),3.11(s,3H),2.55(s,3H).

[0747] Another synthetic route for compound F

[0748] Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)benzene-1,3-diol

[0749] Step 1: Synthesis of 2-(2-((tert-butyldimethylsilyloxy)ethoxy)acetaldehyde

[0750] To a solution of 2-(2-((tert-butyldimethylsilyloxy)ethoxy)-1-ethanol (551 mg, 2.50 mmol) in dichloromethane (5 mL) was added Dess-Martin reagent (1.4 g, 3.25 mmol) under ice-cooling and allowed to react at room temperature for 4 hours. TLC revealed the formation of a yellow spot using 2,4-dinitrophenylhydrazine as a chromogenic reagent. The solvent was evaporated under reduced pressure, and the residue was slurried with methyl tert-butyl ether (20 mL) and filtered. The filtrate was evaporated to dryness to afford 500 mg of a colorless oil, which was used directly in the next reaction.

[0751] Step 2: Synthesis of 3-bromo-2,4-dihydroxybenzaldehyde

[0752] Phosphorus oxychloride (40.6 g, 264.5 mmol, 25 mL) was added dropwise to DMF (50 mL) at 0°C under nitrogen. The reaction mixture was stirred at room temperature for 1.5 hours. A solution of 2-bromo-1,3-benzenediol (5.0 g, 26.45 mmol) in DMF (25 mL) was then added dropwise to the reaction mixture at a temperature not exceeding 30°C. The mixture was allowed to react at room temperature for 16 hours. The reaction mixture was poured into ice water and the pH was adjusted to approximately 2-3 with sodium bicarbonate. The mixture was then extracted with ethyl acetate (200 mL x 3). The combined organic phases were washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a silica gel column (PE:MTBE = 75:25) to afford 450 mg of the product as a white solid in a 7.8% yield. 1 H NMR (400MHz, CDCl3) δ12.16 (s, 1H), 9.70 (s, 1H), 7.45 (d, J = 8.4Hz, 1H), 6.73 (d, J = 8.8Hz, 1H), 6.31 (s, 1H).

[0753] Step 3: Synthesis of 3-bromo-2,4-bis(methoxymethoxy)benzaldehyde

[0754] 3-Bromo-2,4-dihydroxybenzaldehyde (950 mg, 4.38 mmol) was dissolved in DCM (20 mL), triethylamine (2.21 g, 21.90 mmol) was added, and then MOMBr (1.64 g, 13.14 mmol) was added dropwise under ice bath. The reaction was allowed to react at room temperature for 16 hours. The reaction solution was extracted with ethyl acetate (30 mL × 3), and the organic phases were combined and washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column (PE:MTBE=87:13) to give 670 mg of white solid product with a yield of 50.1%. 1 H NMR (400MHz, CDCl3) δ10.23(s,1H),7.81(d,J=8.8Hz,1H),7.07(d,J=8.8Hz,1H),5.33(s,2H),5.21(s,2H),3.64(s,3H),3.52(s,3H).

[0755] Step 4: Synthesis of (E)-2-(3-bromo-2,4-bis(methoxymethoxy)phenylvinyl)-5-methyl-6-nitrobenzo[d]thiazole

[0756] 2,5-Dimethyl-6-nitrobenzothiazole (595 mg, 2.86 mmol) was added to tetrahydrofuran (10 mL). Sodium hydride (205 mg, 5.12 mmol, 60%) was added under ice-cooling and stirred at room temperature for 30 minutes. 3-Bromo-2,4-bis(methoxymethoxy)benzaldehyde (670 mg, 2.20 mmol) was then added and allowed to react at room temperature for 16 hours. The mixture was quenched by the addition of aqueous ammonium chloride and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:DCM = 0-100%) to afford 620 mg of a yellow solid in a 56% yield. LC-MS (ESI): [M+H] + =495.2,497.1; 1 H NMR (400MHz, CDCl3) δ8.55(s,1H),7.99(d,J=16.4Hz,1H),7.91(s,1H),7.64(d,J=8.8Hz,1H),7.38(d, J=8.4Hz,1H),7.06(d,J=8.8Hz,1H),5.31(s,2H),5.19(s,2H),3.75(s,3H),3.54(s,3H),2.74(s,3H).

[0757] Step 5: Synthesis of (E)-2-(3-bromo-2,4-bis(methoxymethoxy)phenylvinyl)-5-methylbenzo[d]thiazol-6-amine

[0758] (E)-2-(3-bromo-2,4-bis(methoxymethoxy)phenylvinyl)-5-methyl-6-nitrobenz[d]thiazole (620 mg, 1.25 mmol) was added to methanol (10 mL), followed by ammonium chloride (669 mg, 12.5 mmol) and iron powder (350 mg, 6.26 mmol). The reaction was incubated at 80°C for 16 hours. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (DCM:MeOH = 98:2) to afford 530 mg of a red solid in a 91.0% yield. LC-MS (ESI): [M+H] + =465.1,467.1; 1 HNMR(400MHz, CDCl3)δ7.75–7.68(m,2H),7.60–7.58(m,1H),7.36–7.32(m,1H),7.12(s, 1H),7.03–7.01(m,1H),5.29(s,2H),5.17(s,2H),3.74(s,3H),3.53(s,3H),2.32(s,3H).

[0759] Step 6: Synthesis of (E)-2-(3-bromo-2,4-bis(methoxymethoxy)phenylvinyl)-N-(2-(2-((tert-butyldimethylsilyloxy)ethoxy)ethyl)-5-methylbenzo[d]thiazol-6-amine

[0760] (E)-2-(3-Bromo-2,4-bis(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-amine (380 mg, 0.82 mmol) was added to a solution of 2-(2-((tert-butyldimethylsilyloxy)ethoxy)acetaldehyde (500 mg, 2.29 mmol) in methanol (3 mL) and stirred at room temperature for 30 minutes. Sodium cyanoborohydride (103 mg, 1.64 mmol) was then added and the mixture was allowed to react at room temperature for 16 hours. Water was added to quench the mixture, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA = 82:18) to afford 330 mg of a yellow oil in a 60.2% yield. LC-MS (ESI): [M+H] + =667.3,669.3; 1 H NMR(400MHz, DMSO_d6)δ7.88(d,J=8.8Hz,1H),7.59–7.54(m,2H),7.43(d,J=16.4Hz,1H),7.11–7.08(m,2H),5.35(s,2H),5.13(s,3H),3.73 –3.69(m,2H),3.68–3.66(m,2H),3.65(s,3H),3.51(t,J=6.4Hz,2H),3 .43(s,3H),3.36–3.32(m,2H),3.20(s,3H),0.86(s,9H),0.04(s,6H).

[0761] Step 7: Synthesis of (E)-2-(3-bromo-2,4-bis(methoxymethoxy)phenylvinyl)-N-(2-(2-((tert-butyldimethylsilyloxy)ethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine

[0762] (E)-2-(3-Bromo-2,4-bis(methoxymethoxy)phenylvinyl)-N-(2-(2-((tert-butyldimethylsilyloxy)ethoxy)ethyl)-5-methylbenzo[d]thiazol-6-amine (300 mg, 0.45 mmol) was added to methanol (2 mL), followed by 30% aqueous formaldehyde solution (0.3 mL). The mixture was stirred on ice for 30 minutes. Sodium cyanoborohydride (85 mg, 1.35 mmol) was added and the mixture was allowed to react at room temperature for 16 hours. The reaction solution was concentrated and purified by silica gel column chromatography (PE:EA=83:17) to give 260 mg of a yellow oil in an 84.7% yield. LC-MS (ESI): [M+H] + =681.3,683.3; 1 H NMR(400MHz, DMSO_d6)δ7.92(d,J=8.0Hz,1H),7.74–7.68(m,3H),7.51–7.47(m,1H),7.11(d,J=8.8Hz,1H),5.36(s,2H),5.14(s,2H), 3.66–3.63(m,5H),3.58(t,J=6Hz,2H),3.44–3.41(m,5H),3.09(t,J=6.0Hz,2H),2.76(s,3H),2.36(s,3H),0.84(s,9H),0.01(s,6H).

[0763] Step 8: Synthesis of ((E)-2-(2-((2-(3-(3-bromo-2,4-bis(methoxymethoxy)phenylvinyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethanol

[0764] To a solution of (E)-2-(3-bromo-2,4-bis(methoxymethoxy)phenylvinyl)-N-(2-(2-((tert-butyldimethylsilyloxy)ethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine (260 mg, 0.38 mmol) in tetrahydrofuran (3 mL) was added tetrabutylammonium fluoride (120 mg, 0.76 mmol). The mixture was reacted at room temperature for 2 hours. Saturated aqueous ammonium chloride was added, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:MTBE = 0-30%, DCM:MeOH = 0-6%) to afford 200 mg of a yellow oil in a 92% yield. LC-MS (ESI): [M+H] + =567.2,569.1; 1HNMR(400MHz,DMSO_d6)δ7.91(d,J=9.2Hz,1H),7.74(s,2H),7.70(d,J=16.4H z,1H),7.49(d,J=16Hz,1H),7.11(d,J=8.4Hz,1H),5.36(s,2H),5.14(s,2H),4 .56(t,J=5.2Hz,1H),3.65(s,3H),3.57(t,J=6.0Hz,2H),3.46(t,J=5.2Hz,2H) ,3.43(s,3H),3.42–3.39(m,2H),3.09–3.07(m,2H),2.76(s,3H),2.37(s,3H).

[0765] Step 9: Synthesis of (E)-2-(2-((2-(3-(3-bromo-2,4-bis(methoxymethoxy)phenylvinyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethyl-4-methylbenzenesulfonate

[0766] (E)-2-(2-((2-(3-(3-bromo-2,4-bis(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethanol (190 mg, 0.33 mmol) was added to dichloromethane (2 mL), followed by the addition of triethylamine (133 mg, 1.32 mmol) and p-toluenesulfonyl chloride (126 mg, 0.66 mmol) under ice-cooling. The mixture was allowed to react at room temperature for 16 hours. Water was added to quench the mixture, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA=70:30) to afford 180 mg of a yellow solid in a 76% yield. LC-MS (ESI): [M+H] + =721.2,723.2; 1 H NMR(400MHz, DMSO_d6)δ7.92(d,J=8.8Hz,1H),7.78–7.69(m,5H),7.52(s,1H),7.48–7.44(m,2H),7.11(d,J=8.8Hz,1H ),5.36(s,2H),5.14(s,2H),4.10(t,J=4.4Hz,2H),3.65(s,3H),3.55(t,J=4.4Hz,2H),3.49(t,J=2.0Hz,2H),3.43(s, 3H), 3.00 (t, J = 6Hz, 2H), 2.70 (s, 3H), 2.39 (s, 3H), 2.33 (s, 3H).

[0767] Step 10: Synthesis of (E)-2-(3-bromo-2,4-bis(methoxymethoxy)phenyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine

[0768] (E)-2-(2-((2-(3-(3-bromo-2,4-bis(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethyl-4-methylbenzenesulfonate (100 mg, 0.14 mmol) was added to anhydrous acetonitrile (2 mL, 20 v), followed by cesium fluoride (106 mg, 0.70 mmol) and 1-butyl-3-methylimidazolium tetrafluoroborate (2 mL, 20 v). The reaction was stirred at 100°C for 2 hours. Water was added to quench the mixture, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (DCM:MeOH=97:3) to afford 38 mg of a yellow-green solid in a 47.7% yield. LC-MS (ESI): [M+H] + =569.2,571.2; 1 H NMR(400MHz, DMSO_d6)δ7.92(d,J=8.8Hz,1H),7.75-7.68(m,3H),7.51–7.47(d,J=16Hz,1H),7.11(d,J=9.2Hz,1H),5.36(s,2H),5.14(s,2H), 4.55(t,J=4.0Hz,1H),4.43(t,J=4.0Hz,1H),3.68-3.65(m,4H),3.62–3 .58(m,3H),3.43(s,3H),3.11(t,J=6Hz,2H),2.76(s,3H),2.37(s,3H).

[0769] Step 11: Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)benzene-1,3-diol

[0770] To a solution of (E)-2-(3-bromo-2,4-bis(methoxymethoxy)phenylvinyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine (38 mg, 0.07 mmol) in 1,4-dioxane (1 mL) was added dropwise a 4 M hydrochloric acid solution in 1,4-dioxane (1 mL) at room temperature. The mixture was allowed to react at room temperature for 16 hours. Ethyl acetate (5 mL) was added to the reaction mixture, which was filtered, rinsed with ethyl acetate and then with diethyl ether, and the filter cake was dried to afford 21.1 mg of an orange solid in a 63% yield. LC-MS (ESI): [M+H] + =481.1,483.1; 19 F NMR (376MHz, DMSO) δ-221.32; 1 H NMR (400MHz, CD3OD) δ8.42(s,1H),8.00(d,J=8.4Hz,1H),7.90(s,1H),7.52–7.47(m,2H),6.56(d,J=8.4Hz,1H),4.56–4. 54(m,1H),4.44–4.42(m,1H),4.00(t,J=0.8Hz,2H),3.63(t,J=4.0Hz,1H),3.57–3.55(m,3H),3.40(s,3H),2.68(s,3H).

[0771] Example 7: Synthesis of Compound G

[0772] Compound G was synthesized according to Examples 1 and 2.

[0773] Compound G: LC-MS (ESI): [M+H] + =480.1,482.1.

[0774] Another synthetic route for compound G

[0775] Step 1: Synthesis of methyl 4-methoxy-2-pivalamidobenzoate

[0776] Methyl 2-amino-4-methoxybenzoate (5.0 g, 27.6 mmol) was added to dichloromethane (50 mL), followed by 4-dimethylaminopyridine (337 mg, 2.76 mmol) and pyridine (4.36 g, 55.2 mmol). Pivaloyl chloride (4.97 g, 41.4 mmol) was added dropwise at 0°C, and the mixture was allowed to react at 0°C for 2 hours. The reaction solution was quenched with 1N hydrochloric acid solution (30 mL) and water (50 mL), extracted with dichloromethane (50 mL x 3), and the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (PE:EA = 10:1) to obtain 7.0 g of a white solid in a 95% yield. 1 H NMR (400MHz, CDCl3): δ11.54(s,1H),8.49(d,J=2.8Hz,1H),7.95(d,J=9.2Hz,1H),6.58(dd,J=8.8,2.8Hz,1H),3.89(s,3H),3.87(s,3H),1.35(s,9H).

[0777] Step 2: Synthesis of methyl 3-bromo-4-methoxy-2-pivalamidobenzoate

[0778] Methyl 4-methoxy-2-pivalamidobenzoate (2 g, 7.54 mmol) and N-bromosuccinimide (2.95 g, 16.6 mmol) were added to toluene (20 mL), followed by p-toluenesulfonic acid (2.59 g, 15.1 mmol) and palladium acetate (341 mg, 1.51 mmol). The mixture was stirred at room temperature under nitrogen for 16 hours. After completion of the reaction, the reaction solution was poured into ice water (30 mL) and filtered. The filtrate was extracted with ethyl acetate (20 mL x 3). The organic phases were combined and washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (PE:EA = 1:1) to obtain 200 mg of the product as a colorless oil in a yield of 7.7%. 1 H NMR (400MHz, CDCl3): δ8.68 (s, 1H), 7.88 (d, J = 8.8 Hz, 1H), 6.77 (d, J = 9.2 Hz, 1H), 3.95 (s, 3H), 3.85 (s, 3H), 1.36 (s, 9H).

[0779] Step 3: Synthesis of methyl 2-amino-3-bromo-4-methoxybenzoate

[0780] Methyl 3-bromo-4-methoxy-2-pivalamidobenzoate (200 mg, 0.58 mmol) was added to methanol (2 mL), and concentrated sulfuric acid (0.4 mL) was added at room temperature. The reaction was allowed to proceed at 70°C under nitrogen for 16 hours. The reaction solution was cooled to room temperature, added to ice water (10 mL), and extracted with ethyl acetate (10 mL x 3). The organic phases were combined and washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography (PE:EA=1:1) to obtain 140 mg of a white solid with a yield of 93%. LC-MS (ESI): [M+H] + =259.9,261.9.

[0781] Step 4: Synthesis of methyl 3-bromo-2-(di(tert-butoxycarbonyl)amino)-4-methoxybenzoate

[0782] Methyl 2-amino-3-bromo-4-methoxybenzoate (130 mg, 0.5 mmol) was added to acetonitrile (40 mL). 4-Dimethylaminopyridine (184 mg, 1.5 mmol) and di-tert-butyl dicarbonate (547 mg, 2.51 mmol) were added at room temperature. The reaction mixture was stirred at 80°C for one hour. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 4:1) to obtain 180 mg of a white solid product in a 78% yield. LC-MS (ESI): [M+Na] + =482.0,484.0; 1 H NMR (400MHz, CDCl3): δ8.01 (d, J = 8.8 Hz, 1H), 6.90 (d, J = 9.2 Hz, 1H), 3.98 (s, 3H), 3.86 (s, 3H), 1.36 (s, 18H).

[0783] Step 5: Synthesis of tert-butyl (2-bromo-6-(hydroxymethyl)-3-methoxyphenyl)carbamate

[0784] Methyl 3-bromo-2-(di(tert-butoxycarbonyl)amino)-4-methoxybenzoate (150 mg, 0.326 mmol) was added to tetrahydrofuran (4 mL) and the atmosphere was replaced with nitrogen three times. Lithium aluminum hydride (25 mg, 0.653 mmol) was then added at 0°C. The reaction mixture was stirred at 0°C for 2 hours. The reaction mixture was quenched with water (0.25 mL), 15% sodium hydroxide solution (0.25 mL), and water (0.75 mL) in sequence, then filtered through celite, and the filter cake was washed with ethyl acetate (5 mL x 3). The combined filtrates were concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA = 4:1) to afford 70 mg of a white solid in a 64% yield. LC-MS (ESI): [M+Na] + =354.0,356.0; 1 H NMR (400MHz, CDCl3): δ7.43 (d, J=8.4Hz, 1H), 6.85 (d, J=8.4Hz, 1H), 6.38 (s, 1H), 4.55 (s, 2H), 3.91 (s, 3H), 1.52 (s, 9H).

[0785] Step 6: Synthesis of tert-butyl (2-bromo-6-formyl-3-methoxyphenyl)carbamate

[0786] Tert-butyl (2-bromo-6-(hydroxymethyl)-3-methoxyphenyl)carbamate (70 mg, 0.21 mmol) was added to dichloromethane (3 mL), and Dess-Martin reagent (134 mg, 0.32 mL) was added at 0°C. The reaction mixture was allowed to react at room temperature for 1 hour. The reaction solution was quenched with sodium thiosulfate solution (2 mL) and sodium bicarbonate solution (3 mL), respectively, and extracted with dichloromethane (3 mL x 3). The organic phases were combined and washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (PE:EA = 3:1) to obtain 60 mg of a white solid in an 86% yield. LC-MS (ESI): [M+Na] + =352.0,354.0; 1 H NMR (400MHz, CDCl3): δ9.90 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.06 (s, 1H), 6.87 (d, J = 8.8 Hz, 1H), 3.98 (s, 3H), 1.50 (s, 9H).

[0787] Step 7: Synthesis of 2-(2-(2,5-dimethylbenzo[d]thiazol-6-yl)amino)ethoxy)ethanol

[0788] 2,5-Dimethylbenzo[d]thiazol-6-amine (2.4 g, 13.5 mmol), 2-(2-chloroethoxy)ethanol (12.0 g, 67.5 mmol), potassium carbonate (5.6 g, 40.5 mmol), and potassium iodide (2.3 g, 13.5 mmol) were added to N,N-dimethylformamide (30 mL) and reacted at 100°C for 16 hours. After completion of the reaction, N,N-dimethylformamide was concentrated using an oil pump and purified by silica gel column chromatography (DCM:MeOH = 10:1) to afford 2.0 g of a yellow solid in a 56.3% yield. LC-MS (ESI): [M+H] + =267.2; 1 H NMR (400MHz, CDCl3) δ7.62 (s, 1H), 6.97 (s, 1H), 3.82-3.77 (m, 4H), 3.64-3.62 (m, 2H), 3.38 (t, J = 4.0Hz, 2H), 2.75 (s, 3H), 2.26 (s, 3H).

[0789] Step 8: Synthesis of 2-(2-(2,5-dimethylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethanol

[0790] 2-(2-(2,5-Dimethylbenzo[d]thiazol-6-yl)amino)ethoxy)ethanol (2.0 g, 7.5 mmol) was added to methanol (30 mL), followed by aqueous formaldehyde (36%, 1.25 g, 15.0 mmol) and sodium cyanoborohydride (0.95 g, 15.0 mmol). The mixture was allowed to react at room temperature for 2 hours. After completion of the reaction, the mixture was diluted with water (20 mL) and extracted with dichloromethane (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and chromatographed on a silica gel column (DCM:MeOH = 92:8) to afford 1.6 g of a yellow oil in a 76.2% yield. LC-MS (ESI): [M+H] + =281.2; 1 HNMR (400MHz, CDCl3) δ7.73(s,1H),7.52(s,1H),3.69(t,J=4.0Hz,2H),3.63(t,J=4.0H z, 2H), 3.54 (t, J = 4.0Hz, 2H), 3.22-3.21 (m, 2H), 2.82 (s, 3H), 2.79 (s, 3H), 2.45 (s, 3H).

[0791] Step 9: Synthesis of ethyl 2-(2-(2,5-dimethylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)4-methylbenzenesulfonate

[0792] 2-(2-(2,5-Dimethylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethanol (1.6 g, 5.7 mmol) and triethylamine (2.3 g, 22.8 mmol) were added to dichloromethane (20 mL). p-Toluenesulfonyl chloride (2.2 g, 11.4 mmol) was then added under ice-cooling and allowed to react at room temperature for 16 hours. The mixture was quenched with water and extracted with dichloromethane (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and chromatographed on a silica gel column (PE:EA = 3:1) to afford 1.9 g of a yellow oil in a 76.6% yield. LC-MS (ESI): [M+H] + =435.2; 1 H NMR (400MHz, CDCl3) δ7.79-7.77(m,3H),7.34-7.26(m,3H),4.11-4.10(m,2H) ,3.59-3.56(m,4H),3.26-3.24(m,2H),2.84-2.80(m,6H),2.44-2.40(m,6H).

[0793] Step 10: Synthesis of N-(2-(2-fluoroethoxy)ethyl)-N,2,5-trimethylbenzo[d]thiazol-6-amine

[0794] Ethyl 2-(2-(2,5-dimethylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)4-methylbenzenesulfonate (1.9 g, 4.37 mmol), [bmim][BF4] (40 mL), and cesium fluoride (3.3 g, 21.8 mmol) were added to acetonitrile (40 mL) and reacted at 100°C under nitrogen for 2 hours. The reaction solution was cooled to room temperature, diluted with water, and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and purified by silica gel column chromatography (PE:EA = 3:1) to afford 1.04 g of a clear oil in an 86.7% yield. LC-MS (ESI): [M+H] + =283.2; 1 HNMR (400MHz, DMSO-d6) δ7.70(s,1H),7.68(s,1H),4.55(t,J=4.0Hz,1H),4.43(t,J=4.0Hz,1H),3.6 5(t,J=4.0Hz,1H),3.60-3.75(m,3H),3.07(t,J=4.0Hz,1H),2.73(s,3H),2.72(s,3H),2.35(s,3H).

[0795] Step 11: Synthesis of tert-butyl (E)-(2-bromo-6-(2-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-3-methoxyphenyl)carbamate

[0796] At 10°C, N-(2-(2-fluoroethoxy)ethyl)-N,2,5-trimethylbenzo[d]thiazol-6-amine (240 mg, 0.80 mmol) was added to a solution of potassium tert-butoxide (180 mg, 1.6 mmol) in DMSO (1 mL). Tert-butyl (2-bromo-6-formyl-3-methoxyphenyl)carbamate (264 mg, 0.8 mmol) was then added to the reaction mixture. The reaction was allowed to react at room temperature for 3 hours. The mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a silica gel column (PE:EA = 60:40) to afford 100 mg of the product as a yellow oil in a 21% yield. LC-MS (ESI): [M+H] + =594.1,596.1; 1 H NMR(400MHz, DMSO-d6)δ7.89(d,J=9.2Hz,1H),7.61–7.51(m,2H),6.90–6.82(m,3H),4.56(t,J=4Hz,1H),4.44 (t,J=4Hz,3H),3.83(s,3H),3.67(t,J=4.4Hz,1H),3.63–3.58(m,3H),2.76(s,3H),2.38(s,3H),1.49(s,9H).

[0797] Step 12: Synthesis of (E)-3-amino-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenol

[0798] Tert-butyl (E)-(2-bromo-6-(2-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-3-methoxyphenyl)carbamate (50 mg, 0.08 mmol) was dissolved in anhydrous DCM (2 mL), followed by the addition of TFA (0.5 mL). The reaction mixture was reacted at 20°C for 0.5 h. The reaction mixture was directly concentrated to dryness to afford the crude product. The crude product was dissolved in DMF (2.5 mL), followed by the addition of EtSNa (34 mg, 0.4 mmol). The reaction mixture was reacted at 100°C for 0.5 h. The reaction mixture was filtered and separated by prep-HPLC to afford 10 mg of the product as a brown solid in a 23% yield. LC-MS (ESI): [M+H] + =480.1,482.1; 1 H NMR (400MHz, CD3OD) δ8.42(s,1H),8.00-7.90(m,2H),7.52–7.47(m,2H),6.56(d,J=8.4Hz,1H),4.56–4.54(m,1H ),4.44–4.42(m,1H),4.00(t,J=0.8Hz,2H),3.63(t,J=4.0Hz,1H),3.57–3.55(m,3H),3.40(s,3H),2.68(s,3H).

[0799] Example 8: Synthesis of Compound H

[0800] Compound H was synthesized by referring to Examples 1 and 2.

[0801] Compound: LC-MS (ESI): [M+H] + =494.1,496.1.

[0802] Step 1: Synthesis of tert-butyl (E)-(2-bromo-6-(2-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-3-methoxyphenyl)(methyl)carbamate

[0803] Tert-butyl (E)-(2-bromo-6-(2-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-3-methoxyphenyl)carbamate (150 mg, 0.25 mmol) was added to N,N-dimethylformamide (3 mL). Sodium hydride (20 mg, 0.5 mmol, w%: 60%) was added under ice-cooling. The mixture was allowed to react under ice-cooling for 0.5 h. Methyl iodide (70 mg, 0.5 mmol) was then added and the reaction was allowed to proceed at room temperature overnight. After completion of the reaction, the mixture was diluted with water (30 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and chromatographed on a silica gel column (PE:EA = 5:1) to afford 90 mg of a yellow solid in a 59% yield. LC-MS (ESI): [M+H] + =608.1,610.1; 1 H NMR (400MHz, DMSO-d6) δ7.89(d,J=9.2Hz,1H),7.61–7.51(m,2H),6.90–6.82(m,3H),4.56(t,J=4Hz,1H),4.44(t,J= 4Hz,3H),3.83(s,3H),3.41(s,3H),3.67(t,J=4.4Hz,1H),3.63–3.58(m,3H),2.76(s,3H),2.38(s,3H),1.49(s,9H).

[0804] Step 2: Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-3-(methylamino)phenol

[0805] Tert-butyl (E)-(2-bromo-6-(2-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-3-methoxyphenyl)(methyl)carbamate (90 mg, 0.15 mmol) was dissolved in anhydrous DCM (5 mL), followed by the addition of TFA (1 mL). The reaction mixture was reacted at 20°C for 0.5 h. The reaction mixture was directly concentrated to dryness to obtain a crude product. The crude product was dissolved in DMF (3 mL), followed by the addition of EtSNa (63 mg, 0.75 mmol). The reaction mixture was reacted at 100°C for 0.5 h. The reaction mixture was filtered and separated by prep-HPLC to obtain 24 mg of the product as a brown solid in a 32% yield. LC-MS (ESI): [M+H] + =494.1,496.1; 1H NMR(400MHz,CD3OD)δ8.42(s,1H),8.00-7.90(m,2H),7.52–7.47(m,2H),6.56(d,J=8.4Hz,1H),4.56–4.54(m,1H),4.4 4–4.42(m,1H),4.00(t,J=0.8Hz,2H),3.63(t,J=4.0Hz,1H),3.57–3.55(m,3H),3.40(s,3H),3.10(s,3H),2.68(s,3H).

[0806] Example 9: Synthesis of Compound I or J

[0807] Compound I or J was synthesized by referring to Examples 1 and 2.

[0808] Compound 1: LC-MS (ESI): [M+H] + =439.0,441.0.

[0809] Compound J: LC-MS (ESI): [M+H] + =439.0,441.0.

[0810] Another synthetic route of compound I or J

[0811] Synthesis of 2-bromo-4-(6-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzothiazol-2-yl)phenol

[0812] Step 1: Synthesis of 2-iodo-5-methyl-4-nitroaniline

[0813] Iodine (43.4 g, 17.11 mmol) was added to ethanol (400 mL), followed by silver sulfate (41.1 g, 13.16 mmol) and 3-methyl-4-nitroaniline (20 g, 13.16 mmol). The mixture was stirred at room temperature for 4 hours. After the reaction, the reaction solution was concentrated, and the concentrated solid was dissolved in dichloromethane (100 mL) and saturated sodium sulfite solution (100 mL). The product was extracted with dichloromethane (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA = 3:1) to obtain 14.2 g of a yellow solid in a 38.9% yield. LC-MS (ESI): [M+H] + =278.9; 1 H NMR (400MHz, CDCl3) δ8.48(s,1H),6.54(s,1H),4.66(s,2H),2.55(s,3H).

[0814] Step 2: Synthesis of 2-(3-bromo-4-methoxyphenyl)-5-methyl-6-nitrobenzo[d]thiazole

[0815] 2-Iodo-5-methyl-4-nitroaniline (14.2 g, 51.08 mmol), 3-bromo-4-methoxybenzaldehyde (10.98 g, 51.08 mmol), sulfur (49.04 g, 153.2 mmol), and cuprous iodide (972 mg, 5.1 mmol) were added to N,N-dimethylformamide (300 mL) and reacted at 130°C for 48 hours. After completion of the reaction, the reaction mixture was filtered, and the filter cake was washed with dichloromethane (60 mL). The reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography (PE:EA = 2:1) to afford 2.87 g of a yellow solid in a 14.8% yield. LC-MS (ESI): [M+H] + =379.1,381.1; 1 H NMR (400MHz, CDCl3) δ 8.58 (s, 1H), 8.32 (d, J = 2.4Hz, 1H), 8.01 (dd, J = 2.4Hz, 2.0Hz, 1H), 7.93 (s, 1H), 7.01 (d, J = 8.4Hz, 1H), 4.00 (s, 3H), 2.75 (s, 3H).

[0816] Step 3: Synthesis of 2-bromo-4-(5-methyl-6-nitrobenzo[d]thiazol-2-yl)phenol

[0817] 2-(3-Bromo-4-methoxyphenyl)-5-methyl-6-nitrobenzo[d]thiazole (2.87 g, 7.57 mmol) was added to dichloromethane (60 mL), and boron tribromide (5.69 g, 22.71 mmol) was slowly added dropwise at -70°C. The reaction was allowed to react at room temperature for 2 hours. After completion, the reaction was quenched with saturated sodium bicarbonate solution at 0°C, extracted with dichloromethane (50 mL x 3), and the organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The product was purified by silica gel column chromatography (PE:EA = 1:1) and concentrated to afford 2.18 g of a yellow solid in a 78.9% yield. LC-MS (ESI): [M+H] + =365.1,367.1; 1 H NMR (400MHz, DMSO-d6) δ 11.3 (s, 1H), 8.92 (s, 1H), 8.23 ​​(d, J = 2.4Hz, 1H), 8.08 (s, 1H), 7.97 (dd, J = 2.0Hz, 1H), 7.13 (d, J = 8.4Hz, 1H), 2.65 (s, 3H).

[0818] Step 4: Synthesis of 2-(3-bromo-4-(methoxymethoxy)phenyl)-5-methyl-6-nitrobenzo[d]thiazole

[0819] 2-Bromo-4-(5-methyl-6-nitrobenzo[d]thiazol-2-yl)phenol (2.18 g, 5.97 mmol) was added to dichloromethane (40 mL), followed by N,N-diisopropylethylamine (2.31 g, 17.91 mmol). Bromo(methoxy)methane (1.11 g, 8.96 mmol) was added dropwise under an ice bath and allowed to react at room temperature for 2 hours. After completion of the reaction, the mixture was diluted with water (30 mL) and extracted with dichloromethane (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and chromatographed on a silica gel column (PE:EA = 3:1) to afford 1.95 g of a yellow solid in a 79.92% yield. LC-MS (ESI): [M+H] + =411.1,413.1; 1 H NMR (400MHz, DMSO-d6) δ8.93(s,1H),8.29(d,J=1.6Hz,1H),8.08-8.06(m,2H),7.39(d,J=8.8Hz,1H),5.43(s,2H),3.44(s,3H),2.64(s,3H).

[0820] Step 5: Synthesis of 2-(3-bromo-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-amine

[0821] 2-(3-Bromo-4-(methoxymethoxy)phenyl)-5-methyl-6-nitrobenz[d]thiazole (1.95 g, 4.77 mmol) was added to ethanol and water (300 mL, v:v = 2:1), followed by iron powder (1.34 g, 23.85 mmol) and ammonium chloride (2.58 g, 47.7 mmol). The mixture was allowed to react at 80°C for 16 hours. After completion of the reaction, the reaction mixture was filtered, the filter cake was washed with methanol, and the filtrate was concentrated under reduced pressure. Water (10 mL) was added to the concentrate, and the mixture was extracted with dichloromethane (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 1.63 g of a yellow solid in a 90.0% yield. LC-MS (ESI): [M+H-56]. + =379.1,381.1; 1H NMR (400MHz, DMSO-d6) δ8.13(d,J=2.4Hz,1H),7.87(dd,J=2.0Hz,1H),7.61(s,1H),7. 32(d,J=8.8Hz,1H),7.13(s,1H),5.37(s,2H),5.27(s,2H),3.43(s,3H),2.19(s,3H).

[0822] Step 6: Synthesis of 2-(3-bromo-4-(methoxymethoxy)phenyl)-N-(2-(2-((tert-butyldimethylsilyl)ethoxy)ethyl)-5-methylbenzo[d]thiazol-6-amine

[0823] 2-(3-Bromo-4-(methoxymethoxy)phenyl)-5-methylbenzo[d]thiazol-6-amine (1.25 g, 3.3 mmol) and 2-(2-(tert-butyldimethylsilyl)ethoxy)acetaldehyde (800 mg, 3.63 mmol) were added to 1,2-dichloroethane (20 mL), followed by acetic acid (18 mg, 0.3 mmol) and sodium triacetoxyborohydride (1.4 g, 6.6 mmol). The mixture was allowed to react at room temperature for 2 hours. After completion of the reaction, the reaction solution was quenched with water and extracted with dichloromethane (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and purified by silica gel column chromatography (PE:EA = 4:1) to afford 560 mg of a yellow oil in a 29.3% yield. LC-MS (ESI): [M+H] + =581.3,583.3; 1 H NMR (400MHz, DMSO-d6) δ8.14(d,J=2.0Hz,1H),7.89(dd,J=2.0Hz,1H),7.66(s,1H),7.32(d,J=8.4Hz,1H),7.15(s,1H),5.37(s,2H),5 .10(t,J=5.6Hz,1H),3.73-3.66(m,4H),3.51(t,J=4.8Hz,2H),3.43(s,3H),3.35-3.32(m,2H),2.21(s,3H),0.85(s,9H),0.04(s,6H).

[0824] Step 7: Synthesis of 2-(3-bromo-4-(methoxymethoxy)phenyl)-N-(2-(2-((tert-butyldimethylsilyl)ethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine

[0825] 2-(3-Bromo-4-(methoxymethoxy)phenyl)-N-(2-(2-((tert-butyldimethylsilyl)ethoxy)ethyl)-5-methylbenzo[d]thiazol-6-amine (560 mg, 0.96 mmol) and formaldehyde (36%) aqueous solution (120 mg, 1.44 mmol) were added to 1,2-dichloroethane (20 mL), followed by acetic acid (6 mg, 0.1 mmol) and sodium triacetoxyborohydride (407 mg, 1.92 mmol). The mixture was allowed to react at room temperature for 2 hours. After completion of the reaction, the reaction solution was quenched with water and extracted with dichloromethane (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and purified by silica gel column chromatography (PE:EA = 4:1) to afford 530 mg of a yellow oil in a 92.5% yield. LC-MS (ESI): [M+H] + =595.3,597.3; 1 H NMR (400MHz, CDCl3) δ8.28(d,J=2.0Hz,1H),7.89(dd,J=2.4Hz,2.0Hz,1H),7.83(s,1H),7.55(s,1H),7.22(d,J=8.8Hz,1H),5.32(s,2H),3.73(t,J =5.2Hz,2H),3.65(t,J=6.0Hz,2H),3.54(s,3H),3.50(t,J=5.2Hz,2H),3 .19(t,J=6.0Hz,2H),2.84(s,3H),2.45(s,3H),0.89(s,9H),0.04(s,6H).

[0826] Step 8: Synthesis of 2-(2-(2-(3-bromo-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)aminoethoxy)ethanol

[0827] 2-(3-Bromo-4-(methoxymethoxy)phenyl)-N-(2-(2-((tert-butyldimethylsilyl)ethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine (530 mg, 0.89 mmol) was added to anhydrous tetrahydrofuran (10 mL), followed by tetrabutylammonium fluoride tetrahydrofuran solution (1.78 mL, 1.78 mmol), and the mixture was allowed to react at room temperature for 2 hours. After completion of the reaction, the reaction solution was quenched with saturated ammonium chloride and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and purified by silica gel column chromatography (PE:EA=2:1) ​​to afford 380 mg of a yellow oil in an 88.7% yield. LC-MS (ESI): [M+H] + =481.2,483.2; 1H NMR (400MHz, CDCl3) δ8.28(d,J=2.0Hz,1H),7.89(dd,J=2.0Hz,2.4Hz,1H),7.84(s,1H),7.56(s,1H),7.22(d,J=8.8Hz,1H),5.32(s,2 H), 3.70 (t, J = 4.4Hz, 2H), 3.66 (t, J = 6.0Hz, 2H), 3.56 (t, J = 4.4Hz, 2H), 3.54 (s, 3H), 3.22 (t, J = 6.0Hz, 2H), 2.84 (s, 3H), 2.47 (s, 3H).

[0828] Step 9: Synthesis of ethyl 2-(2-(2-(3-bromo-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)aminoethoxy)4-methylbenzenesulfonate

[0829] 2-(2-(2-(3-bromo-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)aminoethoxy)ethanol (380 mg, 0.79 mmol) and triethylamine (319 mg, 3.16 mmol) were added to dichloromethane (10 mL). p-Toluenesulfonyl chloride (301 mg, 1.58 mmol) was then added under ice-cooling and allowed to react at room temperature for 16 hours. The mixture was quenched by the addition of water (10 mL) and extracted with dichloromethane (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and chromatographed on a silica gel column (PE:EA = 5:1) to afford 390 mg of a yellow oil in a 77.8% yield. LC-MS (ESI): [M+H] + =635.2,637.2; 1 H NMR (400MHz, DMSO-d6) δ8.22(d,J=2.4Hz,1H),7.97(dd,J=2.0Hz,2.4Hz,1H),7.81(s,1H),7.78-7.76(m,3H),7.46-7.44(m,2H),7.36(d,J =8.8Hz,1H),5.40(s,2H),4.10(t,J=4.4Hz,2H),3.55(t,J=4.4Hz,2H),3.49(t,J=6.0Hz,2H),3.44(s,3H),3.01(t,J=6.0Hz,2H),2.71(s, 3H),2.39(s,3H),2.35(s,3H).

[0830] Step 10: Synthesis of 2-(3-bromo-4-(methoxymethoxy)phenyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine

[0831] Ethyl 2-(2-(2-(3-bromo-4-(methoxymethoxy)phenyl)-5-methylbenzothiazol-6-yl)(methyl)aminoethoxy)-4-methylbenzenesulfonate (300 mg, 0.47 mmol), [bmim][BF4] (6 mL), and cesium fluoride (357 mg, 2.35 mmol) were added to acetonitrile (6 mL) and reacted at 100°C for 2 hours under nitrogen. The reaction solution was cooled to room temperature, diluted with water (10 mL), and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and purified by silica gel column chromatography (PE:EA = 4:1) to afford 175 mg of a yellow oil in a 76.7% yield. LC-MS (ESI): [M+H] + =483.2,485.2; 1 H NMR (400MHz, DMSO-d6) δ8.21(d,J=2.0Hz,1H),7.97(dd,J=2.4Hz,2.0Hz,1H),7.81-7.79(m,2H),7.36(d,J=8.8Hz,1H),5.39(s,2H),4.55(t, J=4.0Hz,1H),4.43(t,J=4.0Hz,1H),3.67(t,J=4.0Hz,1H),3.62-3.58(m,3H),3.44(s,3H),3.11(t,J=6.0Hz,2H),2.76(s,3H),2.38(s,3H).

[0832] Step 11: Synthesis of 2-bromo-4-(6-(2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzothiazol-2-yl)phenol

[0833] 2-(3-Bromo-4-(methoxymethoxy)phenyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine (100 mg, 0.21 mmol) was added to dichloromethane (2 mL), followed by trifluoroacetic acid (0.5 mL), and the mixture was allowed to react at room temperature for 2 hours. The reaction solution was concentrated, saturated sodium carbonate solution was added, and the pH was adjusted to approximately 8. The mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was dissolved in methanol and prepared by MPLC to yield 30.5 mg of a white solid with a yield of 33.9%. LC-MS (ESI): [M+H] + =439.1,441.1; 19 F NMR (376MHz, DMSO) δ-221.35; 1H NMR (400MHz, DMSO-d6) δ11.02(s,1H),8.12(d,J=2.4Hz,1H),7.86(dd,J=2.0,2.0Hz,1H),7.79–7.78(m,2H),7.10(d,J=8.4Hz,1H),4. 56(t,J=4.0Hz,1H),4.44(t,J=4.0Hz,1H),3.67(t,J=4.0Hz,1H),3.63–3.58(m,3H),3.11(t,J=6.0Hz,2H),2.76(s,3H),2.38(s,3H).

[0834] Example 10: Synthesis of Compound K

[0835] Compound K was obtained by referring to Examples 1 and 2.

[0836] Compound K: LC-MS (ESI): [M+H] + =451.0,453.0.

[0837] Another synthetic route of compound K:

[0838] 1-Bromo-7-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-8-methyl-10H-benzo[4,5]thieno[3,2-b]indol-2-ol

[0839] Step 1: Synthesis of 3-amino-2-bromophenol

[0840] 2-Bromo-3-nitrophenol (2.0 g, 9.17 mmol) was added to ethanol (20 mL) and water (10 mL), followed by ammonium chloride (4.908 g, 91.7 mmol) and iron powder (2.564 g, 45.9 mmol). The mixture was stirred at 80°C for 4 hours. After the reaction, the reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (PE:EA = 0-60%) to obtain 1.242 g of a black solid (72.0% yield). LC-MS (ESI): [M+H] + =188.0,190.0; 1 H NMR (400MHz, CD3OD) δ6.86 (t, J = 8.0 Hz, 1H), 6.32 (dd, J = 8.0, 1.6 Hz, 1H), 6.22 (dd, J = 8.0, 1.2 Hz, 1H).

[0841] Step 2: Synthesis of 2-bromo-3-hydrazinophenol

[0842] 3-Amino-2-bromophenol (200 mg, 1.06 mmol) was added to hydrochloric acid (6 M, 3 mL) and added dropwise to an aqueous solution of sodium nitrite (147 mg, 2.12 mmol) (6 mL) under ice-cooling. The mixture was stirred on ice for 30 minutes. The diazonium salt was then added dropwise to a solution of tin dichloride hydrate (480 mg, 2.12 mmol) in hydrochloric acid (6 M, 3 mL) under ice-cooling. The mixture was stirred on ice for 2 hours. After the reaction, the solid was filtered, and the filter cake was washed with methyl tert-butyl ether (20 mL). The filter cake was dried under reduced pressure to yield 83 mg of a tan solid (38.2% yield). LC-MS (ESI): [M+H] + =203.0,205.0; 1 HNMR (400MHz, DMSO-d6) δ7.15 (t, J = 8.0 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 6.46 (d, J = 8.8 Hz, 1H).

[0843] Step 3: 2-Fluoro-4-((2-(2-hydroxyethoxy)ethyl)amino)-5-methylbenzonitrile

[0844] 4-Bromo-2-fluoro-5-methylbenzonitrile (9.0 g, 42.0 mmol), 2-(2-aminoethoxy)ethanol (8.84 g, 84.0 mmol), cesium carbonate (27.38 g, 84.0 mmol), 1,1'-binaphthyl-2,2'-bis(diphenylphosphine) (2.62 g, 4.2 mmol), and Pd2(dba)3 (2.02 g, 2.1 mmol) were added to dioxane (100 mL) in sequence. The mixture was reacted at 100°C for 16 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (PE:EA = 0-60%) to afford 5.3 g of a colorless oil (53.0% yield). LC-MS (ESI): [M+H] + =239.3; 1 H NMR(400MHz, DMSO-d6)δ7.34(d,J=8.0Hz,1H),6.58(d,J=13.2Hz,1H),6.18-6.15(m,1H),4. 62(t,J=5.2Hz,1H),3.59(t,J=6.0Hz,2H),3.51–3.44(m,4H),3.38-3.3(m,2H),2.05(s,3H).

[0845] Step 4: Synthesis of 4-((2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)amino)-2-fluoro-5-methylbenzonitrile

[0846] 2-Fluoro-4-((2-(2-hydroxyethoxy)ethyl)amino)-5-methylbenzonitrile (3.15 g, 13.65 mmol) was added to N,N-dimethylformamide (40 mL), followed by imidazole (1.355 g, 18.80 mmol). Tert-butyldimethylsilyl chloride (2.385 g, 15.90 mmol) was added under ice-cooling, and the mixture was allowed to react at room temperature for 16 hours. After completion of the reaction, water (120 mL) was added to quench the mixture, followed by extraction with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated by silica gel column chromatography (PE:EA = 0-15%) to afford 3.58 g of a colorless oil in a 76.7% yield. LC-MS (ESI): [M+H] + =353.4; 1 H NMR (400MHz, CDCl3) δ7.17(d,J=7.2Hz,1H),6.29(d,J=12.0Hz,1H),3.80-3.75(m,4 H), 3.59-3.57 (m, 2H), 3.33 (t, J = 5.2Hz, 2H), 2.08 (s, 3H), 0.89 (s, 9H), 0.06 (s, 6H).

[0847] Step 5: Synthesis of 4-((2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)(methyl)amino)-2-fluoro-5-methylbenzonitrile

[0848] 4-((2-(2-((tert-Butyldimethylsilyl)oxy)ethoxy)ethyl)amino)-2-fluoro-5-methylbenzonitrile (3.58 g, 9.13 mmol) was added to N,N-dimethylformamide (40 mL). Sodium hydride (1.55 g, 13.70 mmol) was added under ice-cooling. The mixture was stirred at this temperature for 30 minutes, followed by the dropwise addition of iodomethane (1.68 g, 11.83 mmol). The reaction was allowed to react at room temperature for 2 hours. After completion, the reaction was quenched with a protective ammonium chloride solution (10 mL). The mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated by silica gel column chromatography (PE:EA = 0-15%) to afford 2.912 g of a colorless oil in an 80.0% yield. LC-MS (ESI): [M+H] + =367.3; 1H NMR (400MHz, CDCl3) δ7.28(d,J=7.6Hz,1H),6.74(d,J=11.6Hz,1H),3.72-3.69(m,2H),3.64(t,J=5.6 Hz, 2H), 3.48-3.45 (m, 2H), 3.25 (t, J = 5.6Hz, 2H), 2.87 (s, 3H), 2.25 (s, 3H), 0.88 (s, 9H), 0.05 (s, 6H).

[0849] Step 6: Synthesis of 2-fluoro-4-((2-(2-hydroxyethoxy)ethyl)(methyl)amino)-5-methylbenzonitrile

[0850] 4-((2-(2-((tert-Butyldimethylsilyl)oxy)ethoxy)ethyl)(methyl)amino)-2-fluoro-5-methylbenzonitrile (2.0 g, 5.4 mmol) was added to dichloromethane (20 mL), followed by dioxane hydrochloride solution (4 M, 5.31 mmol), and stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was concentrated under reduced pressure and purified by silica gel column chromatography (PE:EA = 0-60%) to afford 1.27 g of a colorless oil (90.0% yield). LC-MS (ESI): [M+H] + =253.1; 1 H NMR (400MHz, DMSO-d6) δ7.55(d,J=8.8Hz,1H),6.97(d,J=12.4Hz,1H),4.54(t,J=5.6Hz,1H),3.58(t, J=5.6Hz,2H),3.45–3.41(m,2H),3.39–3.35(m,2H),3.25(t,J=5.6Hz,2H),2.84(s,3H),2.22(s,3H).

[0851] Step 7: Synthesis of 2-(2-((4-cyano-5-fluoro-2-methylphenyl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate

[0852] 2-Fluoro-4-((2-(2-hydroxyethoxy)ethyl)(methyl)amino)-5-methylbenzonitrile (1.0 g, 3.96 mmol) and triethylamine (1.604 g, 15.85 mmol) were added to dichloromethane (15 mL). p-Toluenesulfonyl chloride (1.510 g, 7.93 mmol) was added under ice-cooling. The mixture was allowed to react at room temperature for 16 hours. After completion of the reaction, the reaction solution was concentrated and purified by silica gel column chromatography (PE:EA = 0-30%) to afford 1.30 g of a colorless oil with a yield of 80.7%. LC-MS (ESI): [M+H] + =407.2;1 H NMR (400MHz, CDCl3) δ7.79–7.77(m,2H),7.34(d,J=8.0Hz,2H),7.28(d,J=7.6Hz,2H),6.73(d,J=11.6Hz,1H), 4.11–4.08(m,2H),3.61–3.57(m,4H),3.22(t,J=5.6Hz,2H),2.83(s,3H),2.45(s,3H),2.23(d,J=0.9Hz,3H).

[0853] Step 8: Synthesis of 2-fluoro-4-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzonitrile

[0854] 2-(2-((4-cyano-5-fluoro-2-methylphenyl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (1.30 mg, 3.2 mmol) and 1-butyl-3-methylimidazolium tetrafluoroborate (20 mL) were added to acetonitrile (20 mL), followed by cesium fluoride (2.433 g, 16.0 mmol). The reaction was allowed to react at 100°C for 1 hour. After completion of the reaction, the reaction solution was quenched with water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated by silica gel column chromatography (PE:EA = 0-30%) to afford 793 mg of a colorless oil in a 97.5% yield. LC-MS (ESI): [M+H] + =255.2; 1 H NMR(400MHz, CDCl3)δ7.30(d,J=7.6Hz,1H),6.76(d,J=11.6Hz,1H),4.58–4.56(m,1H),4.46–4.4 4(m,1H),3.70–3.65(m,3H),3.62–3.60(m,1H),3.28(t,J=5.6Hz,2H),2.88(s,3H),2.26(s,3H).

[0855] Step 9: Synthesis of methyl 3-amino-6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[b]thiophene-2-carboxylate

[0856] 2-Fluoro-4-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzonitrile (793 mg, 3.12 mmol) was added to N,N-dimethylformamide (10 mL), followed by methyl thioglycolate (1.019 g, 9.37 mmol) and potassium tert-butoxide (1.075 g, 9.37 mmol). The mixture was allowed to react at 30°C for 5 hours. After completion of the reaction, the reaction mixture was quenched with water (30 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated by silica gel column chromatography (PE:EA = 0-60%) to afford 300 mg of a yellow oil in a 27.6% yield. LC-MS (ESI): [M+H] + =341.3; 1 H NMR(400MHz,Methanol-d4)δ7.68(s,1H),7.37(s,1H),4.53–4.51(m,1H),4.41–4.39(m ,1H),3.81(s,3H),3.69–3.60(m,4H),3.19(t,J=6.0Hz,2H),2.81(s,3H),2.40(s,3H).

[0857] Step 10: Synthesis of 1-bromo-7-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-8-methyl-10H-benzo[4,5]thieno[3,2-b]indol-2-ol-0.5carboxylic acid

[0858] Methyl 3-amino-6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[b]thiophene-2-carboxylate (200 mg, 0.59 mmol) and sodium hydroxide (95 mg, 2.36 mmol) were added to isopropanol (3 mL) and water (0.5 mL). The reaction was stirred at 80°C for 3 hours, cooled to room temperature, and concentrated under reduced pressure to obtain a brown solid. Acetic acid (3 mL) was then added to dissolve the mixture, and 2-bromo-3-hydrazinophenol (132 mg, 0.70 mmol) was added. The mixture was stirred at 80°C for 30 minutes, cooled to room temperature, and preparative separation afforded 30.4 mg of a light brown solid in an 11.3% yield. LC-MS (ESI): [M+H] + =451.1,453.1; 19 F NMR (376MHz, DMSO-d6): δ-221.44; 1H NMR (400MHz, DMSO-d6) δ11.71(s,1H),9.96(s,1H),8.16(s,0.5H),8.03(s,1H),7.68(s,1H),7.50(d,J=8.4Hz,1H),6.82(d,J=8.4H z,1H),4.57–4.55(m,1H),4.45–4.43(m,1H),3.68–3.66(m,1H),3.63–3.59(m,3H),3.11(t,J=6.0Hz,2H),2.76(s,3H),2.40(s,3H).

[0859] Example 11: Synthesis of Compound L

[0860] Compound L was obtained by referring to Examples 1 and 2.

[0861] Compound L: LC-MS (ESI): [M+H] + =462.1,464.1.

[0862] Example 12: Synthesis of Compound M

[0863] Compound M was obtained by referring to Examples 1 and 2.

[0864] Compound M: LC-MS (ESI): [M+H] + =451.0,453.0.

[0865] Another synthetic route for compound M.

[0866] Step 1: Synthesis of (E)-2-(3-bromo-4-methoxystyrene)-N-(2-(2-bromoethoxy)ethyl)-5-methylbenzo[d]thiazol-6-amine

[0867] (E)-2-(2-((2-(3-bromo-4-methoxyphenylvinyl)-5-methylbenzo[d]thiazol-6-yl)amino)ethoxy)ethane-1-ol (2.1 g, 4.5 mmol) and carbon tetrabromide (6.0 g, 18.2 mmol) were dissolved in anhydrous dichloromethane (100 mL). Triphenylphosphine (4.76 g, 18.2 mmol) was added at 0°C. The reaction solution was protected with nitrogen and stirred at 0°C for 3 hours. The reaction solution was added to water (50 mL) and extracted with dichloromethane (100 mL). The organic phase was concentrated. The crude product was separated by column chromatography to obtain 2.1 g of a yellow solid with a yield of 88%. LC-MS (ESI): [M+H] +=524.9,526.9[M+H] + ; 1 H NMR (400MHz, DMSO-d6): δ8.04(s,1H),7.76–7.74(m,2H),7.71(s,1H),7.50(s,2H),7.18 -7.16(d,J=8.8Hz,1H),3.90(s,3H),3.78-3.75(m,4H),2.92-2.89(m,4H),2.39(s,3H).

[0868] Step 2: Synthesis of (E)-2-(3-bromo-4-methoxyphenyl)-N-(2-(2-fluoroethoxy)ethyl)-5-methylbenzo[d]thiazol-6-amine

[0869] (E)-2-(3-bromo-4-methoxyphenylvinyl)-N-(2-(2-bromoethoxy)ethyl)-5-methylbenzo[d]thiazol-6-amine (1.6 g, 3.0 mmol) was added to anhydrous acetonitrile (16 mL), followed by cesium fluoride (2.65 g, 46.0 mmol) and kryptofix 2.2.2 (3.44 g, 9.2 mmol). The reaction was allowed to proceed at 60°C under nitrogen for 1 hour. The mixture was quenched with water (30 mL) and extracted with ethyl acetate (40 mL x 2). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated by silica gel column chromatography (PE:EA, 0%-30%) to obtain 240 mg of a yellow solid in a 17% yield. LC-MS (ESI): [M+H] + =465.0,467.0; 1 H NMR (400MHz, DMSO-d6): δ7.99(s,1H),7.73-7.71(d,J=8.4Hz,1H),7.58(s,1H),7.44-7.31(m,2H),7.16-7.13(m,2H), 5.17(brs,1H),4.61(d,J=4.0Hz,1H),4.49(d,J=4.0Hz,1H),3.89(s,3H),3.75-3,65(m,4H),3.38(m,2H),2.20(s,3H).

[0870] Step 3: Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenol

[0871] (E)-2-(3-bromo-4-methoxyphenylvinyl)-N-(2-(2-fluoroethoxy)ethyl)-5-methylbenzo[d]thiazol-6-amine (240 mg, 0.52 mmol) was dissolved in anhydrous DMF (2.5 mL), followed by the addition of EtSNa (222 mg, 2.59 mmol). The reaction mixture was reacted at 100°C for 0.5 h. The mixture was quenched with water (20 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA, 0%-35%) to afford 30 mg of a yellow solid in a 13% yield. LC-MS (ESI): [M+H] + =451.0,453.0; 1 H NMR (400MHz, DMSO-d6): δ10.59(s,1H),7.87(s,1H),7.58–7.56(m,2H),7.35-7.26(m,2H),7.12(s,1H),6.98-6.96(d, J=8.4Hz,1H)5.15(m,1H),4.62-4.59(m,1H),4.51-4.47(d,J=4.0Hz,1H),3.75-3.66(m,4H),3.37(m,2H),2.20(s,3H).

[0872] Example 13: Synthesis of Compound N

[0873] Compound N was obtained by referring to Examples 1 and 2.

[0874] Compound N: LC-MS (ESI): [M+H] + =467.0,469.0.

[0875] Example 14: Synthesis of Compound O

[0876] Compound O was obtained by referring to Examples 1 and 2.

[0877] Compound O: LC-MS (ESI): [M+H] + =493.1,495.1.

[0878] Another synthetic route for compound O

[0879] Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(isopropyl)amino)-5-methylbenzothiazol-2-yl)vinyl)phenol

[0880] Step 1: Synthesis of 3-bromo-4-(methoxymethoxy)benzaldehyde

[0881] 3-Bromo-4-hydroxybenzaldehyde (1.0 g, 4.9 mmol) was added to dichloromethane (20 mL), followed by N,N-diisopropylethylamine (1.28 g, 9.9 mmol). Bromomethyl methyl ether (4.7 g, 37.5 mmol) was then added dropwise at room temperature. The mixture was allowed to react for 4 hours. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (PE:EA = 10:1) to afford 1.02 g of a white solid (83.6% yield). 1 H NMR (400MHz, DMSO-d6): δ9.87 (s, 1H), 8.13 (d, J = 2.0 Hz, 1H), 7.90 (dd, J = 8.4, 2.0 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 5.43 (s, 2H), 3.43 (s, 3H).

[0882] Step 2: Synthesis of N-isopropyl-2,5-dimethylbenzothiazol-6-amine

[0883] 2,5-Dimethylbenzothiazol-6-amine (700 mg, 3.9 mmol) was added to dichloromethane (20 mL). Acetone (2.3 g, 39 mmol) and sodium acetate borohydride (2.5 g, 11.8 mmol) were added at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (PE:EA = 4:1) to obtain 680 mg of the product as a yellow solid in a 78.6% yield. LC-MS (ESI): [M+H] + =221.2; 1 HNMR (400MHz, DMSO-d6): δ7.51(s,1H),7.04(s,1H),4.50(d,J=7.9Hz,1H),3.69-3.61(m,1H),2.66(s,3H),2.18(s,3H),1.21(d,J=6.3Hz,6H).

[0884] Step 3: Synthesis of 2-(2-((2,5-dimethylbenzothiazol-6-yl)(isopropyl)amino)ethoxy)ethane-1-ol

[0885] N-isopropyl-2,5-dimethylbenzothiazol-6-amine (680 mg, 3 mmol) was added to DMF (10 mL). 2-Chloroethoxyethanol (1.9 g, 15 mmol), potassium carbonate (854 mg, 6 mmol), and potassium iodide (1 g, 6 mmol) were added sequentially at room temperature. The reaction mixture was stirred in an oil bath at 100°C for 24 hours. The reaction mixture was cooled to room temperature, water (50 mL) was added, and extraction was performed with ethyl acetate (50 mL x 3). The combined organic phases were washed once with saturated NaCl (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Silica gel column chromatography (PE:EA = 1:1) afforded 150 mg of a yellow oil in a 15.7% yield. LC-MS (ESI): [M+H] + =309.4.

[0886] Step 4: Synthesis of 2-(2-((2,5-dimethylbenzothiazol-6-yl)(isopropyl)amino)ethoxy)ethyl-4-methylbenzenesulfonate

[0887] 2-(2-((2,5-Dimethylbenzo[d]thiazol-6-yl)(isopropyl)amino)ethoxy)ethan-1-ol (150 mg, 0.48 mmol) was added to dichloromethane (5 mL). Triethylamine (98 mg, 0.97 mL) and p-toluenesulfonyl chloride (139 mg, 0.73 mmol) were added sequentially at room temperature. The reaction mixture was allowed to react for 4 hours. The reaction mixture was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA = 3:1) to obtain 180 mg of the product as a brown solid in an 80% yield. LC-MS (ESI): [M+H] + =463.4; 1 H NMR (400MHz, DMSO-d6): δ7.79(s,1H),7.77–7.66(m,3H),7.44(d,J=8.0Hz,2H),4.11–3.94(m,2H),3.51–3.39(m,2H ),3.21–3.07(m,4H),3.04(q,J=6.4Hz,1H),2.74(s,3H),2.41(s,3H),2.29(d,J=0.8Hz,3H),1.03(d,J=6.4Hz,6H).

[0888] Step 5: Synthesis of N-(2-(2-fluoroethoxy)ethyl)-N-isopropyl-2,5-dimethylbenzothiazol-6-amine

[0889] 2-(2-((2,5-dimethylbenzothiazol-6-yl)(isopropyl)amino)ethoxy)ethyl-4-methylbenzenesulfonate (150 mg, 0.32 mmol), [bmim][BF4] (3 mL), and cesium fluoride (245 mg, 1.6 mmol) were added sequentially to acetonitrile (3 mL) under nitrogen protection. The mixture was reacted in an oil bath at 100°C for 2 hours. The reaction solution was cooled to room temperature, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed sequentially with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Silica gel column chromatography (PE:EA = 4:1) afforded 90 mg of a brown oil with a yield of 74%. LC-MS (ESI): [M+H] + =311.4; 1 H NMR (400MHz, CDCl3): δ7.71(s,1H),7.53(s,1H),4.44-4.32(m,2H),3.53-3.09(m,7H),2.74(s,3H),2.34(s,3H),1.07(s,6H).

[0890] Step 6: Synthesis of (E)-2-(3-bromo-4-(methoxymethoxy)phenyl)-N-(2-(2-fluoroethoxy)ethyl)-N-isopropyl-5-methylbenzothiazol-6-amine

[0891] N-(2-(2-fluoroethoxy)ethyl)-N-isopropyl-2,5-dimethylbenzothiazol-6-amine (70 mg, 0.22 mmol) was added to DMSO (2 mL), followed by potassium tert-butoxide (50 mg, 0.45 mmol) and 3-bromo-4-(methoxymethoxy)benzaldehyde (55 mg, 0.22 mmol) at room temperature. The reaction mixture was allowed to react for 2 hours at room temperature. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed once with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Silica gel column chromatography (PE:EA = 5:1) afforded 100 mg of the product as a brown solid in a 64.2% yield. LC-MS (ESI): [M+H] + =537.4,539.4; 1H NMR (400MHz, CDCl3): δ7.82–7.65(m,2H),7.55(s,1H),7.40(dd,J=8.6,2.1Hz,1H),7.30(d,J=16.3Hz,1H),7.21(s,1H),7. 11(d,J=8.6Hz,1H),5.22(s,2H),4.46(s,1H),4.34(s,1H),3.46(s,5H),3.23(d,J=90.9Hz,5H),2.35(s,3H),1.09(s,6H).

[0892] Step 7: Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(isopropyl)amino)-5-methylbenzothiazol-2-yl)vinyl)phenol

[0893] (E)-2-(3-bromo-4-(methoxymethoxy)phenylvinyl)-N-(2-(2-fluoroethoxy)ethyl)-N-isopropyl-5-methylbenzothiazol-6-amine (80 mg, 0.14 mmol) was added to dichloromethane (2 mL), followed by a 1,4-dioxane hydrochloride solution (4 M, 2 mL). The mixture was reacted at room temperature for 3 hours, and a solid precipitated. The precipitated solid was filtered and dried under reduced pressure to give 22.4 mg of the product (hydrochloride salt) as a brown solid in a 24.4% yield. LC-MS (ESI): [M+H] + =493.1,495.1; 1 H NMR (400MHz, CD3OD): δ8.31(s,1H),7.95(s,1H),7.85(d,J=2.0Hz,1H),7.69–7.48(m,2H),7.35(d,J=16.0Hz,1H),6.96(d,J=8.4 Hz,1H),4.49(s,1H),4.37(s,1H),4.12-4.04(m,3H),3.69(s,1H),3.48-3.47(m,2H)3.18(s,1H),2.67(s,3H),1.53-1.33(m,6H); 19 FNMR (400MHz, DMSO-d6): δ-221.15.

[0894] Example 15: Synthesis of Compound P

[0895] Compound P was obtained by referring to Examples 1 and 2.

[0896] Compound P: LC-MS (ESI): [M+H] + =479.1,481.1.

[0897] Another synthetic route of compound P:

[0898] Synthesis of (E)-2-bromo-4-(2-(5-ethyl-6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)benzo[d]thiazol-2-yl)vinyl)phenol

[0899] Step 1: Synthesis of 2-methyl-5-vinylbenzo[d]thiazole

[0900] 5-Bromo-2-methylbenzo[d]thiazole (11 g, 48.2 mmol) was added to a mixture of 1,4-dioxane and water (110 mL, v / v = 5 / 1). Potassium ethylene trifluoroborate (9.7 g, 72.3 mmol), potassium carbonate (20 g, 144.6 mmol), and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (1.76 g, 2.41 mmol) were also added. The mixture was reacted at 80°C under nitrogen for 16 hours, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 20:1) to afford 6.87 g of a light yellow oil in an 82% yield. LC-MS (ESI): [M+H] + =176.1; 1 H NMR (400MHz, CDCl3) δ7.95(d,J=1.2Hz,1H),7.75(d,J=8.4Hz,1H),7.43(dd,J=8.4,1.6Hz,1H),6 .83(dd,J=17.6,10.8Hz,1H), 5.83(dd,J=17.6,0.8Hz,1H), 5.31(d,J=10.8Hz,1H), 2.83(s,3H).

[0901] Step 2: Synthesis of 5-ethyl-2-methylbenzo[d]thiazole

[0902] 2-Methyl-5-vinylbenzo[d]thiazole (6.87 g) was added to methanol (70 mL), followed by palladium on carbon (10%, 0.7 g). The mixture was reacted at room temperature under a hydrogen atmosphere for 16 hours, filtered, and the filtrate was concentrated under reduced pressure to obtain 6.74 g of a yellow oil with a yield of 97.1%. LC-MS (ESI): [M+H] + =178.2; 1H NMR (400MHz, CDCl3) δ7.78(d,J=0.8Hz,1H),7.71(d,J=8.4Hz,1H),7.20(dd,J=8 .4,1.6Hz,1H),2.82(s,3H),2.78(dd,J=15.2,7.6Hz,2H),1.30(t,J=7.6Hz,3H).

[0903] Step 3: Synthesis of 5-ethyl-2-methyl-6-nitrobenzo[d]thiazole

[0904] 5-Ethyl-2-methylbenzo[d]thiazole (6.74 g, 38.02 mmol) was added to concentrated sulfuric acid (70 mL) under an ice bath. Potassium nitrate (4.23 g, 41.82 mmol) was added portionwise and stirred at room temperature for 2 hours. After the reaction, the reaction mixture was poured into ice water (200 mL), the pH was adjusted to 8 with saturated sodium carbonate, and ethyl acetate (200 mL x 3) was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA = 20:1) to afford 4.2 g of a yellow solid in a 49.7% yield. LC-MS (ESI): [M+H] + =223.1; 1 H NMR (400MHz, CDCl3) δ8.43 (s, 1H), 7.90 (s, 1H), 3.05 (q, J = 7.6Hz, 2H), 2.89 (s, 3H), 1.35 (t, J = 7.6Hz, 3H).

[0905] Step 4: Synthesis of 5-ethyl-2-methylbenzo[d]thiazol-6-amine

[0906] 5-Ethyl-2-methylbenzo[d]thiazole (3 g, 13.5 mmol) was added to a mixture of ethanol and water (60 mL, v / v = 5 / 1), followed by ammonium chloride (7.2 g, 135 mmol) and iron powder (3.77 g, 67.5 mmol). The reaction was incubated at 80°C for 2 hours. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (PE:EA = 5:1) to afford 2.28 g of a yellow solid in an 87.9% yield. LC-MS (ESI): [M+H] + =193.1; 1 H NMR (400MHz, CDCl3) δ7.67 (s, 1H), 7.11 (s, 1H), 2.76 (s, 3H), 2.63 (q, J = 7.6Hz, 2H), 1.33 (t, J = 7.6Hz, 3H).

[0907] Step 5: Synthesis of 2-(2-((5-ethyl-2-methylbenzo[d]thiazol-6-yl)amino)ethoxy)ethan-1-ol

[0908] 5-Ethyl-2-methylbenzo[d]thiazol-6-amine (2.28 g, 11.88 mmol) was added to N,N-dimethylformamide (30 mL), followed by 2-chloroethoxyethanol (7.4 g, 59.38 mmol), potassium carbonate (4.93 g, 35.64 mmol), and potassium iodide (1.97 g, 11.88 mmol). The mixture was reacted at 100°C for 16 hours. The mixture was concentrated and purified by silica gel column chromatography (PE:EA = 2:1) to afford 2.25 g of a light yellow oil (67.6% yield). LC-MS (ESI): [M+H] + =281.2; 1 H NMR (400MHz, DMSO-d6) δ7.50(s,1H),7.08(s,1H),4.98(t,J=5.6Hz,1H),4.63(t,J=5.2Hz,1H),3.65(t,J=6.0Hz ,2H),3.57–3.43(m,4H),3.30(dd,J=11.6,6.0Hz,2H),2.67(s,3H),2.56(q,J=7.2Hz,2H),1.20(t,J=7.2Hz,3H).

[0909] Step 6: Synthesis of 2-(2-((5-ethyl-2-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethan-1-ol

[0910] 2-(2-((5-ethyl-2-methylbenzo[d]thiazol-6-yl)amino)ethoxy)ethan-1-ol (2.25 g, 8.04 mmol) was added to dichloroethane (23 mL), followed by 30% aqueous formaldehyde solution (1.3 g, 16.08 mmol) and acetic acid (483.0 mg, 8.04 mmol). The mixture was stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (5.11 g, 24.12 mmol) was added and the mixture was allowed to react at room temperature for 1 hour. The reaction solution was concentrated and purified by silica gel column chromatography (PE:EA = 3:2) to afford 1.89 g of a colorless oil with a yield of 80.0%. LC-MS (ESI): [M+H] + =295.2; 1H NMR (400MHz, DMSO-d6) δ7.78(s,1H),7.70(s,1H),4.55(t,J=5.4Hz,1H),3.52(t,J=6.0Hz,2H),3.47(dd,J=10.4,5.2Hz ,2H),3.39(t,J=5.2Hz,2H),3.04(t,J=6.0Hz,2H),2.81–2.75(m,2H),2.74(s,3H),2.70(s,3H),1.22(t,J=7.6Hz,3H).

[0911] Step 7: Synthesis of 2-(2-((5-ethyl-2-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate

[0912] 2-(2-((5-ethyl-2-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethan-1-ol (0.5 g, 1.7 mmol) was added to dichloromethane (5 mL). Triethylamine (687 mg, 6.8 mmol) and p-toluenesulfonyl chloride (324 mg, 3.4 mmol) were then added under ice-cooling. The mixture was allowed to react at room temperature for 16 hours. The reaction mixture was concentrated and purified by silica gel column chromatography (PE:EA = 4:1) to afford 0.53 g of a colorless oil in a 69.6% yield. LC-MS (ESI): [M+H] + =449.2; 1 H NMR (400MHz, CDCl3) δ7.86–7.70(m,3H),7.52(s,1H),7.32(d,J=8.0Hz,2H),4.15–4.10(m,2H),3. 63–3.58(m,2H),3.53(s,2H),3.08(s,2H),2.98-2.65(m,8H),2.43(s,3H),1.26(t,J=7.2Hz,3H).

[0913] Step 8: Synthesis of 5-ethyl-N-(2-(2-fluoroethoxy)ethyl)-N,2-dimethylbenzo[d]thiazol-6-amine

[0914] 2-(2-((5-ethyl-2-methylbenzo[d]thiazol-6-yl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (430 mg, 0.96 mmol), cesium fluoride (724 mg, 4.8 mmol), and 1-butyl-3-methylimidazolium tetrafluoroborate (8 mL) were added to acetonitrile (8 mL) and reacted at 100°C for 4 hours. The reaction solution was extracted with water (20 mL) and ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA = 4:1) to afford 0.2 g of a yellow oil in a 70.4% yield. LC-MS (ESI): [M+H] + =297.2; 1 HNMR(400MHz, CDCl3)δ7.79(s,1H),7.56(s,1H),4.75–4.31(m,2H),3.73–3.67( m,1H),3.66–3.56(m,3H),3.18(s,2H),2.89–2.70(m,8H),1.28(t,J=7.6Hz,3H).

[0915] Step 9: Synthesis of (E)-2-(3-bromo-4-(methoxymethoxy)phenyl)-5-ethyl-N-(2-(2-fluoroethoxy)ethyl)-N-methylbenzo[d]thiazol-6-amine

[0916] 5-Ethyl-N-(2-(2-fluoroethoxy)ethyl)-N,2-dimethylbenzo[d]thiazol-6-amine (0.2 g, 0.68 mmol) was added to dimethyl sulfoxide (4 mL), followed by potassium tert-butoxide (84 mg, 0.75) and 3-bromo-4-(methoxymethoxy)benzaldehyde (174 mg, 0.71 mmol). The mixture was allowed to react at room temperature for 1 hour. Water (20 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was concentrated and purified by silica gel column chromatography (PE:EA = 4:1) to afford 170 mg of a yellow oil in a 47.8% yield. LC-MS (ESI): [M+H] + =523.2,525.2; 1H NMR (400MHz, CDCl3) δ7.84(s,1H),7.78(d,J=2.0Hz,1H),7.59(s,1H),7.46(dd,J=8.4,2.0Hz,1H),7.37(d,J=16.0Hz,1H),7.25(d,J=16.0Hz,1H ),7.17(d,J=8.4Hz,1H),5.29(s,2H),4.67–4.37(m,2H),3.79–3.59(m, 4H), 3.53 (s, 3H), 3.23 (s, 2H), 2.93–2.70 (m, 5H), 1.31 (t, J = 7.6Hz, 3H).

[0917] Step 10: Synthesis of (E)-2-bromo-4-(2-(5-ethyl-6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)benzo[d]thiazol-2-yl)vinyl)phenol

[0918] (E)-2-(3-bromo-4-(methoxymethoxy)phenyl)-5-ethyl-N-(2-(2-fluoroethoxy)ethyl)-N-methylbenzo[d]thiazol-6-amine (70 mg, 0.13 mmol) was added to 1,4-dioxane (2 mL), followed by a 4 M hydrogen chloride / 1,4-dioxane solution (4 mL). The mixture was allowed to react at room temperature for 20 hours. The mixture was filtered, and the filter cake was washed with ethyl acetate and ether, then dried under vacuum at room temperature to yield 49.6 mg of a yellow solid (72.1% yield). LC-MS (ESI): [M+H] + =479.1,481.1; 19 F NMR(376MHz,MeOD)δ-221.40; 1 H NMR (400MHz, MeOD) δ8.50(s,1H),7.97(s,1H),7.87(d,J=1.6Hz,1H),7.72(d,J=16.4Hz,1H),7.58(dd,J=8.4,2.0Hz,1H),7.38(d,J=16.0Hz,1H ),6.96(d,J=8.4Hz,1H),4.57–4.37(m,2H),4.03(t,J=4.4Hz,2H),3.64 –3.47(m,4H),3.43(s,3H),3.05(q,J=7.2Hz,2H),1.43(t,J=7.2Hz,3H).

[0919] Example 16: Synthesis of Compound Q

[0920] Compound Q was obtained by referring to Examples 1 and 2.

[0921] Compound Q: LC-MS (ESI): [M+H] + =493.1,495.1.

[0922] Another synthetic route of compound Q

[0923] Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenol

[0924] Step 1: Synthesis of 2-methyl-5-(prop-1-en-2-yl)benzo[d]thiazole

[0925] 5-Bromo-2-methylbenzo[d]thiazole (11 g, 48.2 mmol) was added to a mixture of 1,4-dioxane and water (110 mL, v / v = 5 / 1). 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (12.1 g, 72.3 mmol), potassium carbonate (20 g, 144.6 mmol), and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (1.76 g, 2.41 mmol) were also added. The mixture was reacted at 70°C under nitrogen for 16 hours, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA = 20:1) to afford 7.2 g of a light yellow oil in a 79.1% yield. LC-MS (ESI): [M+H] + =190.2; 1 H NMR (400MHz, CDCl3) δ8.03(d,J=1.6Hz,1H),7.75(d,J=8.4Hz,1H),7.51(dd, J=8.4,2.0Hz,1H),5.46(s,1H),5.19–5.12(m,1H),2.84(s,3H),2.22(s,3H).

[0926] Step 2: Synthesis of 5-isopropyl-2-methylbenzo[d]thiazole

[0927] 2-Methyl-5-(prop-1-en-2-yl)benzo[d]thiazole (7.2 g) was added to methanol (72 mL), followed by palladium on carbon (0.72 g). The mixture was reacted at room temperature under a hydrogen atmosphere for 16 hours, filtered, and the filtrate was concentrated under reduced pressure to obtain 7.1 g of a yellow oil with a yield of 97.7%. LC-MS (ESI): [M+H] + =192.2.

[0928] Step 3: Synthesis of 5-isopropyl-2-methyl-6-nitrobenzo[d]thiazole

[0929] 5-Isopropyl-2-methylbenzo[d]thiazole (7.1 g, 37.11 mmol) was added to concentrated sulfuric acid (70 mL) under an ice bath. Potassium nitrate (4.12 g, 40.82 mmol) was added portionwise and stirred at room temperature for 2 hours. After the reaction, the reaction mixture was poured into ice water (200 mL), the pH was adjusted to 8 with saturated sodium carbonate, and ethyl acetate (300 mL x 3) was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA = 20:1) to afford 4.7 g of a yellow solid in a 53.6% yield. LC-MS (ESI): [M+H] + =237.2; 1 H NMR (400MHz, CDCl3) δ8.25 (s, 1H), 8.03 (s, 1H), 3.64–3.44 (m, 1H), 2.89 (s, 3H), 1.36 (d, J = 6.8Hz, 6H).

[0930] Step 4: Synthesis of (E)-2-(3-bromo-4-(methoxymethoxy)phenylvinyl)-5-isopropylbenzo[d]thiazol-6-amine

[0931] 5-Isopropyl-2-methyl-6-nitrobenzo[d]thiazole (4.7 g, 19.9 mmol) was added to tetrahydrofuran (47 mL). Sodium hydride (1.6 g, 39.8 mmol) was added under ice-cooling and the mixture was allowed to react at 0°C for half an hour. 3-Bromo-4-(methoxymethoxy)benzaldehyde (5.12 g, 20.9 mmol) was added and the mixture was allowed to react at room temperature overnight. The mixture was quenched with water (20 mL) and extracted with dichloromethane (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and chromatographed on a silica gel column (100% DCM) to afford 4.7 g of a yellow solid in a 50.9% yield. LC-MS (ESI): [M+H] + =463.2,465.2; 1 H NMR (400MHz, CDCl3) δ8.28(s,1H),8.06(s,1H),7.83(d,J=2.0Hz,1H),7.55(d,J=16.0Hz,1H),7.50(dd,J= 8.8, 2.0Hz, 1H), 7.30 (s, 1H), 7.20 (d, J = 8.4Hz, 1H), 5.31 (s, 2H), 3.58–3.50 (m, 4H), 1.38 (d, J = 6.8Hz, 6H).

[0932] Step 5: (E)-2-(3-bromo-4-(methoxymethoxy)phenylvinyl)-5-isopropylbenzo[d]thiazol-6-amine

[0933] (E)-2-(3-bromo-4-(methoxymethoxy)phenylvinyl)-5-isopropylbenzo[d]thiazol-6-amine (4.7 g, 10.14 mmol) was added to a mixture of ethanol and water (60 mL, v / v = 5 / 1). Ammonium chloride (5.42 g, 101.4 mmol) and iron powder (2.83 g, 50.7 mmol) were added and reacted at 80°C for 16 hours. The reaction solution was cooled to room temperature, filtered, concentrated, and purified by silica gel column chromatography to afford 3.85 g of a yellow solid in an 87.5% yield. LC-MS (ESI): [M+H] + =433.2,435.2; 1 H NMR (400MHz, DMSO-d6) δ8.06(d,J=2.0Hz,1H),7.76(dd,J=8.8,2.0Hz,1H),7.63(s,1H),7.49(d,J=16.0Hz,1H),7.37(d,J=1 6.0Hz,1H),7.29(d,J=8.8Hz,1H),7.16(d,J=4.8Hz,1H),5.39(s,4H),3.48(s,3H),3.18-3.05(m,1H),1.28(d,J=6.8Hz,6H).

[0934] Step 6: Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-hydroxyethoxy)ethyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenol

[0935] (E)-2-(3-bromo-4-(methoxymethoxy)phenylvinyl)-5-isopropylbenzo[d]thiazol-6-amine (3.7 g, 8.54 mmol) was added to DMF (50 mL), along with 2-chloroethoxyethanol (10.6 g, 85.4 mmol), potassium carbonate (3.58 g, 25.62 mmol), and potassium iodide (1.42 g, 8.54 mmol). The mixture was reacted at 100°C for 16 hours. The reaction mixture was concentrated and purified by silica gel column chromatography (DCM:MeOH = 20:1) to afford 1.6 g (50% purity) of a yellow crude product in a 20% yield. LC-MS (ESI): [M+H] + =477.2,479.2.

[0936] Step 7: Synthesis of tert-butyl (E)-2-bromo-4-(2-(6-((2-(2-hydroxyethoxy)ethyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenyl carbonate

[0937] (E)-2-Bromo-4-(2-(6-((2-(2-hydroxyethoxy)ethyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenol (1.6 g, 3.35 mmol) was added to dichloromethane (32 mL), followed by N,N-diisopropylethylamine (1.3 g, 10.05 mmol) and di-tert-butyl dicarbonate (0.73 g, 3.35 mmol). The mixture was reacted at 40°C for 16 hours. The reaction mixture was concentrated and purified by silica gel column chromatography (PE:EA = 1:1) to afford 0.33 g of a yellow solid in a 17% yield. LC-MS (ESI): [M+H] + =577.3,579.3; 1 H NMR (400MHz, DMSO-d6) δ8.06(d,J=2.0Hz,1H),7.76(dd,J=8.8,2.0Hz,1H),7.63(s,1H),7.49(d,J=16.0Hz,1H),7.37(d,J=1 6.0Hz, 1H), 7.29 (d, J = 8.8Hz, 1H), 7.16 (d, J = 4.8Hz, 1H), 5.39 (s, 4H), 3.48 (s, 3H), 3.12-3.02 (m, 1H), 1.28 (d, J = 6.8Hz, 6H).

[0938] Step 8: Synthesis of tert-butyl (E)-2-bromo-4-(2-(6-((2-(2-hydroxyethoxy)ethyl)(methyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenyl carbonate

[0939] Tert-butyl (E)-2-bromo-4-(2-(6-((2-(2-hydroxyethoxy)ethyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenyl carbonate (236 mg, 0.41 mmol) was added to dichloroethane (4 mL), followed by 30% aqueous formaldehyde solution (67.0 mg, 0.82 mmol) and acetic acid (25.0 mg, 0.41 mmol). The mixture was stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (260.0 mg, 1.23 mmol) was added. The reaction was allowed to react at room temperature for 0.5 hours. The reaction solution was concentrated and purified by silica gel column chromatography (PE:EA = 2:1) to afford 0.17 g of a yellow oil in a 70.2% yield. LC-MS (ESI): [M+H] + =591.2,593.2;1 H NMR(400MHz,DMSO-d6)δ8.18(d,J=1.6Hz,1H),7.89(s,1H),7.86–7.76(m,2H) ,7.62(q,J=16.0Hz,2H),7.43(d,J=8.4Hz,1H),4.56(t,J=5.2Hz,1H),3.66–3. 57(m,1H),3.53(t,J=6.0Hz,2H),3.48(dd,J=10.4,5.2Hz,2H),3.40(t,J=5.2H z, 2H), 3.08 (t, J = 6.0Hz, 2H), 2.72 (s, 3H), 1.52 (s, 9H), 1.23 (d, J = 6.8Hz, 6H).

[0940] Step 9: (E)-tert-Butyl 2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenyl carbonate

[0941] Tert-butyl (E)-2-bromo-4-(2-(6-((2-(2-hydroxyethoxy)ethyl)(methyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenyl carbonate (0.17 g, 0.29 mmol) was added to dichloromethane (3 mL), followed by diethylaminosulfur trifluoride (92 mg, 0.57 mmol), and the mixture was allowed to react at room temperature for 2 hours. The mixture was quenched with saturated aqueous sodium bicarbonate and extracted with dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and chromatographed on a silica gel column (PE:EA=4:1) to afford 70 mg (80% purity) of a yellow oil. This was then purified on a reverse phase (water and acetonitrile: 0-80%) to afford 49 mg of the yellow oil in a 28.0% yield. LC-MS (ESI): [M+H] + =593.2,595.2; 1 H NMR (400MHz, CDCl3) δ7.90(s,1H),7.80(d,J=2.0Hz,1H),7.60(s,1H),7.52(dd,J=8.4,2.0Hz,1H),7.40(d,J=16.0Hz,1H),7.30(d,J=16.0H z,1H),7.24(d,J=8.4Hz,1H),4.68–4.37(m,2H),3.74–3.57(m,5H),3.20(t,J=6.0Hz,2H),2.79(s,3H),1.58(s,9H),1.27(d,J=6.8Hz,6H).

[0942] Step 10: Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenol

[0943] Tert-butyl (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-isopropylbenzo[d]thiazol-2-yl)vinyl)phenyl carbonate (45 mg, 0.08 mmol) was added to 1,4-dioxane (2 mL), followed by a 4 M hydrogen chloride / 1,4-dioxane solution (8 mL). The mixture was allowed to react at room temperature for 20 hours. The mixture was filtered, and the filter cake was washed with ethyl acetate and diethyl ether, then dried under vacuum at room temperature to afford 29.7 mg of a yellow solid (74.2% yield). LC-MS (ESI): [M+H] + =493.1,495.1; 19 F NMR(376MHz,MeOD)δ-224.14; 1 H NMR (400MHz, MeOD) δ8.43(s,1H),8.06(s,1H),7.86(d,J=2.0Hz,1H),7.65(d,J=16.0Hz,1H),7.56(dd,J=8.4,2.0Hz,1H),7.36(d,J=16.0Hz,1 H),6.97(d,J=8.4Hz,1H),4.59–4.42(m,2H),4.01(t,J=4.8Hz,2H),3.70–3.51(m,4H),3.51–3.45(m,1H),3.43(s,3H),1.42(d,J=6.8Hz,6H).

[0944] Example 17: Synthesis of Compound R

[0945] Synthesis of (E)-2-bromo-4-(2-(6-ethyl(2-(2-fluoroethoxy)ethyl)amino)-5-methylbenzothiazol-2-yl)vinyl)phenol

[0946] Step 1: Synthesis of 2-(2-((2,5-dimethylbenzothiazol-6-yl)(ethyl)amino)ethoxy)ethan-1-ol

[0947] 2-(2-((2,5-dimethylbenzothiazol-6-yl)amino)ethoxy)ethan-1-ol (500 mg, 1.87 mmol) was added to dichloromethane (50 mL), and acetaldehyde (827 mg, 18.7 mmol) and sodium acetate borohydride (1.19 g, 5.64 mmol) were added at room temperature. The mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (PE:EA = 4:1) to obtain 450 mg of a brown solid with a yield of 81%. LC-MS (ESI): [M+H] + =295.3; 1 H NMR (400MHz, Chloroform-d): δ7.68(s,1H),7.47(s,1H),3.64–3.52(m,2H),3.50–3.31(m,4H),3.17 (t, J = 6.0 Hz, 2H), 3.00 (d, J = 8.4 Hz, 2H), 2.72 (s, 3H), 2.37 (d, J = 13.2 Hz, 3H), 0.94 (t, J = 7.2 Hz, 3H).

[0948] Step 2: Synthesis of N-ethyl-N-(2-(2-fluoroethoxy)ethyl)-2,5-dimethylbenzothiazol-6-amine

[0949] 2-(2-((2,5-dimethylbenzothiazol-6-yl)(ethyl)amino)ethoxy)ethane-1-ol (350 mg, 1.2 mmol) was added to dichloromethane (20 mL), and diethylaminosulfur trifluoride (383 g, 2.4 mmol) was slowly added under ice-cooling. The reaction solution was reacted at 0°C for 4 hours. Water (50 mL) was added to the reaction solution to quench the reaction solution, and the solution was extracted with DCM (40 mL x 3). The combined organic phases were washed once with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (PE:EA=4:1) to obtain 120 mg of a brown solid with a yield of 26.5%. LC-MS (ESI): [M+H] + =297.3; 1 H NMR (400MHz, Chloroform-d): δ7.68(s,1H),7.48(s,1H),4.47(s,1H),4.35(s,1H),3.66–3.37(m ,4H),3.19(d,J=6.8Hz,2H),3.09–2.88(m,2H),2.73(s,3H),2.34(s,3H),0.94(t,J=7.2Hz,3H).

[0950] Step 3: Synthesis of (E)-2-(3-bromo-4-(methoxymethoxy)phenyl)-N-ethyl-N-(2-(2-fluoroethoxy)ethyl)-5-methylbenzothiazol-6-amine

[0951] N-Ethyl-N-(2-(2-fluoroethoxy)ethyl)-2,5-dimethylbenzothiazol-6-amine (90 mg, 0.3 mmol) was added to DMSO (10 mL), followed by potassium tert-butoxide (68 mg, 0.6 mmol) and 3-bromo-4-(methoxymethoxy)benzaldehyde (74 mg, 0.3 mmol) at room temperature. The reaction mixture was allowed to react for 4 hours at room temperature. Water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed once with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. Silica gel column chromatography (PE:EA = 4:1) afforded 90 mg of a brown solid in a 42.5% yield. LC-MS (ESI): [M+H] + =523.4,525.4; 1 H NMR (400MHz, DMSO-d6): δ8.07(d,J=2.1Hz,1H),7.84(s,1H),7.80–7.73(m,2H),7. 52(d,J=2.8Hz,2H),7.26(d,J=8.8Hz,1H),5.35(s,2H),4.56–4.46(m,1H),4.45–4. 34(m,1H),3.67–3.59(m,1H),3.56–3.52(m,1H),3.48(t,J=6.0Hz,2H),3.43(s,3H ), 3.19 (t, J = 6.0Hz, 2H), 3.09 (q, J = 7.2Hz, 2H), 2.37 (s, 3H), 0.96 (t, J = 7.2Hz, 3H).

[0952] Step 4: Synthesis of (E)-2-bromo-4-(2-(6-(ethyl(2-(2-fluoroethoxy)ethyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)phenol

[0953] (E)-2-(3-bromo-4-(methoxymethoxy)phenyl)-N-ethyl-N-(2-(2-fluoroethoxy)ethyl)-5-methylbenzothiazol-6-amine (70 mg, 0.13 mmol) was added to dichloromethane (2 mL), followed by a 1,4-dioxane hydrochloride solution (4 M, 2 mL). The mixture was reacted at room temperature for 4 hours, resulting in the precipitation of a large amount of solid. The precipitated solid was filtered and dried under reduced pressure to obtain 26.8 mg of the product as a brown solid, with a yield of 32.5%. LC-MS (ESI): [M+H] + =479.3 / 481.3; 1 H NMR (400MHz, Methanol-d4): δ8.36(s,1H),7.98(s,1H),7.88(d,J=2.4Hz,1H),7.64(d,J=16.4Hz,1H),7.57(dd,J=8.4,2.0 Hz,1H),7.37(d,J=16.0Hz,1H),6.98(d,J=8.4Hz,1H),4.55(s,1H),4.43(s,1H),4.01(d,J=5.2Hz,2H),3.87–3.74(m,2H), 3.61-3.53(m,4H),2.73-2.61(m,3H),1.16(t,J=7.1Hz,3H); 19 F NMR (376MHz, DMSO-d6): δ-221.19.

[0954] Example 18: Synthesis of Compound S

[0955] Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-6-methoxyphenol

[0956] Step 1: Synthesis of 3-bromo-5-methoxy-4-(methoxymethoxy)benzaldehyde

[0957] 3-Bromo-4-hydroxy-5-methoxybenzaldehyde (2.0 g, 8.66 mmol) was dissolved in DCM (20 mL), triethylamine (4.5 g, 34.64 mmol) was added, and MOMBr (2.7 g, 21.65 mmol) was then added dropwise in an ice bath. The mixture was allowed to react at room temperature for 3 hours. The reaction solution was extracted with ethyl acetate (50 mL x 3). The organic phases were combined and washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a silica gel column (PE:MTBE = 75:25) to give 1.3 g of a white solid product in a 55% yield. LC-MS (ESI): [M+H]+ =275.1,277.1; 1 H NMR (400MHz, DMSO-d6) δ9.85 (s, 1H), 7.67 (d, J = 2.0 Hz, 1H), 7.39 (d, J = 2.0 Hz, 1H), 5.30 (s, 2H), 3.92 (s, 3H), 3.65 (s, 3H).

[0958] Step 2: Synthesis of (E)-2-(3-bromo-5-methoxy-4-(methoxymethoxy)phenyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine

[0959] At 10°C, N-(2-(2-fluoroethoxy)ethyl)-N,2,5-trimethylbenzo[d]thiazol-6-amine (62 mg, 0.22 mmol) was added to a solution of potassium tert-butoxide (49 mg, 0.44 mmol) in DMSO (1 mL). 3-Bromo-5-methoxy-4-(methoxymethoxy)benzaldehyde (60 mg, 0.22 mmol) was then added to the reaction mixture. The reaction was allowed to react at room temperature for 3 hours. The mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a silica gel column (PE:EA = 65:35) to afford 32.0 mg of the product as a yellow oil in a 27% yield. LC-MS (ESI): [M+H] + =539.1,541.1; 1 H NMR(400MHz, DMSO_d6)δ7.76(d,J=5.6Hz,2H),7.66–7.60(m,2H),7.53–7.47(m,2H),5.15(s,2H),4.57–4.55(m,1H),4.45–4.43(m,1H),3.90 (s,3H),3.68–3.66(m,1H),3.63–3.58(m,3H),3.54(s,3H),3.11(t,J=6.0Hz,2H),2.76(s,3H),2.38(s,3H).

[0960] Step 3: Synthesis of (E)-2-bromo-4-(2-(6-((2-(2-fluoroethoxy)ethyl)(methyl)amino)-5-methylbenzo[d]thiazol-2-yl)vinyl)-6-methoxyphenol

[0961] To a solution of (E)-2-(3-bromo-5-methoxy-4-(methoxymethoxy)phenylvinyl)-N-(2-(2-fluoroethoxy)ethyl)-N,5-dimethylbenzo[d]thiazol-6-amine (32 g, 0.06 mmol) in 1,4-dioxane (1 mL) was added dropwise a 4 M hydrochloric acid solution in 1,4-dioxane (1 mL) at room temperature. The mixture was allowed to react at room temperature for 1 hour. Ethyl acetate (5 mL) was added to the reaction mixture, which was filtered, rinsed with ethyl acetate and then with diethyl ether, and the filter cake was dried to afford 24.4 mg of an orange solid (83% yield). LC-MS (ESI): [M+H] + =495.2,497.1; 19 F NMR (376MHz, DMSO) δ-223.91; 1 H NMR (400MHz, CD3OD) δ8.37(s,1H),7.92(s,1H),7.59(d,J=16.0Hz,1H),7.42–7.27(m,3H),4.56–4.54( m,1H),4.43–4.42(m,1H),3.99–3.98(m,2H),3.96(s,3H),3.63–3.56(m,4H),3.39(s,3H),2.67(s,3H).

[0962] Effect test example:

[0963] Effect embodiment 1:

[0964] The compounds were first added to 50 mM Tris-buffer (pH 7.0) containing 0.0025% (v / v) DMSO to a final concentration of 5 μM. Aβ, α-synuclein, and tau aggregates were then added to final concentrations of 0.02, 0.04, 0.08, 0.16, 0.32, 0.64, and 1.28 μM, respectively. Fluorescence was measured using a fluorescence spectrophotometer (Horiba, Fluorolog3).

[0965] Aβ aggregates: Aβ(1-42) peptide was purchased from rPeptide, catalog number #A-1163-1. Aβ(1-42) peptide was dissolved in 9 volumes of ice water and shaken intermittently for 30 minutes. One volume of aggregation buffer (0.2 M NaPi, 1.5 M NaCl, 0.2% NaN3, pH 7.5) was added to a final concentration of 1 mg / ml. The mixture was incubated at 37°C for 1 week to prepare Aβ aggregates.

[0966] α-synuclein aggregates: purchased from Proteos. Inc. (RP-002).

[0967] Tau aggregates: The Tau cDNA sequence was inserted into a GST-tagged plasmid and transfected into BL21 bacteria for protein expression. The protein was then sonicated in a high-salt buffer (0.75M NaCl, 50mM Tris, pH 7.4, 1mM EDTA) and centrifuged at 70,000xg for 30 minutes. The protein was then purified using a glutathione agarose bead column (GE Healthcare). Thrombin was added to remove the GST tag, and the protein was dialyzed against FPLC buffer (50mM NaCl, 50mM Tris-HCl, pH 7.4) and filtered through a 0.22μm filter. The Tau concentration was adjusted to 3mg / mL, and 12.5μM heparin was added. The cells were shaken at 300rpm at 37°C for 7 days to prepare Tau aggregates.

[0968] Incubation concentrations: 0.02 μM, 0.04 μM, 0.08 μM, 0.16 μM, 0.32 μM, 0.64 μM, 1.28 μM

[0969] Incubation temperature: 37°C

[0970] Incubation time: 5 min

[0971] Detection wavelength of fluorescence spectrophotometer:

[0972] Computational software: Graphpad Prism 8.2.1

[0973] Experimental results:

[0974] The compounds of the present invention have good binding activity and selectivity to α-Synuclein aggregates. For example, the compounds of the present invention have good binding activity and selectivity to α-Synuclein aggregates. d The value is 1 to 100 nM. The K d :K of the compounds of the present invention on α-Synuclein aggregates d is (2-100):1, the K of the compound of the present invention on Tau aggregates d :The compounds of the present invention have an effect on α-Synuclein aggregate K d is (2~100):1.

[0975] Effect Example 2

[0976] Primary cultured neurons are infected with adeno-associated viruses (AAVs) encoding α-Syn for 7 days and then treated with α-Syn PFFs. Several days later, compounds are added to primary neurons containing the desired aggregates. The desired compounds will selectively produce a positive signal in neurons with α-Syn aggregates.

[0977] Primary hippocampal neurons were isolated from wild-type rats at E16-17 pregnancy. Cortical tissue was isolated and dissociated from embryonic SD-Dawley rats at E18. The cells were incubated with 5 ml of D-Hanks solution containing 0.25% trypsin at 37°C in a humidified atmosphere of 5% CO2 for 5 minutes. 4 ml of DMEM / F12 neuronal culture medium containing 10% fetal bovine serum was added and the cells were centrifuged at 1000 x g for 5 minutes. 1×10 5 Cells were plated in 6-well plates and DIV7 neurons were infected with AAV-α-Syn. At DIV12, 100 ng / ml α-Syn PFFs were added to induce α-Syn aggregation. α-Syn 1-140 was incubated with cultured primary neurons in sterile PBS to a final concentration of 0.1 mg / ml. Sonicated PFFs or an equal amount of monomers as a control were transferred to prewarmed neuronal culture medium at a final concentration of 100 ng / ml. Compounds and the indicated aggregates were added to primary neurons, and α-Syn aggregation was detected by immunostaining with p-α-Syn S129 antibody (purchased from Abcam; Cat. No. ab59264) (pseudo-colored to red). The neurons were then stained with ThT (purchased from Sigma; Cat. No. S96200) or compound (0.1 M) and analyzed using fluorescence microscopy.

[0978] As shown in FIG1 , the compounds of the present invention, such as Compound C, Compound E, and Compound R, selectively generate positive signals in neurons where α-Syn is aggregated.

[0979] Effect Example 3

[0980] To further explore whether the positive compounds selectively bind to Lewy bodies, the binding selectivity of the compounds on mouse brain slices containing Lewy bodies was tested.

[0981] α-Syn protein encoding gene (SNCA) transgenic mice (purchased from The Jackson Laboratory, Catalog No. 017682) were treated with rotenone (rotenone was administered orally; mice were treated with 0.1 mL / 25 g of culture medium containing 1% methylcellulose and 1.25% chloroform or a solution containing 0.625 mg / mL rotenone (purchased from ULTRA Scientific; Catalog No. PST-890), 1% methylcellulose (purchased from Sigma; Catalog No. M0512), and 1.25% chloroform (purchased from Sigma; Catalog No. 2432). Rotenone solution was prepared by dissolving rotenone in chloroform and then diluting it into a 1% methylcellulose solution with vigorous mixing. Rotenone or control was administered using a 1.2 x 60 mm gavage needle (purchased from Unimed, Switzerland) once a day for 5 days / week for 3 months) containing abundant LB-like contents. In addition, brain sections from NFT-enriched Tau P301S mice and Aβ-enriched 5xFAD mice were also used.

[0982] Fixed brain sections were incubated with primary antibodies for 12 hours at 4°C, followed by incubation with Alexa Fluor 568-, Alexa Fluor 488-, or Alexa Fluor 647-conjugated secondary antibodies (purchased from Invitrogen) for 3 hours at room temperature. Staining was performed with ThS (purchased from Sigma; Cat. No. T1892) or compound at room temperature, followed by nuclear staining with 4',6-diamidino-2-phenylindole (DAPI, 1 μg / ml; purchased from Sigma-Aldrich). Slides were imaged using an Olympus FluoView FV1000 confocal laser scanning microscope, and data were acquired using Olympus FluoView software.

[0983] α-Syn deposition was labeled with p-α-Syn S129 antibody. As a positive control, ThS colocalized with p-α-Syn S129 aggregates in brain sections, as shown in Figure 2 . The compounds of the present invention, such as Compound A, Compound C, Compound E, Compound R, and Compound S, all showed strong binding activity. However, it is worth noting that almost no test compounds reacted with NFT.

[0984] Effect Example 4:

[0985] The ex vivo screening was extended to brain sections from human DLB and AD patients. The neurodegenerative disease of DLB ​​is a synucleinopathy with well-defined Lewy bodies. Therefore, positive compounds should show strong signals in both LB and LN.

[0986] For immunohistochemical staining, 20 μm-thick human brain sections, following dehydrogenation and antigen retrieval, were treated with 0.3% H₂O₂ for 10 minutes at room temperature. Sections were then washed three times in 0.3% Triton X-100 in PBS, blocked with 1% BSA for 30 minutes, and incubated with anti-Aβ / AT8 / α-Syn pS129 antibodies overnight at 4°C. Signal extraction was performed using the Histostain-SP kit (Invitrogen; Cat. No. 95-9943). After washing, the sections were covered with a cover glass in mounting solution.

[0987] As shown in Figure 3, compounds of the present invention, such as Compound C, Compound E, and Compound R, co-stained with p-α-Syn S129 in brain sections from patients with DLB, but showed little co-staining with anti-Aβ or AT8-positive aggregate signals in sections from patients with AD. Therefore, these compounds selectively interact with α-Syn aggregates compared to Aβ.

[0988] Effect Example 5

[0989] To test whether these compounds have brain penetrance in vivo, in vivo PK analysis was performed to determine brain exposure.

[0990] In vivo validation of the compounds was performed in CD-1 (ICR) male mice. An appropriate amount of compound was weighed and dissolved in a solvent (5% NMP + 15% Solutol + 80% PBS) to prepare a 1 mg / mL solution for intravenous administration to mice. The administration volume was 5 mL / kg. The compound (dose of 5 mg / kg) was injected through the tail vein. The experiment was divided into five groups. Each administration group (sampling point) consisted of three male CD-1 (ICR) mice with a body weight between 29.1 g and 30.6 g. Serial venous blood samples (approximately 30 μL each) and brain tissue samples were collected from each animal at 0 min, 1 min, 5 min, 15 min, and 30 min after administration. Blood samples were collected in Vacutainer IM tubes containing EDTA-K2 anticoagulant, inverted several times, and immediately placed on wet ice until the plasma was centrifuged. Brain tissue samples were added with PBS (100 mM, pH 5.0) 5 times the weight of the tissue. 7.4) (1:4, w / v) for homogenization. The concentration of the test compound in plasma and brain tissue homogenate was measured by LC / MS / MS as follows: an equal amount of 10 μL plasma sample or 50 μL brain tissue homogenate sample was added to a 96-well plate, and then 200 μL methanol / acetonitrile (1:1, v / v) precipitant (containing 5 ng / mL Terfenadine) was added. After protein precipitation, the supernatant was removed and diluted 3-fold with methanol / water (1:1, v / v, containing 0.1% FA). 1 μL plasma sample or 3 μL brain tissue homogenate sample was taken for LC / MS / MS. Blood and tissue were collected at the corresponding time points for analysis.

[0991] turn out:

[0992] The plasma half-life of Compound C was 1.14 hours, which was 10-fold longer than that of F0502B. The brain / plasma ratio of Compound C was 24% at 1 minute and reached a maximum of 129% at 15 minutes.

[0993] The brain / plasma ratio of Compound E was 12% at 1 minute and continued to increase, reaching a maximum of 337% at 15 minutes.

[0994] The plasma half-life of Compound R was 0.54 hours, which was 4.7 times longer than that of F0502B. The brain / plasma ratio of Compound C was 5% at 1 minute and reached a maximum of 255% at 30 minutes.

[0995] The compounds of the present invention show good PK data, have high brain penetration, can quickly enter the brain (their brain / plasma ratio increases in a time-dependent manner), have good in vivo half-life and can be quickly cleared from the plasma.

[0996] Effect Example 6

[0997] In vivo validation of the compounds was performed using 8-month-old wild-type mice (purchased from Jiangsu Ai Ling Fei Biotechnology Co., Ltd.), 12-month-old 5xFAD mice (purchased from The Jackson Laboratory; Catalog No. 034840), 6-month-old Tau P301S mice (purchased from The Jackson Laboratory; Catalog No. 008169), and rotenone-treated α-Syn A53T mice (purchased from The Jackson Laboratory, Catalog No. 017682). All mice were divided equally into several groups according to sex and injected with the compound via the tail vein at a dose of 2 mg / kg. 0.5 hours after administration, tissues were collected and mouse brain sections were prepared. They were stained with anti-Aβ (purchased from Biolegend; Catalog No. SIG-39300) or AT8 (purchased from Thermo Fisher; Catalog No. MN1020) and the compounds. The results showed that the compounds of the present invention, such as Compound C, Compound E, and Compound R, did not specifically bind to Aβ and AT8, but colocalized with α-Syn-p129 or α-Syn aggregates.

[0998] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.

Claims

1. A sulfur-containing fused ring compound as shown in formula A, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof; in, The sulfur-containing fused ring compound shown in formula A is as follows: In formula A, R 1 F, Cl, Br, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; And when R 5 When it is -OH, R 1 F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced-OC 1-6 alkyl; R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The compound must meet one or more of the following conditions: Condition (1)R 1 F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; Condition (2)R 2 -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; Condition (3)R 3 H, -OH, C 2-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 Substituted 5-10 membered heteroaryl.

2. The sulfur-containing fused ring compound as shown in formula A, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative as claimed in claim 1, characterized in that: The sulfur-containing fused ring compound represented by formula A is represented by formula A-1:

3. The sulfur-containing fused ring compound as shown in formula A, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative as claimed in claim 1, characterized in that: It meets one or more of the following conditions: Condition (1): In formula A, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 ; preferably -OR 1-1 or -NR 1-2 R 1-3 ; More preferably -OH, -OCH3, -NH2 or -NHCH3; Condition (2): In formula A, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; preferably -OH, -OC 1-6 Alkyl or -NR 2-0 R 2- 1 ; More preferably -OH, -OCH3, -NH2 or -NHCH3; Condition (3): In formula A, R 3 H, -OH or C 1-6 Alkyl; preferably H, -OH or C 2-6 Alkyl; more preferably H, -OH or isopropyl, or, more preferably -OH, ethyl or isopropyl; Condition (4): In formula A, R 4 C 1-6 alkyl; Condition (5): In formula A, R 1-1 H or C 1-6 alkyl; Condition (6): In formula A, R 1-2 and R 1-3 independently H or C 1-6 alkyl; Condition (7): In formula A, R 2-1 is H; Condition (8): In formula A, R 2-0 H or C 1-6 Alkyl; and Condition (9): In formula A, R 5 is -OH, -NH2 or -NHCH3; preferably R 5 It is -OH.

4. A sulfur-containing fused ring compound as shown in Formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof; characterized in that: The sulfur-containing fused ring compound shown in Formula IA is as follows: In Formula IA, R 1 F, Cl, Br, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced-OC 1-6 alkyl; R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; And when R 5 When it is -OH, R 1 F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; in the 5-10 membered heteroaryl, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound shown in formula II-A is as follows: In Formula II-A, R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced-OC 1-6 alkyl; R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound represented by formula VA is as follows: In formula VA, R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 2-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced-OC 1-6 alkyl; R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound shown in formula III-A is as follows: In formula III-A, X is N or CR a ; R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 Genso Hoji, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R a H or C 1-6 alkyl; or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced-OC 1-6 alkyl; R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound shown in formula IV-A is as follows: In formula IV-A, X is N or CR a ; R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R a H or C 1-6 alkyl; or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time; R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced-OC 1-6 alkyl; R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound shown in Formula VI-A is as follows: In Formula VI-A, R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 2-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced-OC 1-6 alkyl; R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound shown in Formula VII is as follows: R 1 F, Cl, Br, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; R 6 H, -OC 1-6 Alkyl, or 1, 2 or 3 R 6-1 Replaced-OC 1-6 alkyl; R 6-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; In the 3-6 membered heterocycloalkyl group, the heteroatom type is selected from N, O or S, and the number of the heteroatoms is 1, 2 or 3.

5. The sulfur-containing fused ring compound represented by IA, II-A, III-A, IV-A, VA, VI-A or VII as claimed in claim 4, its pharmaceutically acceptable salt, its tautomer or its radioactive isotope-labeled derivative; characterized in that: The sulfur-containing fused ring compound as shown in Formula IA is shown below: In Formula I, R 1 F, Cl, Br, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; And when R 5 When it is -OH, R 1 F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; in the 5-10 membered heteroaryl, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound as shown in formula II-A is shown in the following formula II-: In Formula II, R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound represented by formula VA is represented by the following formula V: In Formula V, R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 2-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound as shown in formula III-A is shown in the following formula III: In formula III, X is N or CR a ; R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R a H or C 1-6 alkyl; or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p is not 0 at the same time; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound as shown in formula IV-A is shown in the following formula IV: In Formula IV, X is N or CR a ; R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Replaced C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R a H or C 1-6 alkyl; or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; The sulfur-containing fused ring compound as shown in Formula VI-A is shown in the following Formula VI: In Formula VI, R 1 Br, F, Cl, I, -OR 1-1 、-NR 1-2 R 1-3 , 1, 2 or 3 R 1-4 Substituted C 1-6 Alkyl, 1, 2 or 3 R 1-5 Substituted C 2-6 Alkenyl or 1, 2 or 3 R 1-6 Substituted C 3-6 Cycloalkyl; R 1-1 H, C 1-6 Alkyl or 1, 2 or 3 R 1-1-1 Substituted C 1-6 alkyl; R 1-2 and R 1-3 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 1-2-1 Substituted C 1-6 alkyl; R 1-4 , R 1-5 and R 1-6 are independently -OH or -NR 1-4-1 R 1-4-2 ; R 1-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-2-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 1-4-1 and R 1-4-2 independently H or C 1-6 alkyl; R 2 H, -OH, -OC 1-6 Alkyl, -NR 2-0 R 2-1 , 1, 2 or 3 R 2-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 2-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 2-4 Substituted C 3-6 Cycloalkyl or 1, 2 or 3 R 2-5 Replaced-OC 1-6 alkyl; R 2-0 and R 2-1 Independently H, C 1-6 Alkyl or 1, 2 or 3 R 2-1-1 Substituted C 1-6 alkyl; R 2-2 , R 2-3 , R 2-4 and R 2-5 are independently halogen, -OH or -NR 2-2-0 R 2-2-1 ; R 2-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 2-2-0 and R 2-2-1 independently H or C 1-6 alkyl; R 3 H, -OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6- 10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 3-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 3-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 3-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 3-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 3-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 3-7 Replaced-OC 1- 6-alkyl, 1, 2 or 3 R 3-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 3-9 substituted 5-10 membered heteroaryl; R 3-1 C 1-6 Alkyl or 1, 2 or 3 R 3-1-1 Substituted C 1-6 alkyl; R 3-2 , R 3-3 , R 3-4 , R 3-5 , R 3-6 , R 3-7 , R 3-8 and R 3-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 3-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4 H, C 2-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -OC 1-6 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 1, 2 or 3 R 4-2 Substituted C 1-6 Alkyl, 1, 2 or 3 R 4-3 Substituted C 2-6 Alkenyl, 1, 2 or 3 R 4-4 Substituted C 2-6 Alkynyl, 1, 2 or 3 R 4-5 Substituted C 3-6 Cycloalkyl, 1, 2 or 3 R 4-6 substituted 3-6 membered heterocycloalkyl, substituted by 1, 2 or 3 R 4-7 Replaced-OC 1-6 Alkyl, 1, 2 or 3 R 4-8 Substituted C 6-10 Aryl or 1, 2 or 3 R 4-9 substituted 5-10 membered heteroaryl; R 4-1 C 1-6 Alkyl or 1, 2 or 3 R 4-1-1 Substituted C 1-6 alkyl; R 4-2 , R 4-3 , R 4-4 , R 4-5 , R 4-6 , R 4-7 , R 4-8 and R 4-9 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 4-1-1 are independently halogen, -OH, -COOH, -CN, -NO2 or -NH2; R 5 -OH or -NR 5-1 R 5-2 ; R 5-1 and R 5-2 independently H or C 1-6 alkyl; In the 5-10 membered heteroaryl group, the heteroatom species is selected from N, O or S, and the number of heteroatoms is 1, 2 or 3; In the 3-6 membered heterocycloalkyl group, the heteroatom type is selected from N, O or S, and the number of the heteroatoms is 1, 2 or 3.

6. The sulfur-containing fused ring compound as shown in Formula IA, II-A, III-A, IV-A, VA, VI-A or VII as claimed in claim 4 or 5, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof, characterized in that: It meets one or more of the following conditions: Condition (1): In Formula IA or Formula I, R 1 Br, -OR 1-1 or -NR 1-2 R 1-3 ; preferably -OR 1-1 or -NR 1-2 R 1-3 ; More preferably -OH, -OCH3, -NH2 or -NHCH3; Condition (2): In Formula IA or Formula I, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; Condition (3): In Formula IA or Formula I, R 3 H, -OH or C 1-6 alkyl; Condition (4): In Formula IA or Formula I, R 4 C 1-6 alkyl; Condition (5): In Formula IA or Formula I, R 1-1 H or C 1-6 alkyl; Condition (6): In Formula IA or Formula I, R 1-2 and R 1-3 independently H or C 1-6 alkyl; Condition (7): In Formula IA or Formula I, R 2-1 is H; Condition (8): In Formula IA or Formula I, R 2-0 H or C 1-6 Alkyl; and Condition (9): In Formula IA or Formula I, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

7. The sulfur-containing fused ring compound as shown in Formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof according to claim 4 or 5, characterized in that: It meets one or more of the following conditions: Condition (1): In Formula II-A or Formula II, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 ; Condition (2): In Formula II-A or Formula II, R 2 -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; preferably -OH, -OCH3, -NH2 or -NHCH3; Condition (3): In Formula II-A or Formula II, R 3 H, -OH or C 1-6 alkyl; Condition (4): In Formula II-A or Formula II, R 4 C 1-6 alkyl; Condition (5): In Formula II-A or Formula II, R 1-1 H or C 1-6 alkyl; Condition (6): In Formula II-A or Formula II, R 1-2 and R 1-3 independently H or C 1-6 alkyl; Condition (7): In Formula II-A or Formula II, R 2-1 is H; Condition (8): In Formula II-A or Formula II, R 2-0 H or C 1-6 Alkyl; and Condition (9): In Formula II-A or Formula II, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

8. The sulfur-containing fused ring compound as shown in Formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof as claimed in claim 4 or 5, characterized in that: It meets one or more of the following conditions: Condition (1): In Formula VA or Formula V, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 ; Condition (2): In Formula VA or Formula V, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; Condition (3): In Formula VA or Formula V, R 3 H, -OH or C 2-6 Alkyl; preferably H, -OH or isopropyl; or preferably - OH, ethyl or isopropyl; most preferably ethyl; Condition (4): In Formula VA or Formula V, R 4 C 1-6 alkyl; Condition (5): In Formula VA or Formula V, R 1-1 H or C 1-6 alkyl; Condition (6): In Formula VA or Formula V, R 1-2 and R 1-3 independently H or C 1-6 alkyl; Condition (7): In Formula VA or Formula V, R 2-1 is H; Condition (8): In Formula VA or Formula V, R 2-0 H or C 1-6 Alkyl; and Condition (9): In Formula VA or Formula V, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

9. The sulfur-containing fused ring compound as shown in Formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof according to claim 4 or 5, characterized in that: It meets one or more of the following conditions: Condition (1): In Formula III-A or Formula III, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 ; Condition (2): In Formula III-A or Formula III, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time; preferably R 2 H, or R a With R 2 Together they form -NH- or -CH=CH-; Condition (3): In Formula III-A or Formula III, R 3 H, -OH or C 1-6 alkyl; Condition (4): In Formula III-A or Formula III, R 4 C 1-6 alkyl; Condition (5): In Formula III-A or Formula III, R 1-1 H or C 1-6 alkyl; Condition (6): In Formula III-A or Formula III, R 1-2 and R 1-3 independently H or C 1-6 alkyl; Condition (7): In Formula III-A or Formula III, R 2-1 is H; Condition (8): In Formula III-A or Formula III, R 2-0 H or C 1-6 Alkyl; and Condition (9): In Formula III-A or Formula III, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

10. The sulfur-containing fused ring compound of formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof according to claim 4 or 5, characterized in that: It meets one or more of the following conditions: Condition (1): In Formula IV-A or Formula IV, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 ; Condition (2): In Formula IV-A or Formula IV, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 or, R a With R 2 Together they form -(NH) n -(CH2) m -(CH=CH) p -; n, m and p are independently 0, 1, 2 or 3, and n, m and p are not 0 at the same time; preferably R 2 H, or R a With R 2 Together they form -NH- or -CH=CH-; Condition (3): In Formula IV-A or Formula IV, R 3 H, -OH or C 1-6 alkyl; Condition (4): In Formula IV-A or Formula IV, R 4 C 1-6 alkyl; Condition (5): In Formula IV-A or Formula IV, R 1-1 H or C 1-6 alkyl; Condition (6): In Formula IV-A or Formula IV, R 1-2 and R 1-3 independently H or C 1-6 alkyl; Condition (7): In Formula IV-A or Formula IV, R 2-0 C 1-6 Alkyl; and Condition (8): In Formula IV-A or Formula IV, R 2-1 For H.

11. The sulfur-containing fused ring compound of formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof according to claim 4 or 5, characterized in that: It meets one or more of the following conditions: Condition (1): In Formula VI-A or Formula VI, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 ; Condition (2): In Formula VI-A or Formula VI, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; Condition (3): In Formula VI-A or Formula VI, R 3 H, -OH or C 1-6 alkyl; Condition (4): In Formula VI-A or Formula VI, R 4 C 2-6 Alkyl; preferably ethyl or isopropyl; Condition (5): In Formula VI-A or Formula VI, R 1-1 H or C 1-6 alkyl; Condition (6): In Formula VI-A or Formula VI, R 1-2 and R 1-3 independently H or C 1-6 alkyl; Condition (7): In Formula VI-A or Formula VI, R 2-1 is H; Condition (8): In Formula VI-A or Formula VI, R 2-0 H or C 1-6 Alkyl; and Condition (8): In Formula VI-A or Formula VI, R 5 It is -OH, -NH2 or -NHCH3; preferably -OH.

12. The sulfur-containing fused ring compound of formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof according to claim 4 or 5, characterized in that: It meets one or more of the following conditions: Condition (1): In Formula VII, R 1 Br, F, Cl, I, -OR 1-1 or -NR 1-2 R 1-3 ; Condition (2): In Formula VII, R 2 H, -OH, -OC 1-6 Alkyl or -NR 2-0 R 2-1 ; Condition (3): In Formula VII, R 3 H, -OH or C 1-6 alkyl; Condition (4): In Formula VII, R 4 C 2-6 alkyl; Condition (5): In Formula VII, R 1-1 H or C 1-6 alkyl; Condition (6): In Formula VII, R 1-2 and R 1-3 independently H or C 1-6 alkyl; Condition (7): In Formula VII, R 2-1 is H; Condition (8): In Formula VII, R 2-0 H or C 1-6 alkyl; Condition (9): In Formula VII, R 5 is -OH, -NH2 or -NHCH3; preferably -OH; Condition (10) Formula IA, II-A, III-A, IV-A, VA, VI-A or VII, R 6 H, or -OC 1-6 Alkyl; preferably H or methoxy.

13. The sulfur-containing fused ring compound of formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof according to claim 4 or 5, characterized in that: It meets one or more of the following conditions: Condition (1): In Formula IA or Formula I, R 1 is Br, -OH, -OCH3, -NH2 or -NHCH3; R 2 is H, -OH, -OCH3, -NH2 or -NHCH3; R 3 H, -OH or C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 is -OH, -NH2 or -NHCH3; Condition (2): In Formula II-A or Formula II, R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3; R 2 is -OH, -OCH3, -NH2 or -NHCH3; R 3 H, -OH or C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 is -OH, -NH2 or -NHCH3; Condition (3): In formula III-A or formula III, X is N or CR a ; R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3; R 2 H; or, R a With R 2 Together they form -NH- or -CH=CH-; R 3 H, -OH or C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 is -OH, -NH2 or -NHCH3; Condition (4): In formula IV-A or formula IV, X is N or CR a ; R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3; R 2 H; or, R a With R 2 Together they form -NH- or -(CH=CH)-; R 3 H, -OH or C 1-6 alkyl; R 4 C 1-6 alkyl; Condition (5): In Formula VA or Formula V, R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3; R 2 is H, -OH, -OCH3, -NH2 or -NHCH3; R 3 is H, -OH or isopropyl; or R 3 is -OH, ethyl or isopropyl; R 4 C 1-6 alkyl; R 5 is -OH, -NH2 or -NHCH3; and Condition (6): Formula VI-A In Formula VI, R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3; R 2 is H, -OH, -OCH3, -NH2 or -NHCH3; R 3 H, -OH or C 1-6 alkyl; R 4 C 2-6 alkyl; R 5 is -OH, -NH2 or -NHCH3; , preferably, it satisfies one or more of the following conditions: Condition (1): In Formula IA or Formula I, R 1 is Br, -OH, -OCH3, -NH2 or -NHCH3; R 2 is H; R 3 C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 is -OH, -NH2 or -NHCH3; Condition (2): In Formula II-A or Formula II, R 1 for Br; R 2 is -OH, -OCH3, -NH2 or -NHCH3; R 3 C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 is -OH; Condition (3): In formula III-A or formula III, X is N or CR a ; R 1 for Br; R 2 H; or, R a With R 2 Together they form -NH- or -CH=CH-; R 3 C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 is -OH; Condition (4): In formula IV-A or formula IV, X is N or CR a ; R 1 for Br; R 2 H; or, R a With R 2 Together they form -NH- or -(CH=CH)-; R 3 C 1-6 alkyl; R 4 C 1-6 alkyl; Condition (5): In Formula VA or Formula V, R 1 for Br; R 2 is H; R 3 is H, -OH or isopropyl; or R 3 is -OH, ethyl or isopropyl; R 4 C 1-6 alkyl; R 5 is -OH; and Condition (6): In Formula VI-A or Formula VI, R 1 for Br; R 2 is H; R 3 H, -OH or C 1-6 alkyl; R 4 is ethyl or isopropyl; R 5 It is -OH.

14. The sulfur-containing fused ring compound of formula IA, II-A, III-A, IV-A, VA, VI-A or VII, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof according to claim 4 or 5, characterized in that: It meets one or more of the following conditions: Condition (1): In Formula VII, R 1 is Br, F, Cl, I, -OH, -OCH3, -NH2 or -NHCH3; R 2 is H, -OH, -OCH3, -NH2 or -NHCH3; R 3 H, -OH or C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 is -OH, -NH2 or -NHCH3; R 6 is methoxy; Condition (2): R 1 is Br, -OH, -OCH3, -NH2 or -NHCH3; R 2 is H; R 3 C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 is -OH, -NH2 or -NHCH3; R 6 It is a methoxy group.

15. The sulfur-containing fused ring compound of formula A according to claim 1, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative, or the sulfur-containing fused ring compound of formula IA, II-A, III-A, IV-A, VA, VI-A or VII according to claim 4 or 5, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative, characterized in that: It meets one or more of the following conditions: Condition (1): In formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; for example, methyl, ethyl or isopropyl; for example, methyl; Condition (2): In formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, C 2-6 Alkenyl is independently ethenyl, propenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl or tert-butenyl; Condition (3): In formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, C 2-6 Alkynyl is independently ethynyl, n-propynyl, isopropynyl, n-butynyl, isobutynyl, sec-butynyl or tert-butynyl; Condition (4): In formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, C 3-6 Cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopropyl, cyclopentyl or cyclohexyl; Condition (5): In formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, the -OC 1-6 Alkyl is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy; for example, methoxy; Condition (6): In formula A, IA, II-A, III-A, IV-A, VA, VI-A, VII, I, II, III, IV, V or VI, the halogen is independently F, Cl, Br or I; Condition (7): In formula A, IA, II-A, III-A, IV-A, VA, VI-A, VIII, II, III, IV, V or VI, C 6- 10 Aryl is independently phenyl or naphthyl, for example phenyl; and Condition (8): In formula A, VA, VI-A, V or VI, C 2-6 Alkyl is independently ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; for example, ethyl or isopropyl.

16. The sulfur-containing fused ring compound as shown in formula A according to claim 1, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative, or the sulfur-containing fused ring compound as shown in formula IA, II-A, III-A, IV-A, VA, VI-A or VII according to claim 4 or 5, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative, characterized in that: The sulfur-containing fused ring compound as shown in Formula IA is selected from any one of the following compounds: The sulfur-containing fused ring compound as shown in formula II-A is selected from any of the following compounds: The sulfur-containing fused ring compound as shown in formula III-A is selected from any of the following compounds: The sulfur-containing fused ring compound as shown in formula IV-A is selected from any of the following compounds: The sulfur-containing fused ring compound as shown in formula VA is selected from any one of the following compounds: The sulfur-containing fused ring compound as shown in Formula VI-A is selected from any of the following compounds: The sulfur-containing fused ring compound as shown in Formula VII is selected from the following compounds:

17. The sulfur-containing fused ring compound, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative according to any one of claims 1 to 3 or the sulfur-containing fused ring compound, its pharmaceutically acceptable salt, its tautomer or its radioisotope-labeled derivative according to any one of claims 4 to 16, characterized in that: The radioisotope-labeled derivative is 18 F. 11 C. 124 I. 123 I or 13 Compounds obtained by replacing F, C, I or N atoms in the sulfur-containing fused ring compound, its pharmaceutically acceptable salt, or its tautomer; preferably 18 F.

18. A pharmaceutical composition, characterized in that It includes a sulfur-containing fused ring compound as shown in formula A as described in any one of claims 1 to 3, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof, or a sulfur-containing fused ring compound as shown in formula IA, II-A, III-A, IV-A, VA, VI-A or VII as described in any one of claims 4 to 16, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof, and a pharmaceutical excipient.

19. A kit comprising a sulfur-containing fused ring compound as shown in formula A as described in any one of claims 1 to 3, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof, or a sulfur-containing fused ring compound as shown in formula IA, II-A, III-A, IV-A, VA, VI-A or VII as described in any one of claims 4 to 16, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioactive isotope-labeled derivative thereof, and instructions for use.

20. Use of a sulfur-containing fused ring compound as shown in formula A as described in any one of claims 1 to 3, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof, or a sulfur-containing fused ring compound as shown in formula IA, II-A, III-A, IV-A, VA, VI-A or VII as described in any one of claims 4 to 16, a pharmaceutically acceptable salt thereof, a tautomer thereof or a radioisotope-labeled derivative thereof in the preparation of a PET-CT tracer; the PET-CT tracer can be used to image Lewy bodies and α-synuclein aggregates in Lewy neurites; for example, the PET-CT tracer is used to image Parkinson's disease, Lewy body dementia, and multiple system atrophy; for example, the PET-CT tracer can be used to diagnose and exclude progressive supranuclear palsy or corticobasal degeneration.

Citation Information

Patent Citations

  • Styrylbenzothiazole derivatives and uses in imaging

    CN112105393A

  • Methods of preventing, treating and diagnosing disorders of protein aggregation

    WO2004075882A1

  • Compositions and methods for non-invasive imaging of soluble beta-amyloid

    WO2004100998A2

  • Truncated fragments of alpha-synuclein in LEWY body disease

    WO2005013889A2

  • In vivo imaging method

    WO2010063701A2